[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Perkinelmer Life Sciences, Inc.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":292},{"warningLetters":4,"total":291},[5,33,56,79,101,124,145,160,180,199,216,235,253,273],{"id":6,"raw":7,"subject":14,"body_html":15,"body_text":16,"firm_name":17,"letter_id":18,"created_at":19,"fei_number":20,"letter_url":21,"updated_at":22,"action_type":23,"case_status":24,"posted_date":25,"marcs_cms_no":26,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":28,"body_fetched_at":29,"delivery_method":30,"recipient_title":20,"reference_number":31,"action_taken_date":32,"medical_device_id":20,"response_letter_date":20},1073,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2025-02-04T05:00:00Z\">02\u002F04\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-01-17T05:00:00Z\">01\u002F17\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbiostem-life-sciences-673788-01172025\">BioStem Life Sciences\u003C\u002Fa>","Center for Biologics Evaluation and Research (CBER)","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues &amp; Cellular Products (HCT\u002FPs)","","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues & Cellular Products (HCT\u002FPs)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER 25-673788\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jason V. Matuszewski\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>BioStem Life Sciences\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2836 Center Port Circle\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Pompano Beach\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33064\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:quality@biostemtech.com\"> quality@biostemtech.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research (CBER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cbr>January 17, 2025&nbsp;\u003C\u002Fp>\u003Cp>CBER 25-673788\u003C\u002Fp>\u003Cp>Dear Mr. Matuszewski:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your facility, located at the above address, between September 11, 2023, and September 15, 2023. During the inspection, FDA documented that your company manufactures cellular products derived from human umbilical cord, including those labeled as Product 401 (OROPRO®), Product 403 (PROVISCUS®), and Product 404 (NEOFYL®) as well as an amniotic membrane combined with amniotic fluid product labeled as RHEO® (collectively, “your products”).&nbsp;\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of current good manufacturing practice (CGMP) requirements, including violations of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 351(a)(2)(B), and 21 CFR parts 210 and 211. Because your methods, facilities, or controls for manufacturing, processing, packing, or holding drugs do not conform to CGMP, your products are adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. § 351(a)(2)(B). Your adulteration of your products while held for sale after shipment in interstate commerce, or the causing thereof, is a prohibited act under section 301(k) of the FD&amp;C Act, 21 U.S.C. § 331(k).&nbsp;\u003C\u002Fp>\u003Cp>Based on information and records reviewed by FDA, your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body. For example,\u003C\u002Fp>\u003Cul>\u003Cli>\u003Cp>NEOFYL®\u003Cbr>o &nbsp;“Instead of treating pain and injury with surgery and drugs, regenerative medicine supplements your body’s own healing system with natural growth factors, cytokines, collagens, and other proteins. This array of components helps cushion and support damaged tissue and joints while providing structure and ideal microenvironment conditions for rebuilding.”&nbsp;\u003C\u002Fp>\u003Cp>o &nbsp;“The umbilical cord contains a collagenous matrix that is rich in hyaluronic acid, growth factors, and other cytokines. These elements are reported to have anti-inflammatory, anti-bacterial, and anti-scarring properties, making umbilical cord tissue an attractive biomaterial for use in an outpatient clinic or surgical procedures.”\u003C\u002Fp>\u003C\u002Fli>\u003Cli>OROPRO®\u003Cbr>o &nbsp;“Regenerative medicine harnesses your body’s own ability to heal and boosts it in a very powerful and effective way.”\u003Cbr>o &nbsp;“Umbilical cord and Wharton’s jelly allografts demonstrate anti-inflammatory, anti-bacterial and anti-fibrotic properties that support repair of damaged tissue.”\u003C\u002Fli>\u003Cli>PROVISCUS®\u003Cbr>o &nbsp;“Instead of treating pain and injury with surgery and drugs, regenerative medicine supplements your body’s own healing system with natural growth factors, cytokines, collagens, and other proteins.”\u003C\u002Fli>\u003Cli>RHEO®\u003Cbr>o &nbsp;“RHEO® is a human perinatal tissue allograft derived from the extracellular matrix of the amniotic membrane. It is aseptically processed to preserve the endogenous cytokines, growth factors and scaffolding proteins present within the amniotic tissue matrix… By supplementing damaged tissue with these factors, you can stimulate the same scaffold creation naturally found in the body and allow the tissue to ‘self-heal’.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Therefore, your products are drugs as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(i).\u003C\u002Fp>\u003Cp>Your cellular products derived from human umbilical cord labeled as Product 401 (OROPRO®), Product 403 (PROVISCUS®), and Product 404 (NEOFYL®) as well as an amniotic membrane combined with amniotic fluid product labeled as RHEO® are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act and are subject to additional regulation, including applicable premarket review. Based on a review of relevant materials, Biostem Life Sciences does not qualify for any exception in 21 CFR 1271.15, and your products fail to meet all criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\u003Cp>For example, your cellular products derived from human umbilical cord labeled as Product 401 (OROPRO®), Product 403 (PROVISCUS®), and Product 404 (NEOFYL®) as well as an amniotic membrane combined with amniotic fluid product labeled as RHEO® fail to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because your processing alters the original relevant characteristics of the umbilical cord (of products OROPRO®, PROVISCUS® and NEOFYL®) and amniotic membrane (of RHEO®) related to their utility for reconstruction, repair, or replacement. The processing of the umbilical cord from the form of a conduit into an injectable form drastically alters the physical state of the HCT\u002FP. The umbilical cord is more than minimally manipulated because such processing alters the original relevant characteristics of the HCT\u002FP relating to its utility to serve as a conduit by effectively altering or eliminating its physical integrity and tubular form. The processing of the amniotic membrane from the form of a sheet into an injectable form drastically alters the physical state of the HCT\u002FP. The amniotic membrane is more than minimally manipulated because such processing alters the original relevant characteristics of the HCT\u002FP relating to its utility to serve as a barrier by effectively altering or eliminating its physical integrity, tensile strength, and elasticity.\u003C\u002Fp>\u003Cp>In addition, your products fail to meet the criterion that the HCT\u002FPs be “intended for homologous use only,” which means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended to perform “the same basic function or functions in the recipient as in the donor.” 21 CFR 1271.3(c) and 1271.10(a)(2). Your products are not intended solely to perform the same basic function or functions of the HCT\u002FP in the recipient as in the donor (e.g., serving as a conduit for umbilical cord or serving as a barrier for amniotic membrane). Rather, your products are intended for use in treating damaged tissues and joints, which are not basic functions of the umbilical cord and amniotic membrane in the donor.\u003C\u002Fp>\u003Cp>Therefore, these HCT\u002FPs are not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your products are regulated as drugs as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\u003C\u002Fp>\u003Cp>Subject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid biologics license application (BLA) must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your products are not the subject of an approved BLA.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>CGMP Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA’s inspection of your facility documented evidence of significant CGMP violations. At the conclusion of the inspection, FDA investigators issued a Form FDA-483, List of Inspectional Observations (Form FDA-483). FDA identified additional significant violations upon further review of the evidence collected during the inspection, as set forth below.\u003C\u002Fp>\u003Cp>The CGMP violations applicable to your products include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas to prevent contamination [21 CFR 211.42(c)(10)(iv)].\u003C\u002Fstrong> For example,\u003C\u002Fp>\u003Cp>a. Your firm has not performed routine (i.e., during every production batch) non-viable particulate monitoring and surface sampling of the critical area (i.e., \u003Cstrong>(b)(4)\u003C\u002Fstrong> where your products are exposed to the environment). The environmental monitoring frequencies described in SOP QCD-034 titled, “Environmental Controls and Monitoring Procedure” (Effective date: December 12, 2022) are not sufficient to detect potential environmental contamination risks and demonstrate control inside the critical manufacturing area during manufacturing.\u003C\u002Fp>\u003Cp>b. Your firm does not require microbiological monitoring of operators’ arm coverings used in the critical aseptic processing area for manually processing your products.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Your firm failed to establish an adequate system for cleaning and disinfecting the room and equipment to produce aseptic conditions [21 CFR 211.42(c)(10)(v)].\u003C\u002Fstrong> For example, your firm has failed to validate your procedure for cleaning and disinfecting the ISO 5 \u003Cstrong>(b)(4)\u003C\u002Fstrong> and supporting ISO 7 cleanroom where your products are manufactured. Validation of a cleaning process is needed to verify suitable cleaning and disinfecting agents are used to remove potential microbial contaminants from the critical manufacturing areas where your products are exposed during manufacturing.\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)].\u003C\u002Fstrong> For example, your firm has not adequately validated your manufacturing processes for your products with respect to identity, strength, quality, and purity. Your testing is limited to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. These are not sufficient measures of identity, strength, quality, and purity.\u003C\u002Fp>\u003Cp>Process validation studies determine whether an initial state of control has been established while routine monitoring of process performance and product attributes determines whether control is maintained. Establishment of appropriate attributes relating to identity, strength, quality, and purity of drug products is essential for assuring product quality over the product lifecycle.\u003C\u002Fp>\u003Cp>\u003Cstrong>4. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications designed to assure that drug products conform to appropriate standards of identity, strength, quality, and purity [21 CFR 211.160(b)].\u003C\u002Fstrong> The review of batch records and procedure QAD-040 titled “Product Release” (Effective date: September 5, 2023) indicate final product testing is limited to sterility testing and endotoxin testing as measurements of product attributes and such testing does not demonstrate, for example, the identity and\u002For strength of your products.\u003C\u002Fp>\u003Cp>\u003Cstrong>5. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates [21 CFR 211.166(a)].\u003C\u002Fstrong> For example, your firm assigned expiration dates between \u003Cstrong>(b)(4)\u003C\u002Fstrong> months to your products without adequate supporting data that conform to appropriate standards of identity, strength, quality, and purity. For example, your expiration summary reports for RHEO® is limited to \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterility testing only while Product 401 (OROPRO®) is limited to \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterility and endotoxin testing. Product 403 (PROVISCUS®) and Product 404 (NEOFYL®) are limited to Hyaluronic Acid concentration only. Appropriate standards of identity, strength, quality, and purity during intervals through the expiry period are needed to ensure product attributes remain for the shelf life of the product.\u003C\u002Fp>\u003Cp>\u003Cstrong>Responses to the Form FDA-483\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We acknowledge receipt of your correspondences dated September 29, 2023; October 13, 2023; October 27, 2023; November 10, 2023; November 28, 2023; December 8; 2023; December 22, 2023; January 5, 2024; January 9, 2024; February 29, 2024 and September 3, 2024 that provide a response to FDA’s inspectional observations and describe certain corrective actions. We have reviewed your responses and represented corrective actions and have found that they are inadequate. While you assert that your products were manufactured under section 361 of the PHS Act (and thus are not subject to cGMP regulations), the available evidence shows that your products do not meet the relevant criteria to be regulated solely under section 361 of the PHS Act. We acknowledge your commitment to submit a Pre-Request for Designation to FDA by February 29, 2024; however, this process remains incomplete, for you have not responded to the agency’s request for additional information. According to your correspondence, RHEO®, OROPRO®, and 403\u002F404 products have been removed from the market and shall no longer be manufactured by your firm. Your responses do not describe actions you have taken or plan to take to address the impact of the above-described CGMP deficiencies on your distributed products that carry a \u003Cstrong>(b)(4)\u003C\u002Fstrong>-month shelf life and remain within expiry.\u003C\u002Fp>\u003Cp>\u003Cstrong>Additional Concern\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In addition to the violations described above, we offer the following comment:\u003C\u002Fp>\u003Cul>\u003Cli>We note that the Instructions for Use for each of your products state, “This allograft is processed aseptically, but is not sterile.” If your products are not sterile, FDA has serious safety concerns regarding their use on patients via injection.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> FDA expects injectable products to be sterile, consistent with basic quality standards and to ensure patient safety.\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Be advised that, under 21 CFR 211.113(b), appropriate written procedures, designed to prevent microbiological contamination of drug products purporting to be sterile, shall be established and followed, including validation of aseptic and sterilization processes. Please address this issue in your response.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Neither this letter nor the observations noted on the Form FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with all applicable requirements in the FD&amp;C Act, PHS Act, and all applicable regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\u003Cp>Please submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Send your electronic response to CBERDCMRecommendations@fda.hhs.gov. If you have questions regarding this letter, contact the Division of Case Management, CBER at (240) 402-9156.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Melissa J. Mendoza\u003Cbr>Director\u003Cbr>Office of Compliance and Biologics Quality\u003Cbr>Center for Biologics Evaluation and Research\u003C\u002Fp>\u003Cp>________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Because your products fail to meet at least one criterion in 21 CFR 1271.10(a), this letter does not address whether this product meets other criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> The preparation instructions in the IFUs for your products state, “Apply the allograft using an 18g or larger needle. If applied topically, utilize aseptic technique and caution.” While intravenous or intrathecal application are contraindicated, injection is not contraindicated.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> See, e.g., USP&lt;1&gt; (“Parenteral articles are prepared scrupulously by methods designed to ensure that they meet Pharmacopeial requirements for sterility, pyrogens, particulate matter, and other contaminants, and, where appropriate, contain inhibitors of the growth of microorganisms.”).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nCBER 25-673788\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nJason V. Matuszewski\n\nRecipient Title\n\nChief Executive Officer\n\nBioStem Life Sciences\n\n2836 Center Port Circle\n\nPompano Beach, FL 33064\n\nUnited States\n\nquality@biostemtech.com\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research (CBER)\n\nUnited States\n\nWARNING LETTER\n\nJanuary 17, 2025\nCBER 25-673788\nDear Mr. Matuszewski:\nThe United States Food and Drug Administration (FDA) inspected your facility, located at the above address, between September 11, 2023, and September 15, 2023. During the inspection, FDA documented that your company manufactures cellular products derived from human umbilical cord, including those labeled as Product 401 (OROPRO®), Product 403 (PROVISCUS®), and Product 404 (NEOFYL®) as well as an amniotic membrane combined with amniotic fluid product labeled as RHEO® (collectively, “your products”).\nThis warning letter summarizes significant violations of current good manufacturing practice (CGMP) requirements, including violations of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 351(a)(2)(B), and 21 CFR parts 210 and 211. Because your methods, facilities, or controls for manufacturing, processing, packing, or holding drugs do not conform to CGMP, your products are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. § 351(a)(2)(B). Your adulteration of your products while held for sale after shipment in interstate commerce, or the causing thereof, is a prohibited act under section 301(k) of the FD&C Act, 21 U.S.C. § 331(k).\nBased on information and records reviewed by FDA, your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body. For example,\nNEOFYL®\no “Instead of treating pain and injury with surgery and drugs, regenerative medicine supplements your body’s own healing system with natural growth factors, cytokines, collagens, and other proteins. This array of components helps cushion and support damaged tissue and joints while providing structure and ideal microenvironment conditions for rebuilding.”\no “The umbilical cord contains a collagenous matrix that is rich in hyaluronic acid, growth factors, and other cytokines. These elements are reported to have anti-inflammatory, anti-bacterial, and anti-scarring properties, making umbilical cord tissue an attractive biomaterial for use in an outpatient clinic or surgical procedures.”\n\nOROPRO®\no “Regenerative medicine harnesses your body’s own ability to heal and boosts it in a very powerful and effective way.”\no “Umbilical cord and Wharton’s jelly allografts demonstrate anti-inflammatory, anti-bacterial and anti-fibrotic properties that support repair of damaged tissue.”\nPROVISCUS®\no “Instead of treating pain and injury with surgery and drugs, regenerative medicine supplements your body’s own healing system with natural growth factors, cytokines, collagens, and other proteins.”\nRHEO®\no “RHEO® is a human perinatal tissue allograft derived from the extracellular matrix of the amniotic membrane. It is aseptically processed to preserve the endogenous cytokines, growth factors and scaffolding proteins present within the amniotic tissue matrix… By supplementing damaged tissue with these factors, you can stimulate the same scaffold creation naturally found in the body and allow the tissue to ‘self-heal’.”\nTherefore, your products are drugs as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(i).\nYour cellular products derived from human umbilical cord labeled as Product 401 (OROPRO®), Product 403 (PROVISCUS®), and Product 404 (NEOFYL®) as well as an amniotic membrane combined with amniotic fluid product labeled as RHEO® are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act and are subject to additional regulation, including applicable premarket review. Based on a review of relevant materials, Biostem Life Sciences does not qualify for any exception in 21 CFR 1271.15, and your products fail to meet all criteria in 21 CFR 1271.10(a).\nFor example, your cellular products derived from human umbilical cord labeled as Product 401 (OROPRO®), Product 403 (PROVISCUS®), and Product 404 (NEOFYL®) as well as an amniotic membrane combined with amniotic fluid product labeled as RHEO® fail to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because your processing alters the original relevant characteristics of the umbilical cord (of products OROPRO®, PROVISCUS® and NEOFYL®) and amniotic membrane (of RHEO®) related to their utility for reconstruction, repair, or replacement. The processing of the umbilical cord from the form of a conduit into an injectable form drastically alters the physical state of the HCT\u002FP. The umbilical cord is more than minimally manipulated because such processing alters the original relevant characteristics of the HCT\u002FP relating to its utility to serve as a conduit by effectively altering or eliminating its physical integrity and tubular form. The processing of the amniotic membrane from the form of a sheet into an injectable form drastically alters the physical state of the HCT\u002FP. The amniotic membrane is more than minimally manipulated because such processing alters the original relevant characteristics of the HCT\u002FP relating to its utility to serve as a barrier by effectively altering or eliminating its physical integrity, tensile strength, and elasticity.\nIn addition, your products fail to meet the criterion that the HCT\u002FPs be “intended for homologous use only,” which means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended to perform “the same basic function or functions in the recipient as in the donor.” 21 CFR 1271.3(c) and 1271.10(a)(2). Your products are not intended solely to perform the same basic function or functions of the HCT\u002FP in the recipient as in the donor (e.g., serving as a conduit for umbilical cord or serving as a barrier for amniotic membrane). Rather, your products are intended for use in treating damaged tissues and joints, which are not basic functions of the umbilical cord and amniotic membrane in the donor.\nTherefore, these HCT\u002FPs are not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.1 See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your products are regulated as drugs as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\nSubject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid biologics license application (BLA) must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your products are not the subject of an approved BLA.\nCGMP Violations\nFDA’s inspection of your facility documented evidence of significant CGMP violations. At the conclusion of the inspection, FDA investigators issued a Form FDA-483, List of Inspectional Observations (Form FDA-483). FDA identified additional significant violations upon further review of the evidence collected during the inspection, as set forth below.\nThe CGMP violations applicable to your products include, but are not limited to, the following:\n1. Your firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas to prevent contamination [21 CFR 211.42(c)(10)(iv)]. For example,\na. Your firm has not performed routine (i.e., during every production batch) non-viable particulate monitoring and surface sampling of the critical area (i.e., (b)(4) where your products are exposed to the environment). The environmental monitoring frequencies described in SOP QCD-034 titled, “Environmental Controls and Monitoring Procedure” (Effective date: December 12, 2022) are not sufficient to detect potential environmental contamination risks and demonstrate control inside the critical manufacturing area during manufacturing.\nb. Your firm does not require microbiological monitoring of operators’ arm coverings used in the critical aseptic processing area for manually processing your products.\n2. Your firm failed to establish an adequate system for cleaning and disinfecting the room and equipment to produce aseptic conditions [21 CFR 211.42(c)(10)(v)]. For example, your firm has failed to validate your procedure for cleaning and disinfecting the ISO 5 (b)(4) and supporting ISO 7 cleanroom where your products are manufactured. Validation of a cleaning process is needed to verify suitable cleaning and disinfecting agents are used to remove potential microbial contaminants from the critical manufacturing areas where your products are exposed during manufacturing.\n3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)]. For example, your firm has not adequately validated your manufacturing processes for your products with respect to identity, strength, quality, and purity. Your testing is limited to (b)(4). These are not sufficient measures of identity, strength, quality, and purity.\nProcess validation studies determine whether an initial state of control has been established while routine monitoring of process performance and product attributes determines whether control is maintained. Establishment of appropriate attributes relating to identity, strength, quality, and purity of drug products is essential for assuring product quality over the product lifecycle.\n4. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications designed to assure that drug products conform to appropriate standards of identity, strength, quality, and purity [21 CFR 211.160(b)]. The review of batch records and procedure QAD-040 titled “Product Release” (Effective date: September 5, 2023) indicate final product testing is limited to sterility testing and endotoxin testing as measurements of product attributes and such testing does not demonstrate, for example, the identity and\u002For strength of your products.\n5. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates [21 CFR 211.166(a)]. For example, your firm assigned expiration dates between (b)(4) months to your products without adequate supporting data that conform to appropriate standards of identity, strength, quality, and purity. For example, your expiration summary reports for RHEO® is limited to (b)(4) sterility testing only while Product 401 (OROPRO®) is limited to (b)(4) sterility and endotoxin testing. Product 403 (PROVISCUS®) and Product 404 (NEOFYL®) are limited to Hyaluronic Acid concentration only. Appropriate standards of identity, strength, quality, and purity during intervals through the expiry period are needed to ensure product attributes remain for the shelf life of the product.\nResponses to the Form FDA-483\nWe acknowledge receipt of your correspondences dated September 29, 2023; October 13, 2023; October 27, 2023; November 10, 2023; November 28, 2023; December 8; 2023; December 22, 2023; January 5, 2024; January 9, 2024; February 29, 2024 and September 3, 2024 that provide a response to FDA’s inspectional observations and describe certain corrective actions. We have reviewed your responses and represented corrective actions and have found that they are inadequate. While you assert that your products were manufactured under section 361 of the PHS Act (and thus are not subject to cGMP regulations), the available evidence shows that your products do not meet the relevant criteria to be regulated solely under section 361 of the PHS Act. We acknowledge your commitment to submit a Pre-Request for Designation to FDA by February 29, 2024; however, this process remains incomplete, for you have not responded to the agency’s request for additional information. According to your correspondence, RHEO®, OROPRO®, and 403\u002F404 products have been removed from the market and shall no longer be manufactured by your firm. Your responses do not describe actions you have taken or plan to take to address the impact of the above-described CGMP deficiencies on your distributed products that carry a (b)(4)-month shelf life and remain within expiry.\nAdditional Concern\nIn addition to the violations described above, we offer the following comment:\nWe note that the Instructions for Use for each of your products state, “This allograft is processed aseptically, but is not sterile.” If your products are not sterile, FDA has serious safety concerns regarding their use on patients via injection.2 FDA expects injectable products to be sterile, consistent with basic quality standards and to ensure patient safety.3 Be advised that, under 21 CFR 211.113(b), appropriate written procedures, designed to prevent microbiological contamination of drug products purporting to be sterile, shall be established and followed, including validation of aseptic and sterilization processes. Please address this issue in your response.\nConclusion\nNeither this letter nor the observations noted on the Form FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with all applicable requirements in the FD&C Act, PHS Act, and all applicable regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice including, without limitation, seizure and\u002For injunction.\nPlease submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\nSend your electronic response to CBERDCMRecommendations@fda.hhs.gov. If you have questions regarding this letter, contact the Division of Case Management, CBER at (240) 402-9156.\nSincerely,\n\u002FS\u002F\nMelissa J. Mendoza\nDirector\nOffice of Compliance and Biologics Quality\nCenter for Biologics Evaluation and Research\n________________________\n1 Because your products fail to meet at least one criterion in 21 CFR 1271.10(a), this letter does not address whether this product meets other criteria in 21 CFR 1271.10(a).\n2 The preparation instructions in the IFUs for your products state, “Apply the allograft using an 18g or larger needle. If applied topically, utilize aseptic technique and caution.” While intravenous or intrathecal application are contraindicated, injection is not contraindicated.\n3 See, e.g., USP\u003C1> (“Parenteral articles are prepared scrupulously by methods designed to ensure that they meet Pharmacopeial requirements for sterility, pyrogens, particulate matter, and other contaminants, and, where appropriate, contain inhibitors of the growth of microorganisms.”).","BioStem Life Sciences","biostem-life-sciences-673788-01172025","2026-08-18T06:42:28.856152+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbiostem-life-sciences-673788-01172025","2026-10-26T08:08:05.524573+00:00","Warning Letter","Issued","2025-02-04","673788","Biologics","Jason V. Matuszewski","2026-08-19T17:02:42.585+00:00","VIA UPS and Electronic Mail","CBER 25-673788","2025-01-17",{"id":34,"raw":35,"subject":41,"body_html":42,"body_text":43,"firm_name":44,"letter_id":45,"created_at":46,"fei_number":20,"letter_url":47,"updated_at":48,"action_type":23,"case_status":24,"posted_date":49,"marcs_cms_no":50,"product_type":51,"closeout_date":20,"issuing_office":39,"recipient_name":52,"body_fetched_at":53,"delivery_method":54,"recipient_title":20,"reference_number":20,"action_taken_date":55,"medical_device_id":20,"response_letter_date":20},1787,[36,37,38,39,40,13,13,13],"\u003Ctime datetime=\"2023-10-24T13:20:00Z\">10\u002F24\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-10-04T04:00:00Z\">10\u002F04\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fembryll-life-sciences-inc-668858-10042023\">Embryll Life Sciences, Inc.\u003C\u002Fa>","Center for Veterinary Medicine","Unapproved New Animal Drug\u002FAdulterated\u003Cbr \u002F>\r\n","Unapproved New Animal Drug\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Animal &amp; Veterinary\u003Cbr>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Diana Rodriguez\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CCO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Embryll Life Sciences, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>651 N Broad St, Suite 206\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Middletown\u003C\u002Fspan>, \u003Cspan>DE\u003C\u002Fspan> \u003Cspan>19709\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:support@embryll.com\"> support@embryll.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Veterinary Medicine\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nOctober 04, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Re: 668858\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Diana Rodriguez:\u003C\u002Fp>\n\n\u003Cp>This letter concerns your firm’s marketing of an unapproved new animal drug product, Lanomax®, for the treatment of cataracts in animals. The United States Food and Drug Administration (FDA) has reviewed your website at the internet address https:\u002F\u002Fwww.lanomax.com in August and September 2023 and has determined that you promote and offer this product for sale there.\u003C\u002Fp>\n\n\u003Cp>Based on our review of your website at the internet address https:\u002F\u002Fwww.lanomax.com, your Lanomax® product is a drug under section 201(g)(1) of the Federal Food Drug and Cosmetic Act (FD&amp;C Act) [21 U.S.C. 321(g)(1)], because this product is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals and\u002For intended to affect the structure or any function of the body of an animal. This product is an unapproved new animal drug and introducing or delivering this product for introduction into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\n\n\u003Cp>Currently there are no FDA-approved eye drops for use in animals that are labeled for treating, preventing, mitigating, or curing cataracts. Your product, which claims to treat this condition, has not been determined by FDA to be safe and effective. Your unproven treatment could cause animal owners to forgo or delay appropriate veterinary care.\u003C\u002Fp>\n\n\u003Cp>You can find the FD&amp;C Act and FDA regulations through links on FDA’s homepage at www.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Examples of claims FDA observed on your website and product labeling that show the intended use of your Lanomax® product include, but are not limited to the following:\u003C\u002Fp>\n\n\u003Cp>From your home website titled “\u003Cstrong>LANOMAX\u003C\u002Fstrong>®” at the URL https:\u002F\u002Fwww.lanomax.com\u002F:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Lanomax® is the only eye drop on the planet currently that has a real therapeutic effect on cataracts.”\u003C\u002Fli>\n\t\u003Cli>“…in the case of incipient, immature, and mature cataracts, if you administer two vials of Lanomax® eye drops to one eye for six weeks, you will see visible improvements compared to the untreated eye.”\u003C\u002Fli>\n\t\u003Cli>“…there are dramatic cases where a visible effect is even noticed within a short period of 1-2 weeks after beginning to administer Lanomax®.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>From your webpage titled “\u003Cstrong>LANOMAX\u003C\u002Fstrong>®” at the URL https:\u002F\u002Fwww.lanomax.com\u002Fretail\u002Findex.php\u002Flanomax.html:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Lanomax® can cure cataracts in the form of eye drops alone…”\u003C\u002Fli>\n\t\u003Cli>“Lanomax® uses ThruDelivery®, an innovative drug delivery system built using the latest advanced nanotechnology…It is because of this ThruDelivery® system that Lanomax® is the only eye drop on the planet to show a real therapeutic effect on cataracts.”\u003C\u002Fli>\n\t\u003Cli>“Currently, this amazing lanosterol delivery system is only found in Lanomax® eye drops.”\u003C\u002Fli>\n\t\u003Cli>“Lanomax® has an excellent therapeutic effect on incipient, immature, and mature cataracts.”\u003C\u002Fli>\n\t\u003Cli>“The therapeutic effect of Lanomax® varies greatly depending on the type of cataract and the degree of its progression.”\u003C\u002Fli>\n\t\u003Cli>“Sometimes there are dramatic cases where a visible effect can even be noticed within a short period of 1-2 weeks beginning to administer Lanomax®.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>From your webpage titled “\u003Cstrong>FAQ\u003C\u002Fstrong>” at the URL https:\u002F\u002Fwww.lanomax.com\u002Fretail\u002Findex.php\u002Ffaq.html:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Can Lanomax® be used for animals such as birds, minks or horses? Lanomax® can be used for cataracts that occur in all kinds of animals.”\u003C\u002Fli>\n\t\u003Cli>“Can I use Lanomax® for animals with diabetes? Lanomax® is safe for use on animals with age-related diseases, including diabetes.”\u003C\u002Fli>\n\t\u003Cli>“Can Lanomax® be used on animals with glaucoma? Does it increase the intraocular pressure? Lanomax® is safe for use on animals with glaucoma; it will not affect the intraocular pressure.”\u003C\u002Fli>\n\t\u003Cli>“Do I need a prescription and veterinarian involved to use Lanomax®? No, Lanomax® does not require consulting a veterinarian or getting a prescription.”\u003C\u002Fli>\n\t\u003Cli>“During the use of Lanomax®, the cataracts split into multiple fragments. What causes this? It is a desirable phenomenon to see the protein aggregation (the cause of cataract) is dissolving. This is nothing to be alarmed about and you should continue the treatment.”\u003C\u002Fli>\n\t\u003Cli>“Must I continue to use Lanomax® after the cataracts are completely cured? … you may want to continue to use a low dose of Lanomax® as a preventative measure against the recurrence of cataracts.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On your webpage titled “\u003Cstrong>Reviews\u003C\u002Fstrong>” at the URL https:\u002F\u002Fwww.lanomax.com\u002Fretail\u002Findex.php\u002Freviews.html:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\"…I found out about Lanomax…the progression has stopped and his eyes have remained stable every [sic] since…”\u003C\u002Fli>\n\t\u003Cli>\"…was completely blind due to diabetic cataracts. Thanks to Lanomax, his cataracts are dissolving and he can see again…”\u003C\u002Fli>\n\t\u003Cli>\"…I'm writing to tell you your lanomax eye drops helped my dogs [sic] vision immensely…”\u003C\u002Fli>\n\t\u003Cli>\"Just want you to know that Lanomax is helping…He can see something out of his cataract eye [sic] that is not hyper mature.”\u003C\u002Fli>\n\t\u003Cli>\"…has severe cataract on his left eye. We have applied Lanomax on both eyes…We think Lanomax is also helping the right eye from developing cataract.\"\u003C\u002Fli>\n\t\u003Cli>\"Lanomax works well and my dog's vision has improved…”\u003C\u002Fli>\n\t\u003Cli>\"To all who have cataract animals!! This product truly works…”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>This product is a new animal drug under section 201(v) of the FD&amp;C Act, [21 U.S.C. 321(v)], because it is not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling. To be legally marketed, a new animal drug must have an approved new animal drug application, conditionally approved new animal drug application, or index listing under sections 512, 571, and 572 of the FD&amp;C Act [21 U.S.C. § 360b, 360ccc, and 360ccc-1]. This product is not approved or index listed by FDA, and therefore, the product is unsafe within the meaning of section 512(a) of the FD&amp;C Act, [21 U.S.C. § 360b(a)], and adulterated under section 501(a)(5) of the FD&amp;C Act [21 U.S.C. § 351(a)(5)]. The introduction or delivery for introduction into interstate commerce of an adulterated drug is prohibited under section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all the requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to address this matter may lead to legal action without further notice, including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\n\n\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your product is not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Please direct your response to U.S. Food and Drug Administration, Center for Veterinary Medicine, Office of Surveillance and Compliance, Division of Drug Compliance by email to CVMUnapprovedDrugs@fda.hhs.gov. Please include “CMS Case 668858” in the subject line of\u003Cbr>\nyour email.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Neal Bataller, ME, DVM\u003Cbr>\nDirector\u003Cbr>\nDivision of Drug Compliance\u003Cbr>\nOffice of Surveillance and Compliance\u003Cbr>\nCenter for Veterinary Medicine\u003C\u002Fp>\n\n\u003Cp>Cc: media@embryll.com\u003Cbr>\nsupport@lanomax.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nAnimal & Veterinary\nDrugs\n\nRecipient:\n\nRecipient Name\n\nDiana Rodriguez\n\nRecipient Title\n\nCCO\n\nEmbryll Life Sciences, Inc.\n\n651 N Broad St, Suite 206\n\nMiddletown, DE 19709\n\nUnited States\n\nsupport@embryll.com\n\nIssuing Office:\n\nCenter for Veterinary Medicine\n\nUnited States\n\nWARNING LETTER\n\nOctober 04, 2023\n\nRe: 668858\n\nDear Diana Rodriguez:\n\nThis letter concerns your firm’s marketing of an unapproved new animal drug product, Lanomax®, for the treatment of cataracts in animals. The United States Food and Drug Administration (FDA) has reviewed your website at the internet address https:\u002F\u002Fwww.lanomax.com in August and September 2023 and has determined that you promote and offer this product for sale there.\n\nBased on our review of your website at the internet address https:\u002F\u002Fwww.lanomax.com, your Lanomax® product is a drug under section 201(g)(1) of the Federal Food Drug and Cosmetic Act (FD&C Act) [21 U.S.C. 321(g)(1)], because this product is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals and\u002For intended to affect the structure or any function of the body of an animal. This product is an unapproved new animal drug and introducing or delivering this product for introduction into interstate commerce is prohibited under section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].\n\nCurrently there are no FDA-approved eye drops for use in animals that are labeled for treating, preventing, mitigating, or curing cataracts. Your product, which claims to treat this condition, has not been determined by FDA to be safe and effective. Your unproven treatment could cause animal owners to forgo or delay appropriate veterinary care.\n\nYou can find the FD&C Act and FDA regulations through links on FDA’s homepage at www.fda.gov.\n\nExamples of claims FDA observed on your website and product labeling that show the intended use of your Lanomax® product include, but are not limited to the following:\n\nFrom your home website titled “LANOMAX®” at the URL https:\u002F\u002Fwww.lanomax.com\u002F:\n\n“Lanomax® is the only eye drop on the planet currently that has a real therapeutic effect on cataracts.”\n\n“…in the case of incipient, immature, and mature cataracts, if you administer two vials of Lanomax® eye drops to one eye for six weeks, you will see visible improvements compared to the untreated eye.”\n\n“…there are dramatic cases where a visible effect is even noticed within a short period of 1-2 weeks after beginning to administer Lanomax®.”\n\nFrom your webpage titled “LANOMAX®” at the URL https:\u002F\u002Fwww.lanomax.com\u002Fretail\u002Findex.php\u002Flanomax.html:\n\n“Lanomax® can cure cataracts in the form of eye drops alone…”\n\n“Lanomax® uses ThruDelivery®, an innovative drug delivery system built using the latest advanced nanotechnology…It is because of this ThruDelivery® system that Lanomax® is the only eye drop on the planet to show a real therapeutic effect on cataracts.”\n\n“Currently, this amazing lanosterol delivery system is only found in Lanomax® eye drops.”\n\n“Lanomax® has an excellent therapeutic effect on incipient, immature, and mature cataracts.”\n\n“The therapeutic effect of Lanomax® varies greatly depending on the type of cataract and the degree of its progression.”\n\n“Sometimes there are dramatic cases where a visible effect can even be noticed within a short period of 1-2 weeks beginning to administer Lanomax®.”\n\nFrom your webpage titled “FAQ” at the URL https:\u002F\u002Fwww.lanomax.com\u002Fretail\u002Findex.php\u002Ffaq.html:\n\n“Can Lanomax® be used for animals such as birds, minks or horses? Lanomax® can be used for cataracts that occur in all kinds of animals.”\n\n“Can I use Lanomax® for animals with diabetes? Lanomax® is safe for use on animals with age-related diseases, including diabetes.”\n\n“Can Lanomax® be used on animals with glaucoma? Does it increase the intraocular pressure? Lanomax® is safe for use on animals with glaucoma; it will not affect the intraocular pressure.”\n\n“Do I need a prescription and veterinarian involved to use Lanomax®? No, Lanomax® does not require consulting a veterinarian or getting a prescription.”\n\n“During the use of Lanomax®, the cataracts split into multiple fragments. What causes this? It is a desirable phenomenon to see the protein aggregation (the cause of cataract) is dissolving. This is nothing to be alarmed about and you should continue the treatment.”\n\n“Must I continue to use Lanomax® after the cataracts are completely cured? … you may want to continue to use a low dose of Lanomax® as a preventative measure against the recurrence of cataracts.”\n\nOn your webpage titled “Reviews” at the URL https:\u002F\u002Fwww.lanomax.com\u002Fretail\u002Findex.php\u002Freviews.html:\n\n\"…I found out about Lanomax…the progression has stopped and his eyes have remained stable every [sic] since…”\n\n\"…was completely blind due to diabetic cataracts. Thanks to Lanomax, his cataracts are dissolving and he can see again…”\n\n\"…I'm writing to tell you your lanomax eye drops helped my dogs [sic] vision immensely…”\n\n\"Just want you to know that Lanomax is helping…He can see something out of his cataract eye [sic] that is not hyper mature.”\n\n\"…has severe cataract on his left eye. We have applied Lanomax on both eyes…We think Lanomax is also helping the right eye from developing cataract.\"\n\n\"Lanomax works well and my dog's vision has improved…”\n\n\"To all who have cataract animals!! This product truly works…”\n\nThis product is a new animal drug under section 201(v) of the FD&C Act, [21 U.S.C. 321(v)], because it is not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling. To be legally marketed, a new animal drug must have an approved new animal drug application, conditionally approved new animal drug application, or index listing under sections 512, 571, and 572 of the FD&C Act [21 U.S.C. § 360b, 360ccc, and 360ccc-1]. This product is not approved or index listed by FDA, and therefore, the product is unsafe within the meaning of section 512(a) of the FD&C Act, [21 U.S.C. § 360b(a)], and adulterated under section 501(a)(5) of the FD&C Act [21 U.S.C. § 351(a)(5)]. The introduction or delivery for introduction into interstate commerce of an adulterated drug is prohibited under section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].\n\nConclusion\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all the requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to address this matter may lead to legal action without further notice, including, without limitation, seizure and\u002For injunction.\n\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your product is not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nPlease direct your response to U.S. Food and Drug Administration, Center for Veterinary Medicine, Office of Surveillance and Compliance, Division of Drug Compliance by email to CVMUnapprovedDrugs@fda.hhs.gov. Please include “CMS Case 668858” in the subject line of\n\nyour email.\n\nSincerely,\n\n\u002FS\u002F\n\nNeal Bataller, ME, DVM\n\nDirector\n\nDivision of Drug Compliance\n\nOffice of Surveillance and Compliance\n\nCenter for Veterinary Medicine\n\nCc: media@embryll.com\n\nsupport@lanomax.com","Embryll Life Sciences, Inc.","embryll-life-sciences-inc-668858-10042023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fembryll-life-sciences-inc-668858-10042023","2026-10-26T08:08:34.981632+00:00","2023-10-24","668858","Animal & VeterinaryDrugs","Diana Rodriguez","2026-08-20T00:34:53.678+00:00","Via Email","2023-10-04",{"id":57,"raw":58,"subject":63,"body_html":64,"body_text":65,"firm_name":66,"letter_id":67,"created_at":68,"fei_number":20,"letter_url":69,"updated_at":70,"action_type":23,"case_status":24,"posted_date":71,"marcs_cms_no":72,"product_type":73,"closeout_date":20,"issuing_office":62,"recipient_name":74,"body_fetched_at":75,"delivery_method":76,"recipient_title":20,"reference_number":77,"action_taken_date":78,"medical_device_id":20,"response_letter_date":20},21634,[59,60,61,62,63,13,13,13],"\u003Ctime datetime=\"2026-09-01T04:00:00Z\">09\u002F01\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-08-18T04:00:00Z\">08\u002F18\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Freliance-life-sciences-private-limited-730801-08182026\">Reliance Life Sciences Private Limited\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-117\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Santhosh Mathai\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Business Head-Pharmaceuticals\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Reliance Life Sciences Private Limited\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Dhirubhai Ambani Life Sciences Centre\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>R-282 Ttc Area of MIDC, Thane Belapur Road, Rabale\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Navi Mumbai\u003C\u002Fspan> \u003Cspan>400701\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Maharashtra\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>India\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)\"> (b)(6)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>August 18, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>Reference number: 320-26-117\u003C\u002Fp>\u003Cp>To Mr. Santhosh Mathai:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) inspection of your facility. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory action without further notice.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Inspection\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Violations were observed and documented during an inspection of your drug manufacturing facility, Reliance Life Sciences Private Limited, FDA Establishment Identifier (FEI) 3009510975, at Dhirubhai Ambani Life Sciences Centre, R-282 Ttc Area Of MIDC, Thane Belapur Road, Rabale, Navi Mumbai, Maharashtra, 400701 India, from February 19 to February 27, 2026. This inspection was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your March 20, 2026, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The following are violations identified during our inspection. As a reminder, this is not an all-inclusive list of violations at your facility.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>Inaccurate Microbiology Laboratory Records\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You failed to accurately document microbiology testing results. Specifically, multiple environmental monitoring and \u003Cstrong>(b)(4)\u003C\u002Fstrong> samples were documented in logbooks as collected and incubated; however, the corresponding plates could not be located in incubators during the inspection. Colony forming unit (cfus) counts had been recorded as if incubation was actively in progress. In interviews conducted by your management, your analysts confirmed these samples were not collected.\u003C\u002Fp>\u003Cp>In addition, your Laboratory Information Management System (LIMS) did not include a dilution factor to calculate the number of cfus per gram or milliliter of product for microbial limit test results, as required by your own procedures and applicable compendial methods. By releasing drug products based solely on raw plate count averages entered into your LIMS without applying the required dilution factor, you lack scientific evidence that each batch conforms to predetermined specifications prior to distribution. Appropriate testing is an essential part of ensuring that the drug products you manufacture conform to CGMP.\u003C\u002Fp>\u003Cp>Collectively, these deficiencies indicate a significant risk of systematic underreporting of microbial findings, which directly undermines your firm's ability to ensure the safety and quality of drug products distributed to patients.\u003C\u002Fp>\u003Cp>Reliability of data is fundamentally compromised when there is a failure to record data or to maintain complete and accurate records of test results. Furthermore, the lack of reliable data compromises the ability of your quality unit (QU) to exercise its function of ensuring compliance to applicable standards and deprives you of the ability to adequately investigate deviations.\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Electronic Records Controls\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your firm did not have adequate controls to prevent the deletion or overwriting of \u003Cstrong>(b)(4)\u003C\u002Fstrong> integrity testing electronic data. Specifically, reports were not saved with unique file names, resulting in data being overwritten after every \u003Cstrong>(b)(4)\u003C\u002Fstrong> tests. In addition, \u003Cstrong>(b)(4)\u003C\u002Fstrong> integrity testing was not performed for Plant \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Therefore, your firm has no means of tracking or retrieving records of failed leak tests. The lack of adequate electronic records controls undermines the reliability and integrity of your laboratory data.\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong> integrity is critical to preventing product contamination. Routine \u003Cstrong>(b)(4)\u003C\u002Fstrong> integrity tests should be performed. The monitoring and maintenance program should identify and eliminate any \u003Cstrong>(b)(4)\u003C\u002Fstrong> lacking integrity and minimize the possibility of placing a sterile product at risk.\u003C\u002Fp>\u003Cp>All data must be complete, accurate and retained to enable appropriate assessment and decisions by the QU. The lack of control over the integrity of your data raises questions about the authenticity and reliability of your analytical data and the quality of your drug products.\u003C\u002Fp>\u003Cp>Your response states “the unaccounted samples may have been misplaced”. This explanation is contradictory as it does not address the fact that your own analysts confirmed during management interviews that the microbiological samples were never collected, nor does it address the broader pattern of inaccurate recordkeeping identified during the inspection. Your response indicates your commitment to hiring third parties to conduct a data integrity remediation plan, risk assessment, and product impact assessment. Your response is inadequate. You do not provide sufficient detail including specific timelines and deliverables on your data integrity remediation plan, risk assessment and product assessment. Furthermore, your response does not define the scope of third-party oversight responsibilities or establish accountability measures for the remediation effort.\u003C\u002Fp>\u003Cp>Additionally, you acknowledge deficiencies in your “\u003Cstrong>(b)(4)\u003C\u002Fstrong> integrity testing controls” and conducted a retrospective review. Your response is inadequate because although you conclude there is, “no evidence of product contamination attributable to \u003Cstrong>(b)(4)\u003C\u002Fstrong> failure”, the thoroughness of this review cannot fully support a definitive risk-based conclusion since you acknowledge that “historical traceability was incomplete”.\u003C\u002Fp>\u003Cp>We acknowledge your firm’s long-term commitment to improving your manufacturing operation, including, but not limited to, hiring additional microbiological laboratory staff and building a larger microbiological laboratory.\u003C\u002Fp>\u003Cp>Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document \u003Cem>Data Integrity and Compliance With Drug CGMP: Questions and\u003C\u002Fem> \u003Cem>Answers\u003C\u002Fem> for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\u003C\u002Fp>\u003Cp>We acknowledge that you are using independent third-party consultants to audit your operation and assist in meeting FDA requirements. In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive investigation into the extent of the inaccuracies in data records and reporting. Your investigation should include:\u003Cbr>o A detailed investigation protocol and methodology; a summary of all laboratories, manufacturing operations, and systems to be covered by the assessment; and a justification for any part of your operation that you propose to exclude.\u003Cbr>o Interviews of current and former employees to identify the nature, scope, and root cause of data inaccuracies. We recommend that these interviews be conducted by a qualified third party.\u003Cbr>o An assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered data integrity lapses.\u003Cbr>o A comprehensive retrospective evaluation of the nature of the testing data integrity deficiencies. We recommend that a qualified third party with specific expertise in the area where potential breaches were identified should evaluate all data integrity lapses.\u003C\u002Fli>\u003Cli>A retrospective review of all microbial limit test results to include the proper dilution factor to calculate the number of cfus per gram or milliliter of product for products currently in the U.S. market and within expiry as of the date of this letter and a report summarizing the findings of the analysis. Your action plan to address any product quality or patient safety risks for your drug products in U.S. distribution, including potential customer notifications and recalls.\u003C\u002Fli>\u003Cli>A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\u003C\u002Fli>\u003Cli>A management strategy for your firm that includes the details of your global corrective action and preventive action (CAPA) plan. Your strategy should include:\u003Cbr>o A detailed corrective action plan that describes how you intend to ensure the reliability and completeness of all the data you generate including analytical data, manufacturing records, and all data submitted to FDA.\u003Cbr>o A comprehensive description of the root causes of your data integrity lapses including evidence that the scope and depth of the current action plan is commensurate with the findings of the investigation and risk assessment. Indicate whether individuals responsible for data integrity lapses remain able to influence CGMP-related or drug application data at your firm.\u003Cbr>o Interim measures describing the actions you have taken or will take to protect patients and to ensure the quality of your drugs, such as notifying your customers, recalling product, conducting additional testing, adding lots to your stability programs to assure stability, drug application actions, and enhanced complaint monitoring.\u003Cbr>o Long-term measures describing any remediation efforts and enhancements to procedures, processes, methods, controls, systems, management oversight, and human resources (e.g., training, staffing improvements) designed to ensure the integrity of your company’s data.\u003Cbr>o A commitment to have a qualified consultant conduct extensive annual audits, for at least two years, to assist in evaluating CAPA effectiveness after you have executed your data integrity remediation protocol.\u003Cbr>o An indication of whether you plan to hire a data integrity officer who is fully empowered to receive anonymous complaints from employees reporting data integrity concerns and with the authority to ensure any potential breach is promptly investigated (by independent quality assurance function, along with expertise from outside entities whenever needed).\u003Cbr>o A status report for any of the above activities already underway or completed.\u003C\u002Fli>\u003Cli>A comprehensive assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous (ALCOA) records throughout your operation.\u003C\u002Fli>\u003Cli>A comprehensive independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\u003Cli>An action plan and timelines for conducting full microbiological testing of reserve samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment of the design and control of your firm’s manufacturing operations, with a detailed and thorough review of all microbiological hazards.\u003C\u002Fli>\u003Cli>A detailed risk assessment addressing the hazards posed by distributing drug products with potentially objectionable contamination. Specify actions you will take in response to the risk assessment, such as customer notifications and product recalls.\u003C\u002Fli>\u003Cli>Complete investigations into all batches with potential objectionable microbial contamination. The investigations should detail your findings regarding the root causes of the contamination.\u003C\u002Fli>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to, the following:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>Poor Aseptic Practices\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Our inspection identified aseptic processing design deficiencies that pose significant hazards to drug product sterility. During a mock filling operation and during review of your unidirectional smoke studies, our investigators observed multiple instances of inappropriate aseptic behavior in which operators blocked unidirectional airflow at critical locations without implementing appropriate corrective measures, including discarding potentially compromised vials. Specific examples include:\u003C\u002Fp>\u003Cul>\u003Cli>Blocking airflow over the stopper bowl and \u003Cstrong>(b)(4)\u003C\u002Fstrong> vials while refilling the stopper bowl\u003C\u002Fli>\u003Cli>Passing forceps over the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and removing fallen vials from the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> over \u003Cstrong>(b)(4)\u003C\u002Fstrong> vials\u003C\u002Fli>\u003Cli>Blocking airflow during \u003Cstrong>(b)(4)\u003C\u002Fstrong> transfer operations, including \u003Cstrong>(b)(4)\u003C\u002Fstrong> repositioning of filled vials onto a \u003Cstrong>(b)(4)\u003C\u002Fstrong> and mechanical displacement of \u003Cstrong>(b)(4)\u003C\u002Fstrong> vials into the \u003Cstrong>(b)(4)\u003C\u002Fstrong> via forceps\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Any compromise of first-air protection exposes sterile drug products to potential microbiological contamination.\u003C\u002Fp>\u003Cp>\u003Cem>Cleaning, Decontamination, and Maintenance\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You failed to adequately clean, decontaminate, and maintain your \u003Cstrong>(b)(4)\u003C\u002Fstrong> used for aseptic drug product manufacturing. For example, our investigator observed multiple instances of deterioration and damage inside the \u003Cstrong>(b)(4)\u003C\u002Fstrong> used for manufacturing sterile drug products. These instances of deterioration and damage were not adequately addressed through your cleaning, decontamination, and maintenance programs. For example, our investigator observed:\u003C\u002Fp>\u003Cul>\u003Cli>Deteriorated \u003Cstrong>(b)(4)\u003C\u002Fstrong> used to support the \u003Cstrong>(b)(4)\u003C\u002Fstrong> tank\u003C\u002Fli>\u003Cli>Excess sealant adjacent to the HEPA filters in the filling and \u003Cstrong>(b)(4)\u003C\u002Fstrong> areas\u003C\u002Fli>\u003Cli>Use of nonsterile wipes soaked in \u003Cstrong>(b)(4)\u003C\u002Fstrong> to clean \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In addition, our investigator observed accumulation of standing water and unknown \u003Cstrong>(b)(4)\u003C\u002Fstrong> staining on the wall surface adjacent to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> pipelines, located outside the \u003Cstrong>(b)(4)\u003C\u002Fstrong> room within the HVAC area.\u003C\u002Fp>\u003Cp>All equipment and associated operational areas should follow a reliable, comprehensive preventive maintenance program. This program should be designed to ensure sustained operational integrity through the systematic implementation of validated cleaning and disinfection protocols, as well as the proactive replacement of components before they deteriorate or degrade. Maintenance and change management procedures should prevent practices that may compromise equipment or introduce contamination risks.\u003C\u002Fp>\u003Cp>Aseptic processes need to be designed to minimize exposure of sterile articles to potential contamination hazards. A suitable monitoring system is critical to maintain appropriate environmental conditions throughout your \u003Cstrong>(b)(4)\u003C\u002Fstrong> and cleanrooms. Prompt detection of an emerging problem is essential to preventing contamination of your aseptic production operations.\u003C\u002Fp>\u003Cp>Your response states existing procedures \"did not adequately define acceptable hand positioning, intervention speed, first-air protection requirements, rejection criteria for potentially affected exposed units, or required actions following airflow interruption\" and acknowledges “equipment design and ergonomic limitations within the \u003Cstrong>(b)(4)\u003C\u002Fstrong>”. Additionally, you state you will not resume operations until “successful aseptic process simulation run incorporating all listed interventions under worst-case conditions are completed”. Furthermore, you commit to updating procedures for \u003Cstrong>(b)(4)\u003C\u002Fstrong> sanitization and cleaning to include sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> and sterile wipes. Your response also states that remediations were made to equipment, including repairing all sealant joints in the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, smoothing internal machine surfaces to meet cleanability requirements, and updating maintenance checklists to include criteria for wear, damage, smoothness, cleanability, and material suitability.\u003C\u002Fp>\u003Cp>Your response is inadequate. You do not provide sufficient detail including deliverables on your third-party risk assessment of all aseptic filling lines. Additionally, your response does not sufficiently address the lack of oversight of operator aseptic behavior, equipment cleaning and maintenance, various manual activities, and intervention ergonomics.\u003C\u002Fp>\u003Cp>See FDA’s guidance document \u003Cem>Sterile Drug Products Produced by Aseptic Processing - Current Good Manufacturing Practice\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\u003C\u002Fp>\u003Cp>In your response to this letter, provide the following:\u003C\u002Fp>\u003Cul>\u003Cli>Your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should incorporate oversight from a qualified independent consultant and ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\u003C\u002Fli>\u003Cli>A CAPA plan, based on the retrospective assessment of your cleaning and disinfection program, that includes appropriate remediations to your cleaning and disinfection processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning and disinfection. Describe improvements to your cleaning and disinfection program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning and disinfection execution for all products and equipment; and all other needed remediations.\u003C\u002Fli>\u003Cli>A comprehensive, independent risk assessment by a qualified consultant of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including, but not limited to, the following:\u003Cbr>o All human interactions within the ISO 5 area (e.g., risk reduction or elimination of manual interventions wherever possible).\u003Cbr>o Equipment suitability (e.g., reliability, capability, ergonomics, placement) and sufficient cleanroom space.\u003Cbr>o Personnel Flow and Material Flow (movement throughout all rooms used to conduct and support sterile operations, and all material transfers).\u003Cbr>o Specific CAPA recommendations that will comprehensively address the design and control hazards identified in the risk assessment.\u003C\u002Fli>\u003Cli>A detailed remediation plan from the independent consultant with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control at your facility and explain how this CAPA plan will robustly remediate your deficient sterile manufacturing operations. Include comprehensive changes to the design of both your aseptic processing lines and cleanrooms, the specific barrier system to be used (e.g., Restricted Access Barrier, \u003Cstrong>(b)(4)\u003C\u002Fstrong>), and associated timelines. Also, describe your plans for qualification and validation of your extensively remediated operations.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Ineffective Quality System\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Significant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective management oversight of your production and laboratory operations, we found your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\u003C\u002Fp>\u003Cp>\u003Cstrong>Drug Recall and Drug Production Suspended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>On June 18, 2026, FDA held a teleconference with you recommending you consider removing any batches of sterile drugs currently in distribution from the U.S. market. On June 19, 2026, you agreed to recall all sterile drug products.\u003C\u002Fp>\u003Cp>We acknowledge your commitment to suspend production of all drugs at this facility for the U.S. market.\u003C\u002Fp>\u003Cp>You are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance prior to resumption of any manufacturing operations. In addition, based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of all CAPA, before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all CAPA.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\u003C\u002Fp>\u003Cp>FDA placed all drugs and drug products offered for import into the United States from your firm on Import Alert 66-40 on July 9, 2026.\u003C\u002Fp>\u003Cp>FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Reliance Life Sciences Private Limited, Navi Mumbai, India into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>Send your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>. Identify your written response with FEI 3009510975 and ATTN: Claire Minden in the letter or in the subject line of the email.\u003C\u002Fp>\u003Cp>If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration.\u003C\u002Fp>\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\u003Cp>FDA posts warning letters on www.FDA.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>cc: Dr. Sandhya Narasimhan\u003Cbr>usagent1@masuuglobal.com\u003C\u002Fp>\u003Cp>___________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nReference #:\n\n320-26-117\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Santhosh Mathai\n\nRecipient Title\n\nBusiness Head-Pharmaceuticals\n\nReliance Life Sciences Private Limited\n\nDhirubhai Ambani Life Sciences Centre\n\nR-282 Ttc Area of MIDC, Thane Belapur Road, Rabale\n\nNavi Mumbai 400701\n\nMaharashtra\n\nIndia\n\n(b)(6)\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nAugust 18, 2026\nWARNING LETTER\nReference number: 320-26-117\nTo Mr. Santhosh Mathai:\nThis warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) inspection of your facility. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory action without further notice.\nFDA Inspection\nViolations were observed and documented during an inspection of your drug manufacturing facility, Reliance Life Sciences Private Limited, FDA Establishment Identifier (FEI) 3009510975, at Dhirubhai Ambani Life Sciences Centre, R-282 Ttc Area Of MIDC, Thane Belapur Road, Rabale, Navi Mumbai, Maharashtra, 400701 India, from February 19 to February 27, 2026. This inspection was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your March 20, 2026, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nViolations of the Federal Food, Drug, and Cosmetic Act\nThe following are violations identified during our inspection. As a reminder, this is not an all-inclusive list of violations at your facility.\n1. Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).\nInaccurate Microbiology Laboratory Records\nYou failed to accurately document microbiology testing results. Specifically, multiple environmental monitoring and (b)(4) samples were documented in logbooks as collected and incubated; however, the corresponding plates could not be located in incubators during the inspection. Colony forming unit (cfus) counts had been recorded as if incubation was actively in progress. In interviews conducted by your management, your analysts confirmed these samples were not collected.\nIn addition, your Laboratory Information Management System (LIMS) did not include a dilution factor to calculate the number of cfus per gram or milliliter of product for microbial limit test results, as required by your own procedures and applicable compendial methods. By releasing drug products based solely on raw plate count averages entered into your LIMS without applying the required dilution factor, you lack scientific evidence that each batch conforms to predetermined specifications prior to distribution. Appropriate testing is an essential part of ensuring that the drug products you manufacture conform to CGMP.\nCollectively, these deficiencies indicate a significant risk of systematic underreporting of microbial findings, which directly undermines your firm's ability to ensure the safety and quality of drug products distributed to patients.\nReliability of data is fundamentally compromised when there is a failure to record data or to maintain complete and accurate records of test results. Furthermore, the lack of reliable data compromises the ability of your quality unit (QU) to exercise its function of ensuring compliance to applicable standards and deprives you of the ability to adequately investigate deviations.\nInadequate Electronic Records Controls\nYour firm did not have adequate controls to prevent the deletion or overwriting of (b)(4) integrity testing electronic data. Specifically, reports were not saved with unique file names, resulting in data being overwritten after every (b)(4) tests. In addition, (b)(4) integrity testing was not performed for Plant (b)(4). Therefore, your firm has no means of tracking or retrieving records of failed leak tests. The lack of adequate electronic records controls undermines the reliability and integrity of your laboratory data.\n(b)(4) integrity is critical to preventing product contamination. Routine (b)(4) integrity tests should be performed. The monitoring and maintenance program should identify and eliminate any (b)(4) lacking integrity and minimize the possibility of placing a sterile product at risk.\nAll data must be complete, accurate and retained to enable appropriate assessment and decisions by the QU. The lack of control over the integrity of your data raises questions about the authenticity and reliability of your analytical data and the quality of your drug products.\nYour response states “the unaccounted samples may have been misplaced”. This explanation is contradictory as it does not address the fact that your own analysts confirmed during management interviews that the microbiological samples were never collected, nor does it address the broader pattern of inaccurate recordkeeping identified during the inspection. Your response indicates your commitment to hiring third parties to conduct a data integrity remediation plan, risk assessment, and product impact assessment. Your response is inadequate. You do not provide sufficient detail including specific timelines and deliverables on your data integrity remediation plan, risk assessment and product assessment. Furthermore, your response does not define the scope of third-party oversight responsibilities or establish accountability measures for the remediation effort.\nAdditionally, you acknowledge deficiencies in your “(b)(4) integrity testing controls” and conducted a retrospective review. Your response is inadequate because although you conclude there is, “no evidence of product contamination attributable to (b)(4) failure”, the thoroughness of this review cannot fully support a definitive risk-based conclusion since you acknowledge that “historical traceability was incomplete”.\nWe acknowledge your firm’s long-term commitment to improving your manufacturing operation, including, but not limited to, hiring additional microbiological laboratory staff and building a larger microbiological laboratory.\nYour quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP: Questions and Answers for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\nWe acknowledge that you are using independent third-party consultants to audit your operation and assist in meeting FDA requirements. In response to this letter, provide:\nA comprehensive investigation into the extent of the inaccuracies in data records and reporting. Your investigation should include:\no A detailed investigation protocol and methodology; a summary of all laboratories, manufacturing operations, and systems to be covered by the assessment; and a justification for any part of your operation that you propose to exclude.\no Interviews of current and former employees to identify the nature, scope, and root cause of data inaccuracies. We recommend that these interviews be conducted by a qualified third party.\no An assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered data integrity lapses.\no A comprehensive retrospective evaluation of the nature of the testing data integrity deficiencies. We recommend that a qualified third party with specific expertise in the area where potential breaches were identified should evaluate all data integrity lapses.\nA retrospective review of all microbial limit test results to include the proper dilution factor to calculate the number of cfus per gram or milliliter of product for products currently in the U.S. market and within expiry as of the date of this letter and a report summarizing the findings of the analysis. Your action plan to address any product quality or patient safety risks for your drug products in U.S. distribution, including potential customer notifications and recalls.\nA current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\nA management strategy for your firm that includes the details of your global corrective action and preventive action (CAPA) plan. Your strategy should include:\no A detailed corrective action plan that describes how you intend to ensure the reliability and completeness of all the data you generate including analytical data, manufacturing records, and all data submitted to FDA.\no A comprehensive description of the root causes of your data integrity lapses including evidence that the scope and depth of the current action plan is commensurate with the findings of the investigation and risk assessment. Indicate whether individuals responsible for data integrity lapses remain able to influence CGMP-related or drug application data at your firm.\no Interim measures describing the actions you have taken or will take to protect patients and to ensure the quality of your drugs, such as notifying your customers, recalling product, conducting additional testing, adding lots to your stability programs to assure stability, drug application actions, and enhanced complaint monitoring.\no Long-term measures describing any remediation efforts and enhancements to procedures, processes, methods, controls, systems, management oversight, and human resources (e.g., training, staffing improvements) designed to ensure the integrity of your company’s data.\no A commitment to have a qualified consultant conduct extensive annual audits, for at least two years, to assist in evaluating CAPA effectiveness after you have executed your data integrity remediation protocol.\no An indication of whether you plan to hire a data integrity officer who is fully empowered to receive anonymous complaints from employees reporting data integrity concerns and with the authority to ensure any potential breach is promptly investigated (by independent quality assurance function, along with expertise from outside entities whenever needed).\no A status report for any of the above activities already underway or completed.\nA comprehensive assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous (ALCOA) records throughout your operation.\nA comprehensive independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\nAn action plan and timelines for conducting full microbiological testing of reserve samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\nA comprehensive, independent assessment of the design and control of your firm’s manufacturing operations, with a detailed and thorough review of all microbiological hazards.\nA detailed risk assessment addressing the hazards posed by distributing drug products with potentially objectionable contamination. Specify actions you will take in response to the risk assessment, such as customer notifications and product recalls.\nComplete investigations into all batches with potential objectionable microbial contamination. The investigations should detail your findings regarding the root causes of the contamination.\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to, the following:\no A determination of whether procedures used by your firm are robust and appropriate.\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\no A complete and final review of each batch and its related information before the QU disposition decision.\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\n2. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\nPoor Aseptic Practices\nOur inspection identified aseptic processing design deficiencies that pose significant hazards to drug product sterility. During a mock filling operation and during review of your unidirectional smoke studies, our investigators observed multiple instances of inappropriate aseptic behavior in which operators blocked unidirectional airflow at critical locations without implementing appropriate corrective measures, including discarding potentially compromised vials. Specific examples include:\nBlocking airflow over the stopper bowl and (b)(4) vials while refilling the stopper bowl\nPassing forceps over the (b)(4) and removing fallen vials from the (b)(4) and (b)(4) over (b)(4) vials\nBlocking airflow during (b)(4) transfer operations, including (b)(4) repositioning of filled vials onto a (b)(4) and mechanical displacement of (b)(4) vials into the (b)(4) via forceps\nAny compromise of first-air protection exposes sterile drug products to potential microbiological contamination.\nCleaning, Decontamination, and Maintenance\nYou failed to adequately clean, decontaminate, and maintain your (b)(4) used for aseptic drug product manufacturing. For example, our investigator observed multiple instances of deterioration and damage inside the (b)(4) used for manufacturing sterile drug products. These instances of deterioration and damage were not adequately addressed through your cleaning, decontamination, and maintenance programs. For example, our investigator observed:\nDeteriorated (b)(4) used to support the (b)(4) tank\nExcess sealant adjacent to the HEPA filters in the filling and (b)(4) areas\nUse of nonsterile wipes soaked in (b)(4) to clean (b)(4)\nIn addition, our investigator observed accumulation of standing water and unknown (b)(4) staining on the wall surface adjacent to the (b)(4) pipelines, located outside the (b)(4) room within the HVAC area.\nAll equipment and associated operational areas should follow a reliable, comprehensive preventive maintenance program. This program should be designed to ensure sustained operational integrity through the systematic implementation of validated cleaning and disinfection protocols, as well as the proactive replacement of components before they deteriorate or degrade. Maintenance and change management procedures should prevent practices that may compromise equipment or introduce contamination risks.\nAseptic processes need to be designed to minimize exposure of sterile articles to potential contamination hazards. A suitable monitoring system is critical to maintain appropriate environmental conditions throughout your (b)(4) and cleanrooms. Prompt detection of an emerging problem is essential to preventing contamination of your aseptic production operations.\nYour response states existing procedures \"did not adequately define acceptable hand positioning, intervention speed, first-air protection requirements, rejection criteria for potentially affected exposed units, or required actions following airflow interruption\" and acknowledges “equipment design and ergonomic limitations within the (b)(4)”. Additionally, you state you will not resume operations until “successful aseptic process simulation run incorporating all listed interventions under worst-case conditions are completed”. Furthermore, you commit to updating procedures for (b)(4) sanitization and cleaning to include sterile (b)(4) and sterile wipes. Your response also states that remediations were made to equipment, including repairing all sealant joints in the (b)(4), smoothing internal machine surfaces to meet cleanability requirements, and updating maintenance checklists to include criteria for wear, damage, smoothness, cleanability, and material suitability.\nYour response is inadequate. You do not provide sufficient detail including deliverables on your third-party risk assessment of all aseptic filling lines. Additionally, your response does not sufficiently address the lack of oversight of operator aseptic behavior, equipment cleaning and maintenance, various manual activities, and intervention ergonomics.\nSee FDA’s guidance document Sterile Drug Products Produced by Aseptic Processing - Current Good Manufacturing Practice to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\nIn your response to this letter, provide the following:\nYour CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should incorporate oversight from a qualified independent consultant and ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\nA CAPA plan, based on the retrospective assessment of your cleaning and disinfection program, that includes appropriate remediations to your cleaning and disinfection processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning and disinfection. Describe improvements to your cleaning and disinfection program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning and disinfection execution for all products and equipment; and all other needed remediations.\nA comprehensive, independent risk assessment by a qualified consultant of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including, but not limited to, the following:\no All human interactions within the ISO 5 area (e.g., risk reduction or elimination of manual interventions wherever possible).\no Equipment suitability (e.g., reliability, capability, ergonomics, placement) and sufficient cleanroom space.\no Personnel Flow and Material Flow (movement throughout all rooms used to conduct and support sterile operations, and all material transfers).\no Specific CAPA recommendations that will comprehensively address the design and control hazards identified in the risk assessment.\nA detailed remediation plan from the independent consultant with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control at your facility and explain how this CAPA plan will robustly remediate your deficient sterile manufacturing operations. Include comprehensive changes to the design of both your aseptic processing lines and cleanrooms, the specific barrier system to be used (e.g., Restricted Access Barrier, (b)(4)), and associated timelines. Also, describe your plans for qualification and validation of your extensively remediated operations.\nIneffective Quality System\nSignificant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective management oversight of your production and laboratory operations, we found your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\nDrug Recall and Drug Production Suspended\nOn June 18, 2026, FDA held a teleconference with you recommending you consider removing any batches of sterile drugs currently in distribution from the U.S. market. On June 19, 2026, you agreed to recall all sterile drug products.\nWe acknowledge your commitment to suspend production of all drugs at this facility for the U.S. market.\nYou are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance prior to resumption of any manufacturing operations. In addition, based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of all CAPA, before you pursue resolution of your firm’s compliance status with FDA.\nIn your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all CAPA.\nConclusion\nYou are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\nFDA placed all drugs and drug products offered for import into the United States from your firm on Import Alert 66-40 on July 9, 2026.\nFDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Reliance Life Sciences Private Limited, Navi Mumbai, India into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nSend your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter1. Identify your written response with FEI 3009510975 and ATTN: Claire Minden in the letter or in the subject line of the email.\nIf you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\nFDA posts warning letters on www.FDA.gov.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\ncc: Dr. Sandhya Narasimhan\nusagent1@masuuglobal.com\n___________________________\n1 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","Reliance Life Sciences Private Limited","reliance-life-sciences-private-limited-730801-08182026","2026-09-07T05:14:13.57002+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Freliance-life-sciences-private-limited-730801-08182026","2026-10-26T08:09:48.525245+00:00","2026-09-01","730801","Drugs","Mr. Santhosh Mathai","2026-09-07T05:14:54.57+00:00","VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED","320-26-117","2026-08-18",{"id":80,"raw":81,"subject":85,"body_html":86,"body_text":87,"firm_name":88,"letter_id":89,"created_at":90,"fei_number":20,"letter_url":91,"updated_at":92,"action_type":23,"case_status":24,"posted_date":93,"marcs_cms_no":94,"product_type":95,"closeout_date":20,"issuing_office":62,"recipient_name":96,"body_fetched_at":97,"delivery_method":98,"recipient_title":20,"reference_number":99,"action_taken_date":100,"medical_device_id":20,"response_letter_date":20},118,[82,83,84,62,85,13,13,13],"\u003Ctime datetime=\"2026-06-09T04:00:00Z\">06\u002F09\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-06-02T04:00:00Z\">06\u002F02\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fumendra-life-sciences-private-limited-721752-06022026\">Umendra Life Sciences Private Limited\u003C\u002Fa>","CGMP\u002FOTC Finished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-91\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Ankur Sharma Sr.\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>General Manager – Quality \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Umendra Life Sciences Private Limited\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>New Survey No. 211, Village Account No. 170 Old Block\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Survey No. 158, Bavla, Taulka Mauje\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Ahmedabad\u003C\u002Fspan> \u003Cspan>382220\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Gujarat\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>India\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-91\u003C\u002Fp>\u003Cp>June 2, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Sharma:\u003C\u002Fp>\u003Cp>Your facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our August 14, 2025 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) for your facility, Umendra Life Sciences Private Limited, FEI 3035187076, at New Survey No. 211, Village Account No. 170 Old Block \u002F Survey No. 158, Bavla, Taulka Mauje, Amipura, Ahmedabad, Gujarat.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 351(a)(2)(B)).\u003C\u002Fp>\u003Cp>Following review of records and other information provided pursuant to section 704(a)(4) of the FD&amp;C Act, significant violations were observed including, but not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products are manufactured in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures OTC \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products labeled to contain the active ingredient \u003Cstrong>(b)(4)\u003C\u002Fstrong>. This drug product is also labeled and formulated to contain the inactive ingredient talc. For one of the drug products, the formulation is composed of more than \u003Cstrong>(b)(4)\u003C\u002Fstrong>% talc. Both talc and asbestos are naturally occurring minerals that may be found in close proximity in the earth. Asbestos is a potential contaminant in talc and is a known human carcinogen when inhaled.\u003Cem>\u003Cstrong>\u003Csup>1,2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Additionally, published scientific literature dating back to the 1960s has suggested a possible association between the use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> containing talc in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> area and the incidence of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, potentially linked to asbestos contamination of the talc.\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> The \u003Cstrong>(b)(4)\u003C\u002Fstrong> you produce can be used on areas of the body which may be an exposure risk (e.g., inhalation or \u003Cstrong>(b)(4)\u003C\u002Fstrong> area). Your drug products are considered a higher-risk drugs as it pertains to patient safety regarding asbestos contamination of talc due to the risk of inadvertent inhalation or potential use in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> area.\u003C\u002Fp>\u003Cp>Your quality unit (QU) did not effectively exercise its responsibility to ensure the acceptability of your drug components. For example, your QU did not ensure that test procedures and specifications for talc are scientifically sound and appropriate (see 21 CFR 211.160(b)). In addition, you did not demonstrate that your firm’s QU has adequate oversight of your contract testing facility. Your QU approved and accepted talc for use in drug manufacturing without ensuring compliance with CGMP.\u003C\u002Fp>\u003Cp>Your QU failed to assure that contract facilities are testing according to your procedures which require you to follow current United States Pharmacopeia (USP) specifications and that results are supported by sufficient information to provide an accurate determination of compliance. In particular, your QU did not adequately review or approve methods used by your contract laboratory, and review and approve data to ensure results are supported by accurate data.\u003C\u002Fp>\u003Cp>The tests included in the specification were not performed according to current USP. You did not conduct testing using Atomic Absorption for Calcium and Assay Content of Magnesium as required by USP. For identification and asbestos testing conducted, the documentation does not fully support results reported. Current USP identification procedure acceptance criteria is “the IR spectrum of a \u003Cstrong>(b)(4)\u003C\u002Fstrong> of it exhibits maxima at \u003Cstrong>(b)(4)\u003C\u002Fstrong> ± \u003Cstrong>(b)(4)\u003C\u002Fstrong> cm–1, at \u003Cstrong>(b)(4)\u003C\u002Fstrong> ± \u003Cstrong>(b)(4)\u003C\u002Fstrong> cm–1, and at \u003Cstrong>(b)(4)\u003C\u002Fstrong> ± \u003Cstrong>(b)(4)\u003C\u002Fstrong> cm–1” and absence of asbestos procedure \u003Cstrong>(b)(4)\u003C\u002Fstrong> by Infrared (IR) Spectroscopy includes the evaluation of the presence of tremolite, chlorite and serpentines, through scale expansions of spectra at the required wavenumbers of \u003Cstrong>(b)(4)\u003C\u002Fstrong> cm-1, and in the range of \u003Cstrong>(b)(4)\u003C\u002Fstrong> cm-1 to \u003Cstrong>(b)(4)\u003C\u002Fstrong> cm-1. Your instrument reports for the identification spectroscopy report was from \u003Cstrong>(b)(4)\u003C\u002Fstrong> cm–1 to \u003Cstrong>(b)(4)\u003C\u002Fstrong> cm–1 and did not identify peak maxima wavenumbers as required in USP for the one identification test performed. For tests conducted for asbestos, data does not include expansion of spectra at the required wavenumber of \u003Cstrong>(b)(4)\u003C\u002Fstrong>cm-1 and the range of \u003Cstrong>(b)(4)\u003C\u002Fstrong> cm-1 to \u003Cstrong>(b)(4)\u003C\u002Fstrong> cm-1 was covered in by the spectral analysis. Your identification spectra does not evaluate for the presence of serpentines between wavenumbers \u003Cstrong>(b)(4)\u003C\u002Fstrong> cm–1 and \u003Cstrong>(b)(4)\u003C\u002Fstrong> cm–1.\u003C\u002Fp>\u003Cp>Furthermore, your specifications for talc components did not include testing for multiple impurities (e.g., limits of \u003Cstrong>(b)(4)\u003C\u002Fstrong>) and lacks identification procedures \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your QU approved and accepted talc for use in drug manufacturing with deficient specifications.\u003C\u002Fp>\u003Cp>Your QU is responsible for fully exercising its authority and responsibilities, including responsibility for approving or rejecting all procedures or specifications impacting the identity, strength, quality, and purity of the drug product. Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem>, for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide a comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fp>\u003Cul>\u003Cli>A determination of whether procedures used by your firm are robust and appropriate.\u003C\u002Fli>\u003Cli>Provisions for QU oversight throughout your operations, including an evaluation of your contract facility qualification program, to evaluate adherence to appropriate practices.\u003C\u002Fli>\u003Cli>Gap analysis for your approved specifications, test methods and laboratory practices against the USP, where applicable, for drug components (active and inactive) and those conducted at your contract facility. If notable differences are observed, provide an impact analysis and corrective actions, which may include retrospective testing.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)(1) and 21 CFR 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm has not demonstrated that you appropriately tested incoming talc drug components or validated and established the reliability of your component supplier’s test analyses at appropriate intervals for talc.\u003C\u002Fp>\u003Cp>You provided records to demonstrate you had conducted identity testing pursuant to the applicable USP test to satisfy the requirements for identity testing in 211.84(d)(1) and (2), the testing does not conform to the current USP testing method, in that it is incomplete (i.e., lacks identification \u003Cstrong>(b)(4)\u003C\u002Fstrong>). A representative certificates of analysis (COA) indicated that the material supplied appears to be Indian Pharmacopeia (IP) grade and sufficient information was not submitted to support that materials meet USP monograph standards. Our review of the IP talc monograph revealed that the IP provides less details and lacks some critical requirements such as assay and several impurities (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong>). Additionally, you relied on the COA from your suppliers and failed to establish the reliability of each of your suppliers’ COA for component specifications and characteristics at appropriate intervals. Although 21 CFR 211.84(d)(2) provides for some reliance on a COA from the supplier of the component, such reliance is permissible only if the drug product manufacturer establishes the reliability of the supplier’s test results through appropriate validation of the test results at appropriate intervals. Without adequate testing, you lack scientific evidence that the components conform to appropriate specifications prior to use in the manufacture of your drug products.\u003C\u002Fp>\u003Cp>As a manufacturer, you have a responsibility to sample, test, and examine, as appropriate, drug components before use in production to ensure acceptable specifications for identity, strength, quality, and purity are met. Because you have not performed appropriate testing that detects asbestos in your talc components, among other things, you failed to assure the acceptability of these drug components for use in manufacture of your drug products.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>Identity, assay and impurity test results from testing retains for all lots of talc containing drug components used in the manufacture of your drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for asbestos. Provide this information within 30 calendar days of the date of this letter.\u003C\u002Fli>\u003Cli>A description of how you will test each component lot for conformity with all appropriate written specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\u003C\u002Fli>\u003Cli>A full risk assessment for drug products that are within expiry which contain any ingredient at risk for asbestos contamination. Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain asbestos. Appropriate actions could include customer notifications and drug product recalls for any contaminated lots.\u003C\u002Fli>\u003Cli>The chemical quality control specifications you use to evaluate each incoming lot of drug component to determine acceptability for use in manufacturing.\u003C\u002Fli>\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure that describes this COA validation program.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Reformulation to No Longer Use Talc in High-Risk Dosage Forms\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In response to our request for records you indicated that you are in the process of reformulating to remove talc as an ingredient and replace with corn starch. In response to this letter provide an update on your talc.\u003C\u002Fp>\u003Cp>\u003Cstrong>Quality Specifications Regarding Talc\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Talc is a USP article, whose specification can be found in the current USP talc monograph. As mentioned above, the specific test for asbestos is included in the talc monograph. Be advised that drugs including components, such as talc, that are recognized in the USP are generally required to meet the current applicable USP monograph under section 501(b) of the FD&amp;C Act. FDA reviewed your specifications for talc components and they are incomplete when compared to the current USP specification. We note that the USP has recently revised its monograph for talc which includes updated technical requirements for asbestos testing in talc and is currently scheduled to be official in \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>\u003Cstrong>Use of Contract Manufacturers\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Drugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\u003C\u002Fp>\u003Cp>You are responsible for the quality of your drugs regardless of agreements in place with your contract facilities. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act to ensure safety, identity, strength, quality, and purity. See FDA’s guidance document \u003Cem>Contract Manufacturing Arrangements for Drugs: Quality Agreements\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violation promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA refusing admission of articles manufactured at Umendra Life Sciences Private Limited, New Survey No. 211, Village Account No. 170 Old, Block \u002F Survey No. 158, Bavla, Taluka Mauje, Amipura, Ahmedabad, Gujarat into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion. If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3035187076 and ATTN: Nancy Espinal.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>_______________________\u003C\u002Fp>\u003Cp>\u003Cstrong>1\u003C\u002Fstrong> https:\u002F\u002Fwww.cancer.gov\u002Fabout-cancer\u002Fcauses-prevention\u002Frisk\u002Fsubstances\u002Fasbestos\u003C\u002Fp>\u003Cp>\u003Cstrong>2\u003C\u002Fstrong> https:\u002F\u002Fwww.atsdr.cdc.gov\u002Fasbestos\u002Fhealth-effects\u002F\u003C\u002Fp>\u003Cp>\u003Cstrong>3\u003C\u002Fstrong> https:\u002F\u002Fwww.fda.gov\u002Fcosmetics\u002Fcosmetic-ingredients\u002Ftalc\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nReference #:\n\n320-26-91\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nMr. Ankur Sharma Sr.\n\nRecipient Title\n\nGeneral Manager – Quality\n\nUmendra Life Sciences Private Limited\n\nNew Survey No. 211, Village Account No. 170 Old Block\n\nSurvey No. 158, Bavla, Taulka Mauje\n\nAhmedabad 382220\n\nGujarat\n\nIndia\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-91\nJune 2, 2026\nDear Mr. Sharma:\nYour facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our August 14, 2025 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility, Umendra Life Sciences Private Limited, FEI 3035187076, at New Survey No. 211, Village Account No. 170 Old Block \u002F Survey No. 158, Bavla, Taulka Mauje, Amipura, Ahmedabad, Gujarat.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 351(a)(2)(B)).\nFollowing review of records and other information provided pursuant to section 704(a)(4) of the FD&C Act, significant violations were observed including, but not limited to, the following:\n1. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products are manufactured in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nYour firm manufactures OTC (b)(4) drug products labeled to contain the active ingredient (b)(4). This drug product is also labeled and formulated to contain the inactive ingredient talc. For one of the drug products, the formulation is composed of more than (b)(4)% talc. Both talc and asbestos are naturally occurring minerals that may be found in close proximity in the earth. Asbestos is a potential contaminant in talc and is a known human carcinogen when inhaled.1,2 Additionally, published scientific literature dating back to the 1960s has suggested a possible association between the use of (b)(4) containing talc in the (b)(4) area and the incidence of (b)(4), potentially linked to asbestos contamination of the talc.3 The (b)(4) you produce can be used on areas of the body which may be an exposure risk (e.g., inhalation or (b)(4) area). Your drug products are considered a higher-risk drugs as it pertains to patient safety regarding asbestos contamination of talc due to the risk of inadvertent inhalation or potential use in the (b)(4) area.\nYour quality unit (QU) did not effectively exercise its responsibility to ensure the acceptability of your drug components. For example, your QU did not ensure that test procedures and specifications for talc are scientifically sound and appropriate (see 21 CFR 211.160(b)). In addition, you did not demonstrate that your firm’s QU has adequate oversight of your contract testing facility. Your QU approved and accepted talc for use in drug manufacturing without ensuring compliance with CGMP.\nYour QU failed to assure that contract facilities are testing according to your procedures which require you to follow current United States Pharmacopeia (USP) specifications and that results are supported by sufficient information to provide an accurate determination of compliance. In particular, your QU did not adequately review or approve methods used by your contract laboratory, and review and approve data to ensure results are supported by accurate data.\nThe tests included in the specification were not performed according to current USP. You did not conduct testing using Atomic Absorption for Calcium and Assay Content of Magnesium as required by USP. For identification and asbestos testing conducted, the documentation does not fully support results reported. Current USP identification procedure acceptance criteria is “the IR spectrum of a (b)(4) of it exhibits maxima at (b)(4) ± (b)(4) cm–1, at (b)(4) ± (b)(4) cm–1, and at (b)(4) ± (b)(4) cm–1” and absence of asbestos procedure (b)(4) by Infrared (IR) Spectroscopy includes the evaluation of the presence of tremolite, chlorite and serpentines, through scale expansions of spectra at the required wavenumbers of (b)(4) cm-1, and in the range of (b)(4) cm-1 to (b)(4) cm-1. Your instrument reports for the identification spectroscopy report was from (b)(4) cm–1 to (b)(4) cm–1 and did not identify peak maxima wavenumbers as required in USP for the one identification test performed. For tests conducted for asbestos, data does not include expansion of spectra at the required wavenumber of (b)(4)cm-1 and the range of (b)(4) cm-1 to (b)(4) cm-1 was covered in by the spectral analysis. Your identification spectra does not evaluate for the presence of serpentines between wavenumbers (b)(4) cm–1 and (b)(4) cm–1.\nFurthermore, your specifications for talc components did not include testing for multiple impurities (e.g., limits of (b)(4)) and lacks identification procedures (b)(4) and (b)(4). Your QU approved and accepted talc for use in drug manufacturing with deficient specifications.\nYour QU is responsible for fully exercising its authority and responsibilities, including responsibility for approving or rejecting all procedures or specifications impacting the identity, strength, quality, and purity of the drug product. Your firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations, for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nIn response to this letter, provide a comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\nA determination of whether procedures used by your firm are robust and appropriate.\nProvisions for QU oversight throughout your operations, including an evaluation of your contract facility qualification program, to evaluate adherence to appropriate practices.\nGap analysis for your approved specifications, test methods and laboratory practices against the USP, where applicable, for drug components (active and inactive) and those conducted at your contract facility. If notable differences are observed, provide an impact analysis and corrective actions, which may include retrospective testing.\n2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)(1) and 21 CFR 211.84(d)(2)).\nYour firm has not demonstrated that you appropriately tested incoming talc drug components or validated and established the reliability of your component supplier’s test analyses at appropriate intervals for talc.\nYou provided records to demonstrate you had conducted identity testing pursuant to the applicable USP test to satisfy the requirements for identity testing in 211.84(d)(1) and (2), the testing does not conform to the current USP testing method, in that it is incomplete (i.e., lacks identification (b)(4)). A representative certificates of analysis (COA) indicated that the material supplied appears to be Indian Pharmacopeia (IP) grade and sufficient information was not submitted to support that materials meet USP monograph standards. Our review of the IP talc monograph revealed that the IP provides less details and lacks some critical requirements such as assay and several impurities (e.g., (b)(4)). Additionally, you relied on the COA from your suppliers and failed to establish the reliability of each of your suppliers’ COA for component specifications and characteristics at appropriate intervals. Although 21 CFR 211.84(d)(2) provides for some reliance on a COA from the supplier of the component, such reliance is permissible only if the drug product manufacturer establishes the reliability of the supplier’s test results through appropriate validation of the test results at appropriate intervals. Without adequate testing, you lack scientific evidence that the components conform to appropriate specifications prior to use in the manufacture of your drug products.\nAs a manufacturer, you have a responsibility to sample, test, and examine, as appropriate, drug components before use in production to ensure acceptable specifications for identity, strength, quality, and purity are met. Because you have not performed appropriate testing that detects asbestos in your talc components, among other things, you failed to assure the acceptability of these drug components for use in manufacture of your drug products.\nIn response to this letter, provide:\nIdentity, assay and impurity test results from testing retains for all lots of talc containing drug components used in the manufacture of your drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for asbestos. Provide this information within 30 calendar days of the date of this letter.\nA description of how you will test each component lot for conformity with all appropriate written specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\nA full risk assessment for drug products that are within expiry which contain any ingredient at risk for asbestos contamination. Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain asbestos. Appropriate actions could include customer notifications and drug product recalls for any contaminated lots.\nThe chemical quality control specifications you use to evaluate each incoming lot of drug component to determine acceptability for use in manufacturing.\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure that describes this COA validation program.\nReformulation to No Longer Use Talc in High-Risk Dosage Forms\nIn response to our request for records you indicated that you are in the process of reformulating to remove talc as an ingredient and replace with corn starch. In response to this letter provide an update on your talc.\nQuality Specifications Regarding Talc\nTalc is a USP article, whose specification can be found in the current USP talc monograph. As mentioned above, the specific test for asbestos is included in the talc monograph. Be advised that drugs including components, such as talc, that are recognized in the USP are generally required to meet the current applicable USP monograph under section 501(b) of the FD&C Act. FDA reviewed your specifications for talc components and they are incomplete when compared to the current USP specification. We note that the USP has recently revised its monograph for talc which includes updated technical requirements for asbestos testing in talc and is currently scheduled to be official in (b)(4).\nUse of Contract Manufacturers\nDrugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\nYou are responsible for the quality of your drugs regardless of agreements in place with your contract facilities. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act to ensure safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violation promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA refusing admission of articles manufactured at Umendra Life Sciences Private Limited, New Survey No. 211, Village Account No. 170 Old, Block \u002F Survey No. 158, Bavla, Taluka Mauje, Amipura, Ahmedabad, Gujarat into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion. If you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3035187076 and ATTN: Nancy Espinal.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n_______________________\n1 https:\u002F\u002Fwww.cancer.gov\u002Fabout-cancer\u002Fcauses-prevention\u002Frisk\u002Fsubstances\u002Fasbestos\n2 https:\u002F\u002Fwww.atsdr.cdc.gov\u002Fasbestos\u002Fhealth-effects\u002F\n3 https:\u002F\u002Fwww.fda.gov\u002Fcosmetics\u002Fcosmetic-ingredients\u002Ftalc","Umendra Life Sciences Private Limited","umendra-life-sciences-private-limited-721752-06022026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fumendra-life-sciences-private-limited-721752-06022026","2026-10-26T08:10:17.28862+00:00","2026-06-09","721752","Drugs Over-the-Counter Drugs","Mr. Ankur Sharma Sr.","2026-08-19T04:38:23.105+00:00","VIA UPS","320-26-91","2026-06-02",{"id":102,"raw":103,"subject":109,"body_html":110,"body_text":111,"firm_name":112,"letter_id":113,"created_at":114,"fei_number":20,"letter_url":115,"updated_at":116,"action_type":23,"case_status":24,"posted_date":117,"marcs_cms_no":118,"product_type":119,"closeout_date":20,"issuing_office":120,"recipient_name":121,"body_fetched_at":122,"delivery_method":98,"recipient_title":20,"reference_number":20,"action_taken_date":123,"medical_device_id":20,"response_letter_date":20},2232,[104,105,106,107,108,13,13,13],"\u003Ctime datetime=\"2023-01-31T14:20:00Z\">01\u002F31\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-01-24T05:00:00Z\">01\u002F24\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fadept-life-science-llc-635400-01242023\">Adept Life Science, LLC\u003C\u002Fa>"," Division of Human and Animal Food Operations East IV","CGMP\u002FDietary Supplement\u002FMisbranded\u003Cbr \u002F>\r\n","CGMP\u002FDietary Supplement\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Dietary Supplements\u003Cbr>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Michael T. Shields and Ms. Windy N. Shields\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owners\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Adept Life Science, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2215 E Germann Rd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Chandler\u003C\u002Fspan>, \u003Cspan>AZ\u003C\u002Fspan> \u003Cspan>85286\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Human and Animal Food Operations East IV\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>January 24, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER 635400\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nIn reply, refer to CMS 635400\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Michael T. Shields and Ms. Windy N. Shields:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) conducted an inspection of your facility located at 2215 E Germann Rd, Chandler, Arizona, from April 11 through April 27, 2022. Based on the inspectional findings we have identified serious violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links in FDA's home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>The inspection of your facility revealed serious violations of FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). These violations cause your dietary supplement products to be adulterated within the meaning of section 402(g)(1) of the Act [21 United States Code (U.S.C.) § 342(g)(1)] because they have been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements. In addition, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong> (in \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> sizes) dietary supplement products that you manufacture are misbranded within the meaning of section 403 of the Act [21 U.S.C. § 343].\u003C\u002Fp>\n\n\u003Cp>FDA acknowledges the receipt of your e-mail correspondence dated May 20, 2022 and June 23, 2022, written in response to the Form FDA 483, Inspectional Observations, issued to you at the close of the inspection. Not all of the items on the issued Form FDA 483 were addressed in your response. We address your response below, in relation to the applicable violations to which you responded.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Dietary Supplement CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your significant violations of CGMP requirements are as follows:\u003C\u002Fp>\n\n\u003Cp>1. You failed to establish an identity specification for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> used in the manufacture of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong> product. Your raw material data sheet for \u003Cstrong>(b)(4)\u003C\u002Fstrong> states “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Potency” as the specification for identity, but this does not establish standards to confirm the identity of the component used in the manufacture of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong> product, as required in 21 CFR 111.70(b)(1). Additionally, your raw material data sheet for \u003Cstrong>(b)(4)\u003C\u002Fstrong> used in the manufacture of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong> product has five minerals in the blend but your purported ICP-MS specification for identity lists “mineral detected” as the specification and fails to establish standards which can be used to confirm the identity of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> component, as required in 21 CFR 111.70(b)(1).\u003C\u002Fp>\n\n\u003Cp>2. You failed to establish component specifications that are necessary to ensure that specifications for the purity and composition of the dietary supplement manufactured using the components are met, as required in 21 CFR 111.70(b)(2). For example, you have not established specifications for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Premix used in the manufacture of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong> product and specifications for several of the components used in the manufacture of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong> product to ensure that specifications for purity and composition of these products are met.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your June 23, 2022 response to the form FDA 483. We are unable to evaluate the adequacy of your response because you did not provide documentation demonstrating you have established specifications in accordance with 21 CFR 111.70(b)(1) and 21 CFR 111.70(b)(2). You provide documents you describe as revised finished product specifications for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong> product and \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong> product. We note that these documents do not demonstrate that you have established specifications that provide standards to confirm the identity, purity, strength, and composition of the finished batch of your dietary supplements. For example, the finished product specification for \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong> product lists an “identification” specification of “Conforms to Standard” with a test method of “Eurofins or eq.” and a frequency of “Rotational.” “Conforms to standard” does not specify the extent to which the component must conform. “Eurofins or eq.” is not a test method and “Rotational” does not describe the frequency of when testing is to occur.\u003C\u002Fp>\n\n\u003Cp>Similarly, the finished product specification for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong> product states testing “Frequency” as “Rotation” for several components, and does not describe the frequency of when testing is to occur.\u003C\u002Fp>\n\n\u003Cp>3. You failed to establish and follow laboratory control processes that are reviewed and approved by quality control personnel, for use of criteria for selecting standard reference materials used in performing tests and examinations, as required by 21 CFR 111.315(d). Specifically, the FTIR analysis performed by your third-party laboratory uses previous shipments of components as the reference for testing and they do not own a reference library for the FTIR tests. Testing components against previous shipments of the component may confirm receipt of the same component but this does not ensure the identity, purity, quality, and strength of the component is thoroughly characterized .\u003C\u002Fp>\n\n\u003Cp>4. Your quality control operations did not approve and release, or reject, each finished batch for distribution as required by 21 CFR 111.123(a)(8). Specifically, your firm distributed \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong> product, Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong>, without quality control review, approval and release of the finished batch for distribution.\u003C\u002Fp>\n\n\u003Cp>5. Your quality control personnel must not approve and release for distribution any batch of dietary supplement, including any reprocessed batch, that does not meet all product specifications established in accordance with 21 CFR 111.70(e), as required by 21 CFR 111.123(b)(2). Your quality control personnel released \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong>, when the specification for pH was not met. Specifically, your established finished product specification for pH for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong> product is \u003Cstrong>(b)(4)\u003C\u002Fstrong> and the pH of the product in Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong> released for distribution was 6.34.\u003C\u002Fp>\n\n\u003Cp>6. Your quality control personnel neither rejected a component or dietary supplement when that component or dietary supplement failed to meet a specification established in accordance with 21 CFR 111.70, nor did they approve a treatment, an in-process adjustment, or reprocessing, as permitted in 21 CFR 111.77, in accordance with 21 CFR 111.113(b)(2). Specifically, \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong>, uses \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> as components. Testing of these two components by a third-party laboratory found both were not within your established specifications. Your quality control personnel failed to reject these components used in the manufacturing of your finished product and failed to reject the \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong> product, Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>7. Your quality control operations failed to approve, and release from quarantine, all components, before they are used as required by 21 CFR 111.120(e). Specifically, your quality control operations approved, and released from quarantine several components used in the manufacture of \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong> product, Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and components used in the manufacture of \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong>. For example, the raw material data sheets for the components \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> used in the manufacture of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and the raw material data sheets for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and the \u003Cstrong>(b)(4)\u003C\u002Fstrong> used in the manufacture of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong> product, Lot # \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>do not show a disposition by your quality control operations to approve, and release these components for use in manufacturing your finished products.\u003C\u002Fp>\n\n\u003Cp>8. You failed to prepare and follow a master manufacturing record (MMR) for each unique formulation of dietary supplement that you manufacture, and for each batch size, to ensure uniformity in the finished batch from batch to batch, which includes all required information, as required by 21 CFR 111.205(a) and 21 CFR 111.210. Specifically, the Master Manufacturing Records for the following \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand products which you manufacture were missing the following required elements:\u003C\u002Fp>\n\n\u003Cp>a. \u003Cstrong>(b)(4)\u003C\u002Fstrong> Item # \u003Cstrong>(b)(4)\u003C\u002Fstrong>:\u003Cbr>\n&nbsp; i. A statement of theoretical yield of a manufactured dietary supplement expected at each point, step, or stage of the manufacturing process and the maximum and minimum percentages of theoretical yield beyond which a deviation investigation of a batch is necessary. (21 CFR 111.210(f)).\u003Cbr>\n&nbsp; ii. Procedures for sampling and a cross-reference to procedures for tests or examinations. (21 CFR 111.210(h)(2)).\u003C\u002Fp>\n\n\u003Cp>b. \u003Cstrong>(b)(4)\u003C\u002Fstrong> Item # \u003Cstrong>(b)(4)\u003C\u002Fstrong>:\u003Cbr>\n&nbsp; i. A statement of theoretical yield of a manufactured dietary supplement expected at each point, step, or stage of the manufacturing process and the maximum and minimum percentages of theoretical yield beyond which a deviation investigation of a batch is necessary. (21 CFR 111.210(f)).\u003Cbr>\n&nbsp; ii. Procedures for sampling and a cross-reference to procedures for tests or examinations. (21 CFR 111.210(h)(2)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbrand Dietary Supplements\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>1. Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> sizes) products are misbranded within the meaning of section 403(q)(5)(F) of the Act (21 U.S.C. 343 (q)(5)(F)) in that the presentation of the nutrition information on the labeling of your product does not comply with 21 CFR 101.36. For example,\u003C\u002Fp>\n\n\u003Cp>&nbsp; a. Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong> (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) includes a Supplement Facts label with columns for “Amount per Serving (29.6 mL),” “Ages 4+ yrs,” “Pregnant and Lactating,” “Per serving (2.5 mL),” and “Ages 2-3 yrs.” Your “Suggested Use” panel includes different serving instructions for “2-3 Years,” “4-10 Years,” “11-17 Years,” “18 Years+,” and “Pregnant\u002FLactating &amp; Seniors (65+).” Therefore, your Supplement Facts label fails to list all of the groups of individuals, by age or status (Pregnant\u002FLactating). for which the products are intended.\u003C\u002Fp>\n\n\u003Cp>&nbsp; b. Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong> (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) includes a Supplement Facts label with columns for “Amount per Serving” and “% DV” for unspecified intended consumers; however, your “Suggested Use” panel lists several intended consumers, including “children, 1-3 years,” “Children, 4-13 years,” “Adults, 14-64 years” (the serving size indicated on the Supplement Facts label), and “Pregnant\u002FLactating and Seniors, 65+.” Therefore, your Supplement Facts label fails to list all of the groups of individuals, by age or status (Pregnant\u002FLactating), for which the products are intended.\u003C\u002Fp>\n\n\u003Cp>&nbsp; c. Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong> (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) product labels use the incorrect unit of measurement for copper for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> serving size. The amount must use the unit of measurement given in 21 CFR 101.9(c)(8)(iv), as required by 21 CFR 101.36(b)(2)(ii)(B).\u003C\u002Fp>\n\n\u003Cp>2. Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong> (\u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>) and \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong> (\u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> sizes) products are misbranded within the meaning of section 403(q)(1)(A) of the Act [21 U.S.C. § 343(q)(1)(A)] because the serving size declared on the label is incorrect. Specifically, your product labels only list the serving size for one of the intended consumer groups listed in the “Suggested Use” panel. As your products are intended for several other age groups\u002Fcategories of individual (Pregnant\u002FLactating or Senior), you must list the serving size for each group\u002Fcategory in your Supplement Facts label.\u003C\u002Fp>\n\n\u003Cp>3. Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong> (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) and \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong> (\u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>) products are misbranded within the meaning of section 403(q)(1)(B) of the Act [21 U.S.C. § 343(q)(1)(B)] because the number of servings per container declared on the label is incorrect. Specifically, your product labels only list the number of servings for one of the intended consumer groups listed in the “Suggested Use” panel. As your products are intended for several other age groups\u002Fcategories of individuals, you must list the number of servings for each group\u002Fcategory in your Supplement Facts label.\u003C\u002Fp>\n\n\u003Cp>4. Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong> (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) are misbranded within the meaning of section 403(i)(2) of the Act [21 U.S.C. § 343(i)(2)] in that the product label fails to declare the common or usual names of each ingredient used as required by 21 CFR 101.36 and 21 CFR 101.4. Specifically, the label declares trace minerals as part of the proprietary blend, but this is not the common or usual name of a dietary ingredient.\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction.\u003C\u002Fp>\n\n\u003Cp>We also have the following comment:\u003C\u002Fp>\n\n\u003Cp>Based on further review of your product and process information, your firm’s “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” products appear to meet the definition of an acidified food (AF) and your firm’s “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” products appear to meet the definition of a low-acid canned food (LACF) as defined in 21 CFR Parts 108, 113 and 114. Consequently, your firm may be required to register as an LACF\u002FAF processor and file the necessary scheduled processes with FDA. We recommend working with a process authority to further evaluate your products in order to establish and file scheduled processes in accordance with 21 CFR Part 108.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written response should be sent to the following address: U.S. Food and Drug Administration, DFC Bldg 20 - W. 6th Ave &amp; Kipling St., P.O. Box 25087, Denver, CO 80225, CO, to the attention of Jennifer A. Hicks, Director of Compliance Branch. If you need additional information or have questions concerning any products distributed through your website, please contact me at 303-236-9723 or at the above address or via email at: Jennifer.Hicks@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>E. Mark Harris\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Foods–\u003Cbr>\nWest Division 4\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDietary Supplements\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Michael T. Shields and Ms. Windy N. Shields\n\nRecipient Title\n\nOwners\n\nAdept Life Science, LLC\n\n2215 E Germann Rd\n\nChandler, AZ 85286\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations East IV\n\nUnited States\n\nJanuary 24, 2023\n\nWARNING LETTER 635400\n\nIn reply, refer to CMS 635400\n\nDear Mr. Michael T. Shields and Ms. Windy N. Shields:\n\nThis is to advise you that the United States Food and Drug Administration (FDA) conducted an inspection of your facility located at 2215 E Germann Rd, Chandler, Arizona, from April 11 through April 27, 2022. Based on the inspectional findings we have identified serious violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links in FDA's home page at www.fda.gov.\n\nThe inspection of your facility revealed serious violations of FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). These violations cause your dietary supplement products to be adulterated within the meaning of section 402(g)(1) of the Act [21 United States Code (U.S.C.) § 342(g)(1)] because they have been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements. In addition, the (b)(4) brand (b)(4) and (b)(4) brand (b)(4) (in (b)(4) and (b)(4) sizes) dietary supplement products that you manufacture are misbranded within the meaning of section 403 of the Act [21 U.S.C. § 343].\n\nFDA acknowledges the receipt of your e-mail correspondence dated May 20, 2022 and June 23, 2022, written in response to the Form FDA 483, Inspectional Observations, issued to you at the close of the inspection. Not all of the items on the issued Form FDA 483 were addressed in your response. We address your response below, in relation to the applicable violations to which you responded.\n\nDietary Supplement CGMP Violations\n\nYour significant violations of CGMP requirements are as follows:\n\n1. You failed to establish an identity specification for your (b)(4) used in the manufacture of the (b)(4) brand (b)(4) product. Your raw material data sheet for (b)(4) states “(b)(4) Potency” as the specification for identity, but this does not establish standards to confirm the identity of the component used in the manufacture of your (b)(4) brand (b)(4) product, as required in 21 CFR 111.70(b)(1). Additionally, your raw material data sheet for (b)(4) used in the manufacture of the (b)(4) brand (b)(4) product has five minerals in the blend but your purported ICP-MS specification for identity lists “mineral detected” as the specification and fails to establish standards which can be used to confirm the identity of the (b)(4) component, as required in 21 CFR 111.70(b)(1).\n\n2. You failed to establish component specifications that are necessary to ensure that specifications for the purity and composition of the dietary supplement manufactured using the components are met, as required in 21 CFR 111.70(b)(2). For example, you have not established specifications for the (b)(4) Premix used in the manufacture of the (b)(4) brand (b)(4) product and specifications for several of the components used in the manufacture of the (b)(4) brand (b)(4) product to ensure that specifications for purity and composition of these products are met.\n\nWe have reviewed your June 23, 2022 response to the form FDA 483. We are unable to evaluate the adequacy of your response because you did not provide documentation demonstrating you have established specifications in accordance with 21 CFR 111.70(b)(1) and 21 CFR 111.70(b)(2). You provide documents you describe as revised finished product specifications for the (b)(4) brand (b)(4) product and (b)(4) brand (b)(4) product. We note that these documents do not demonstrate that you have established specifications that provide standards to confirm the identity, purity, strength, and composition of the finished batch of your dietary supplements. For example, the finished product specification for (b)(4) brand (b)(4) product lists an “identification” specification of “Conforms to Standard” with a test method of “Eurofins or eq.” and a frequency of “Rotational.” “Conforms to standard” does not specify the extent to which the component must conform. “Eurofins or eq.” is not a test method and “Rotational” does not describe the frequency of when testing is to occur.\n\nSimilarly, the finished product specification for your (b)(4) brand (b)(4) product states testing “Frequency” as “Rotation” for several components, and does not describe the frequency of when testing is to occur.\n\n3. You failed to establish and follow laboratory control processes that are reviewed and approved by quality control personnel, for use of criteria for selecting standard reference materials used in performing tests and examinations, as required by 21 CFR 111.315(d). Specifically, the FTIR analysis performed by your third-party laboratory uses previous shipments of components as the reference for testing and they do not own a reference library for the FTIR tests. Testing components against previous shipments of the component may confirm receipt of the same component but this does not ensure the identity, purity, quality, and strength of the component is thoroughly characterized .\n\n4. Your quality control operations did not approve and release, or reject, each finished batch for distribution as required by 21 CFR 111.123(a)(8). Specifically, your firm distributed (b)(4) brand (b)(4) product, Lot # (b)(4), without quality control review, approval and release of the finished batch for distribution.\n\n5. Your quality control personnel must not approve and release for distribution any batch of dietary supplement, including any reprocessed batch, that does not meet all product specifications established in accordance with 21 CFR 111.70(e), as required by 21 CFR 111.123(b)(2). Your quality control personnel released (b)(4) brand (b)(4), Lot # (b)(4), when the specification for pH was not met. Specifically, your established finished product specification for pH for the (b)(4) brand (b)(4) product is (b)(4) and the pH of the product in Lot # (b)(4) released for distribution was 6.34.\n\n6. Your quality control personnel neither rejected a component or dietary supplement when that component or dietary supplement failed to meet a specification established in accordance with 21 CFR 111.70, nor did they approve a treatment, an in-process adjustment, or reprocessing, as permitted in 21 CFR 111.77, in accordance with 21 CFR 111.113(b)(2). Specifically, (b)(4) brand (b)(4), Lot # (b)(4), uses (b)(4) and (b)(4) as components. Testing of these two components by a third-party laboratory found both were not within your established specifications. Your quality control personnel failed to reject these components used in the manufacturing of your finished product and failed to reject the (b)(4) brand (b)(4) product, Lot # (b)(4).\n\n7. Your quality control operations failed to approve, and release from quarantine, all components, before they are used as required by 21 CFR 111.120(e). Specifically, your quality control operations approved, and released from quarantine several components used in the manufacture of (b)(4) brand (b)(4) product, Lot # (b)(4), and components used in the manufacture of (b)(4) brand (b)(4), Lot # (b)(4). For example, the raw material data sheets for the components (b)(4), and (b)(4) used in the manufacture of your (b)(4) brand (b)(4), Lot # (b)(4), and the raw material data sheets for the (b)(4) and the (b)(4) used in the manufacture of your (b)(4) brand (b)(4) product, Lot # (b)(4) do not show a disposition by your quality control operations to approve, and release these components for use in manufacturing your finished products.\n\n8. You failed to prepare and follow a master manufacturing record (MMR) for each unique formulation of dietary supplement that you manufacture, and for each batch size, to ensure uniformity in the finished batch from batch to batch, which includes all required information, as required by 21 CFR 111.205(a) and 21 CFR 111.210. Specifically, the Master Manufacturing Records for the following (b)(4) brand products which you manufacture were missing the following required elements:\n\na. (b)(4) Item # (b)(4):\n\ni. A statement of theoretical yield of a manufactured dietary supplement expected at each point, step, or stage of the manufacturing process and the maximum and minimum percentages of theoretical yield beyond which a deviation investigation of a batch is necessary. (21 CFR 111.210(f)).\n\nii. Procedures for sampling and a cross-reference to procedures for tests or examinations. (21 CFR 111.210(h)(2)).\n\nb. (b)(4) Item # (b)(4):\n\ni. A statement of theoretical yield of a manufactured dietary supplement expected at each point, step, or stage of the manufacturing process and the maximum and minimum percentages of theoretical yield beyond which a deviation investigation of a batch is necessary. (21 CFR 111.210(f)).\n\nii. Procedures for sampling and a cross-reference to procedures for tests or examinations. (21 CFR 111.210(h)(2)).\n\nMisbrand Dietary Supplements\n\n1. Your (b)(4) brand (b)(4) and (b)(4) brand (b)(4) and (b)(4) sizes) products are misbranded within the meaning of section 403(q)(5)(F) of the Act (21 U.S.C. 343 (q)(5)(F)) in that the presentation of the nutrition information on the labeling of your product does not comply with 21 CFR 101.36. For example,\n\na. Your (b)(4) brand (b)(4) ((b)(4)) includes a Supplement Facts label with columns for “Amount per Serving (29.6 mL),” “Ages 4+ yrs,” “Pregnant and Lactating,” “Per serving (2.5 mL),” and “Ages 2-3 yrs.” Your “Suggested Use” panel includes different serving instructions for “2-3 Years,” “4-10 Years,” “11-17 Years,” “18 Years+,” and “Pregnant\u002FLactating & Seniors (65+).” Therefore, your Supplement Facts label fails to list all of the groups of individuals, by age or status (Pregnant\u002FLactating). for which the products are intended.\n\nb. Your (b)(4) brand (b)(4) ((b)(4)) includes a Supplement Facts label with columns for “Amount per Serving” and “% DV” for unspecified intended consumers; however, your “Suggested Use” panel lists several intended consumers, including “children, 1-3 years,” “Children, 4-13 years,” “Adults, 14-64 years” (the serving size indicated on the Supplement Facts label), and “Pregnant\u002FLactating and Seniors, 65+.” Therefore, your Supplement Facts label fails to list all of the groups of individuals, by age or status (Pregnant\u002FLactating), for which the products are intended.\n\nc. Your (b)(4) brand (b)(4) ((b)(4)) product labels use the incorrect unit of measurement for copper for the (b)(4) serving size. The amount must use the unit of measurement given in 21 CFR 101.9(c)(8)(iv), as required by 21 CFR 101.36(b)(2)(ii)(B).\n\n2. Your (b)(4) brand (b)(4) ((b)(4) and (b)(4)) and (b)(4) brand (b)(4) ((b)(4) and (b)(4) sizes) products are misbranded within the meaning of section 403(q)(1)(A) of the Act [21 U.S.C. § 343(q)(1)(A)] because the serving size declared on the label is incorrect. Specifically, your product labels only list the serving size for one of the intended consumer groups listed in the “Suggested Use” panel. As your products are intended for several other age groups\u002Fcategories of individual (Pregnant\u002FLactating or Senior), you must list the serving size for each group\u002Fcategory in your Supplement Facts label.\n\n3. Your (b)(4) brand (b)(4) ((b)(4)) and (b)(4) brand (b)(4) ((b)(4) and (b)(4)) products are misbranded within the meaning of section 403(q)(1)(B) of the Act [21 U.S.C. § 343(q)(1)(B)] because the number of servings per container declared on the label is incorrect. Specifically, your product labels only list the number of servings for one of the intended consumer groups listed in the “Suggested Use” panel. As your products are intended for several other age groups\u002Fcategories of individuals, you must list the number of servings for each group\u002Fcategory in your Supplement Facts label.\n\n4. Your (b)(4) brand (b)(4) ((b)(4)) are misbranded within the meaning of section 403(i)(2) of the Act [21 U.S.C. § 343(i)(2)] in that the product label fails to declare the common or usual names of each ingredient used as required by 21 CFR 101.36 and 21 CFR 101.4. Specifically, the label declares trace minerals as part of the proprietary blend, but this is not the common or usual name of a dietary ingredient.\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction.\n\nWe also have the following comment:\n\nBased on further review of your product and process information, your firm’s “(b)(4)” products appear to meet the definition of an acidified food (AF) and your firm’s “(b)(4)” products appear to meet the definition of a low-acid canned food (LACF) as defined in 21 CFR Parts 108, 113 and 114. Consequently, your firm may be required to register as an LACF\u002FAF processor and file the necessary scheduled processes with FDA. We recommend working with a process authority to further evaluate your products in order to establish and file scheduled processes in accordance with 21 CFR Part 108.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour written response should be sent to the following address: U.S. Food and Drug Administration, DFC Bldg 20 - W. 6th Ave & Kipling St., P.O. Box 25087, Denver, CO 80225, CO, to the attention of Jennifer A. Hicks, Director of Compliance Branch. If you need additional information or have questions concerning any products distributed through your website, please contact me at 303-236-9723 or at the above address or via email at: Jennifer.Hicks@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nE. Mark Harris\n\nProgram Division Director\n\nOffice of Human and Animal Foods–\n\nWest Division 4","Adept Life Science, LLC","adept-life-science-llc-635400-01242023","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fadept-life-science-llc-635400-01242023","2026-10-26T08:07:50.072651+00:00","2023-01-31","635400","Dietary SupplementsFood & Beverages","Division of Human and Animal Food Operations East IV","Mr. Michael T. Shields and Ms. Windy N. Shields","2026-08-20T01:16:44.743+00:00","2023-01-24",{"id":125,"raw":126,"subject":63,"body_html":131,"body_text":132,"firm_name":133,"letter_id":134,"created_at":135,"fei_number":20,"letter_url":136,"updated_at":137,"action_type":23,"case_status":24,"posted_date":138,"marcs_cms_no":139,"product_type":73,"closeout_date":20,"issuing_office":62,"recipient_name":140,"body_fetched_at":141,"delivery_method":142,"recipient_title":20,"reference_number":143,"action_taken_date":144,"medical_device_id":20,"response_letter_date":20},863,[127,128,129,62,130,13,13,13],"\u003Ctime datetime=\"2025-06-03T04:00:00Z\">06\u002F03\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-04-30T04:00:00Z\">04\u002F30\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frechon-life-science-ab-701040-04302025\">Rechon Life Science AB\u003C\u002Fa>","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated\u003Cbr \u002F>\r\n","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL WITH READ RECEIPT\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-68\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Roland Holmqvist\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Rechon Life Science AB\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Soldattorpsvagen 5\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Limhamn\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>216 13\u003C\u002Fspan> \u003Cspan>Skane Lan\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Sweden\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-68\u003C\u002Fp>\u003Cp>April 30, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Holmqvist:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Rechon Life Sciences AB, FEI 3002806978, at Soldattorpsvagen 5, Limhamn, Skane Lan, 216 13, Sweden, from August 26 to September 6, 2024.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your September 27, 2024 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to ensure adequate aseptic behavior and establish appropriate written procedures designed to prevent microbiological contamination risks during the manufacture of drug products purported to be sterile. On August 26, 2024, our investigators observed an operator touching the \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> with their gloved hand during the set up and assembly of the aseptic processing line.\u003C\u002Fp>\u003Cp>This unacceptable practice of touching the \u003Cstrong>(b)(4)\u003C\u002Fstrong> with gloved hands was permitted in your standard operating procedure (SOP-0870-3.0) for filling and sealing on the ampoule line. For example, your procedure allowed the operator to adjust the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, “with the fingertip” of a sanitized gloved hand.\u003C\u002Fp>\u003Cp>Your smoke studies simulated multiple adjustments of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> with gloved hands during interventions and assembly. In one smoke study video, the operator made contact with the \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the ampoule line \u003Cstrong>(b)(4)\u003C\u002Fstrong> during the “Assembly” phase.\u003C\u002Fp>\u003Cp>In your response, you provide corrective actions and preventative actions (CAPAs), including awareness training for all operators, a deviation investigation that examined 2 years of \u003Cstrong>(b)(4)\u003C\u002Fstrong> swab samples, a procedure revision, and the rejection of the affected batch.\u003C\u002Fp>\u003Cp>Your response is inadequate. You state that there was no intentional or accidental contact of the gloved hand with the \u003Cstrong>(b)(4)\u003C\u002Fstrong> during inspection. You also state the SOP for filling and sealing on the ampoule line “specifically stated that operators are not allowed to touch the \u003Cstrong>(b)(4)\u003C\u002Fstrong>.” However, this assertion conflicts with your procedure and operator practices demonstrated in your smoke study videos. You did not provide environmental monitoring trend data for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> swab samples. Furthermore, your revised procedure still allows for \u003Cstrong>(b)(4)\u003C\u002Fstrong> adjustments with sanitized, gloved fingertips, instructing operators to touch the \u003Cstrong>(b)(4)\u003C\u002Fstrong> as “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and to not “touch the \u003Cstrong>(b)(4)\u003C\u002Fstrong>.” It is important that personnel avoid direct contact of critical surfaces with any part of their gown or gloves. Only sterile instruments should be used for manipulations and interventions on the aseptic processing line when handling sterilized materials. These sterile instruments should be stored in ISO 5 conditions when not in use to prevent contamination.\u003C\u002Fp>\u003Cp>For additional guidance on aseptic processing see FDA’s guidance document \u003Cem>Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including an independent assessment that includes, but is not limited to:\u003Cbr>o All human interactions within the ISO 5 area\u003Cbr>o Equipment placement and ergonomics\u003Cbr>o Air quality in the ISO 5 area and surrounding room\u003Cbr>o Facility layout\u003Cbr>o Personnel Flows and Material Flows (throughout all rooms used to conduct and support sterile operations)\u003C\u002Fli>\u003Cli>A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control.\u003C\u002Fli>\u003Cli>Your plan to ensure appropriate aseptic practices and cleanroom behavior during production. Include steps to better assure routine and effective supervisory oversight for all production batches. Also, describe the frequency of quality assurance oversight (e.g., audit) during aseptic processing and other operations.\u003C\u002Fli>\u003Cli>A thorough risk assessment that evaluates how poor aseptic technique and cleanroom behavior, such as those observed during the inspection, may have affected quality and sterility of your drugs.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your investigations into environmental monitoring (EM) excursion results and out-of- specification (OOS) assay results were inadequate.\u003C\u002Fp>\u003Cp>A. Your CAPAs to the persistent contamination of objectionable microorganisms were not robust, as evidenced by the continued recovery of gram-negative organisms and spore formers in the ISO 5 and 7 areas and on personnel since 2022. This deficiency was also cited during the previous inspection when an adverse trend of gram-negative rods (\u003Cem>Moraxella osloensis\u003C\u002Fem>) were recovered from operators’ clothing.\u003C\u002Fp>\u003Cp>For example, your investigation into the trend of eight occurrences of gram-negative organisms recovered from either operators’ gowning or from an ISO 7 air sample, was inadequate. You concluded that the adverse trend was due to operators talking in the ISO 7 areas and an increase of staff illness. Your CAPA included awareness training for operators and a procedural update for persons who perform sampling in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, your investigation did not provide a holistic evaluation of all potential contamination sources and personnel practices in the facility contributing to the adverse trend.\u003C\u002Fp>\u003Cp>In your response, you state you will implement additional immediate actions, including the requirement for mouth covers in ISO 8 areas and having operators apply a second layer of shoe covers as they pass through the \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Your response is inadequate. Although you state you do not have a “current issue related to objectionable microorganisms, i.e. spore formers and gram-negative bacteria,” you fail to provide sufficient evidence to support this statement. In addition, you do not address ill operators working in aseptic areas as noted in your deviation as the identified root cause for the trend.\u003C\u002Fp>\u003Cp>B. Your investigations into OOS results were inadequate because they lacked scientific rationale for root cause determinations. For example, you initiated an OOS investigation for \u003Cstrong>(b)(4)\u003C\u002Fstrong> assay content for \u003Cstrong>(b)(4)\u003C\u002Fstrong> Injection, \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg\u002FmL, batch \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The specification for \u003Cstrong>(b)(4)\u003C\u002Fstrong> content was \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg\u002FmL. The sample was injected \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and your initial test yielded an \u003Cstrong>(b)(4)\u003C\u002Fstrong> result of \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg\u002FmL \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your investigation concluded, without adequate scientific justification, that a non-functional injector syringe was the probable root cause. You invalidated the original results without an obvious laboratory error and no manufacturing assessment was performed. A new analysis was performed and the passing results were recorded.\u003C\u002Fp>\u003Cp>In your response, you acknowledge that the laboratory investigations “contain gaps” and your procedure for conducting OOS investigations can be improved. You revised your procedures to include hypothesis testing during the laboratory investigations.\u003C\u002Fp>\u003Cp>Your response is inadequate. Your revised procedures do not require a manufacturing investigation to be conducted prior to invalidating data unless it is an obvious laboratory error. In addition, your company did not conduct a retrospective review of invalidated laboratory data for drug products marketed in the United States to ensure the drug meets the identity, strength, quality and purity it purports.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality assurance unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\u003Cli>A comprehensive independent review of your personnel and environmental monitoring program, including but not limited to:\u003Cbr>o A plan to fully remediate these programs. For example, describe changes to equipment, procedures and practices that will ensure meaningful ongoing data is collected to promptly detect and respond to emerging microbial trends from your classified areas. Provide an updated timeline for implementation of your program, including procedural changes.\u003C\u002Fli>\u003Cli>A retrospective, independent review of all invalidated OOS (including in-process and release\u002Fstability testing) results for U.S. products currently in the U.S. market and within expiry as of the date of this letter and a report summarizing the findings of the analysis, including the following for each OOS:\u003Cbr>o Determine whether the scientific justification and evidence relating to the invalidated OOS result conclusively or inconclusively demonstrates causative laboratory error.\u003Cbr>o For investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\u003Cbr>o For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.\u003Cbr>o A comprehensive review and remediation plan for your OOS result investigation systems. The CAPA should include, but not be limited to, addressing the following:\u003Cbr>&nbsp; &nbsp; o Quality unit oversight of laboratory investigations.\u003Cbr>&nbsp; &nbsp; o Identification of adverse laboratory control trends.\u003Cbr>&nbsp; &nbsp; o Resolution of causes of laboratory variation.\u003Cbr>&nbsp; &nbsp; o Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified.\u003Cbr>&nbsp; &nbsp; o Adequately scoping of each investigation and its CAPA.\u003Cbr>&nbsp; &nbsp; o Revised OOS investigation procedures with these and other remediations.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to establish an adequate system for cleaning and disinfecting the room and equipment to produce aseptic conditions (21 CFR 211.42(c)(10)(v)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>A. Your firm failed to validate and assess the effectiveness, distribution, and reproducibility of \u003Cstrong>(b)(4)\u003C\u002Fstrong> decontamination to ensure it can safely achieve a state of control in aseptic rooms against objectionable microorganisms.\u003C\u002Fp>\u003Cp>For example, your firm utilized \u003Cstrong>(b)(4)\u003C\u002Fstrong> as an \u003Cstrong>(b)(4)\u003C\u002Fstrong> decontamination of aseptic filling lines \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your investigation reported several instances of spore-forming bacteria during \u003Cstrong>(b)(4)\u003C\u002Fstrong>, in ISO 7 areas. The identified bacteria included species such as \u003Cem>Paenibacillus provencensis\u002Fshunpengii\u002Furinalis, Bacillus infantis, Niallia circulans complex, Metabacillus halosaccharovorans, Peribacillus simplex, Bacillus subtilis\u003C\u002Fem> group and \u003Cem>Bacillus cereus\u003C\u002Fem> group. The root cause was identified as an “inadequate process for \u003Cstrong>(b)(4)\u003C\u002Fstrong> sanitization,” which was “unclear and may be causing the growth of spore forming bacteria in Grade B.” Additionally, the same \u003Cstrong>(b)(4)\u003C\u002Fstrong> decontamination cycle showed positive biological indicators (BIs) on aseptic lines \u003Cstrong>(b)(4)\u003C\u002Fstrong> during \u003Cstrong>(b)(4)\u003C\u002Fstrong> periods (\u003Cstrong>(b)(4)\u003C\u002Fstrong>). The results indicate the \u003Cstrong>(b)(4)\u003C\u002Fstrong> decontamination process is ineffective.\u003C\u002Fp>\u003Cp>In your response, you state the BIs were used for informational purposes only and not as an evaluation of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> decontamination process. You acknowledge the title of the SOP “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Sanitization – Decontamination of rooms at Bulk Production” is misleading and the use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> is not implemented as a routine decontamination process. You corrected the title to be “Disinfection of grade A and B areas within Bulk Production with \u003Cstrong>(b)(4)\u003C\u002Fstrong>.” You state that you will collaborate with your vendor to perform a mapping study to verify the effectiveness of the disinfection process.\u003C\u002Fp>\u003Cp>Your response is inadequate. You do not provide evidence the \u003Cstrong>(b)(4)\u003C\u002Fstrong> decontamination process provides adequate surface coverage of all areas on the aseptic line, is compatible with materials, and ensures that residual \u003Cstrong>(b)(4)\u003C\u002Fstrong> that may remain on equipment does not affect product quality. Critical cleaning and sanitization agents must be validated. A mapping study is not validation of the disinfectant. Validation requires documented evidence that the disinfection process consistently removes or inactivates known or possible pathogens.\u003C\u002Fp>\u003Cp>B. Our investigators observed walls and floors of numerous ISO 8 production rooms were sticky and left visible \u003Cstrong>(b)(4)\u003C\u002Fstrong> residue when wiped by the hand. The investigators additionally noted fibers from disposable coveralls stuck to the walls in one of the production rooms. Such residual contamination can compromise product sterility and safety potentially resulting in patient harm.\u003C\u002Fp>\u003Cp>In your response, you state that your Quality Control Microbiology (QCM) group discovered the sticky floors and walls \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your deviation investigation concluded that the probable root causes were a build-up of new cleaning disinfectants and a possible interaction with materials in the facility. Your CAPA included wiping surfaces with \u003Cstrong>(b)(4)\u003C\u002Fstrong> after cleaning.\u003C\u002Fp>\u003Cp>Your response is inadequate. You did not provide the deviation investigation for the evaluation and identification of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> residue and a risk assessment of contamination to the drug product. Furthermore, you did not provide an assessment of your cleaning validation with regard to the new cleaning agents.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A CAPA plan, based on the retrospective assessment of your cleaning and disinfection program, that includes appropriate remediations to your cleaning and disinfection processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning and disinfection. Describe improvements to your cleaning and disinfection program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning and disinfection execution for all products and equipment; and all other needed remediations.\u003C\u002Fli>\u003Cli>Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include, but not be limited to, identification and evaluation of all worst-case:\u003Cbr>o Drugs with higher toxicities\u003Cbr>o Drugs with higher drug potencies\u003Cbr>o Drugs of lower solubility in their cleaning solvents\u003Cbr>o Drugs with characteristics that make them difficult to clean\u003Cbr>o Swabbing locations for areas that are most difficult to clean\u003Cbr>o Maximum hold times before cleaning\u003Cbr>In addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\u003C\u002Fli>\u003Cli>A summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>4. Your firm failed to maintain buildings used in the manufacture, processing, packing, or holding of drug products in a good state of repair (21 CFR 211.58).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm did not properly maintain classified areas and cleanrooms used in the manufacture of drug products. Our investigators observed peeling paint on the ceiling as well as bubbled paint and rust at the bottom of the door in ISO 7 room \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Room \u003Cstrong>(b)(4)\u003C\u002Fstrong> provides access into aseptic filling line \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>These deficiencies were discussed with your management at the time of the walk-through of the aseptic areas. Management stated the peeling paint surfaces above the \u003Cstrong>(b)(4)\u003C\u002Fstrong> door may be caused by the surface material being incompatible with the cleaning agent used to clean the production facility. It is critical that the building is maintained to prevent exposure of sterile articles to potential contamination hazards in the manufacturing operation.\u003C\u002Fp>\u003Cp>In response to this letter, provide your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA refusing admission of articles manufactured at Rechon Life Science AB at Soldattorpsvagen 5, Limhamn, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3002806978 and ATTN: Erika V. Butler.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>___________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL WITH READ RECEIPT\n\nReference #:\n\n320-25-68\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Roland Holmqvist\n\nRecipient Title\n\nChief Executive Officer\n\nRechon Life Science AB\n\nSoldattorpsvagen 5\n\nLimhamn\n\n216 13 Skane Lan\n\nSweden\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-68\nApril 30, 2025\nDear Mr. Holmqvist:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Rechon Life Sciences AB, FEI 3002806978, at Soldattorpsvagen 5, Limhamn, Skane Lan, 216 13, Sweden, from August 26 to September 6, 2024.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your September 27, 2024 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n1. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\nYou failed to ensure adequate aseptic behavior and establish appropriate written procedures designed to prevent microbiological contamination risks during the manufacture of drug products purported to be sterile. On August 26, 2024, our investigators observed an operator touching the (b)(4) of the (b)(4) with their gloved hand during the set up and assembly of the aseptic processing line.\nThis unacceptable practice of touching the (b)(4) with gloved hands was permitted in your standard operating procedure (SOP-0870-3.0) for filling and sealing on the ampoule line. For example, your procedure allowed the operator to adjust the (b)(4), “with the fingertip” of a sanitized gloved hand.\nYour smoke studies simulated multiple adjustments of the (b)(4) with gloved hands during interventions and assembly. In one smoke study video, the operator made contact with the (b)(4) of the ampoule line (b)(4) during the “Assembly” phase.\nIn your response, you provide corrective actions and preventative actions (CAPAs), including awareness training for all operators, a deviation investigation that examined 2 years of (b)(4) swab samples, a procedure revision, and the rejection of the affected batch.\nYour response is inadequate. You state that there was no intentional or accidental contact of the gloved hand with the (b)(4) during inspection. You also state the SOP for filling and sealing on the ampoule line “specifically stated that operators are not allowed to touch the (b)(4).” However, this assertion conflicts with your procedure and operator practices demonstrated in your smoke study videos. You did not provide environmental monitoring trend data for the (b)(4) swab samples. Furthermore, your revised procedure still allows for (b)(4) adjustments with sanitized, gloved fingertips, instructing operators to touch the (b)(4) as “(b)(4)” and to not “touch the (b)(4).” It is important that personnel avoid direct contact of critical surfaces with any part of their gown or gloves. Only sterile instruments should be used for manipulations and interventions on the aseptic processing line when handling sterilized materials. These sterile instruments should be stored in ISO 5 conditions when not in use to prevent contamination.\nFor additional guidance on aseptic processing see FDA’s guidance document Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\nIn response to this letter, provide:\nA comprehensive risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including an independent assessment that includes, but is not limited to:\no All human interactions within the ISO 5 area\no Equipment placement and ergonomics\no Air quality in the ISO 5 area and surrounding room\no Facility layout\no Personnel Flows and Material Flows (throughout all rooms used to conduct and support sterile operations)\nA detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control.\nYour plan to ensure appropriate aseptic practices and cleanroom behavior during production. Include steps to better assure routine and effective supervisory oversight for all production batches. Also, describe the frequency of quality assurance oversight (e.g., audit) during aseptic processing and other operations.\nA thorough risk assessment that evaluates how poor aseptic technique and cleanroom behavior, such as those observed during the inspection, may have affected quality and sterility of your drugs.\n2. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\nYour investigations into environmental monitoring (EM) excursion results and out-of- specification (OOS) assay results were inadequate.\nA. Your CAPAs to the persistent contamination of objectionable microorganisms were not robust, as evidenced by the continued recovery of gram-negative organisms and spore formers in the ISO 5 and 7 areas and on personnel since 2022. This deficiency was also cited during the previous inspection when an adverse trend of gram-negative rods (Moraxella osloensis) were recovered from operators’ clothing.\nFor example, your investigation into the trend of eight occurrences of gram-negative organisms recovered from either operators’ gowning or from an ISO 7 air sample, was inadequate. You concluded that the adverse trend was due to operators talking in the ISO 7 areas and an increase of staff illness. Your CAPA included awareness training for operators and a procedural update for persons who perform sampling in (b)(4). However, your investigation did not provide a holistic evaluation of all potential contamination sources and personnel practices in the facility contributing to the adverse trend.\nIn your response, you state you will implement additional immediate actions, including the requirement for mouth covers in ISO 8 areas and having operators apply a second layer of shoe covers as they pass through the (b)(4).\nYour response is inadequate. Although you state you do not have a “current issue related to objectionable microorganisms, i.e. spore formers and gram-negative bacteria,” you fail to provide sufficient evidence to support this statement. In addition, you do not address ill operators working in aseptic areas as noted in your deviation as the identified root cause for the trend.\nB. Your investigations into OOS results were inadequate because they lacked scientific rationale for root cause determinations. For example, you initiated an OOS investigation for (b)(4) assay content for (b)(4) Injection, (b)(4) mg\u002FmL, batch (b)(4). The specification for (b)(4) content was (b)(4) mg\u002FmL. The sample was injected (b)(4), and your initial test yielded an (b)(4) result of (b)(4) mg\u002FmL (b)(4). Your investigation concluded, without adequate scientific justification, that a non-functional injector syringe was the probable root cause. You invalidated the original results without an obvious laboratory error and no manufacturing assessment was performed. A new analysis was performed and the passing results were recorded.\nIn your response, you acknowledge that the laboratory investigations “contain gaps” and your procedure for conducting OOS investigations can be improved. You revised your procedures to include hypothesis testing during the laboratory investigations.\nYour response is inadequate. Your revised procedures do not require a manufacturing investigation to be conducted prior to invalidating data unless it is an obvious laboratory error. In addition, your company did not conduct a retrospective review of invalidated laboratory data for drug products marketed in the United States to ensure the drug meets the identity, strength, quality and purity it purports.\nIn response to this letter, provide:\nA comprehensive independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality assurance unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\nA comprehensive independent review of your personnel and environmental monitoring program, including but not limited to:\no A plan to fully remediate these programs. For example, describe changes to equipment, procedures and practices that will ensure meaningful ongoing data is collected to promptly detect and respond to emerging microbial trends from your classified areas. Provide an updated timeline for implementation of your program, including procedural changes.\nA retrospective, independent review of all invalidated OOS (including in-process and release\u002Fstability testing) results for U.S. products currently in the U.S. market and within expiry as of the date of this letter and a report summarizing the findings of the analysis, including the following for each OOS:\no Determine whether the scientific justification and evidence relating to the invalidated OOS result conclusively or inconclusively demonstrates causative laboratory error.\no For investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\no For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.\no A comprehensive review and remediation plan for your OOS result investigation systems. The CAPA should include, but not be limited to, addressing the following:\no Quality unit oversight of laboratory investigations.\no Identification of adverse laboratory control trends.\no Resolution of causes of laboratory variation.\no Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified.\no Adequately scoping of each investigation and its CAPA.\no Revised OOS investigation procedures with these and other remediations.\n3. Your firm failed to establish an adequate system for cleaning and disinfecting the room and equipment to produce aseptic conditions (21 CFR 211.42(c)(10)(v)).\nA. Your firm failed to validate and assess the effectiveness, distribution, and reproducibility of (b)(4) decontamination to ensure it can safely achieve a state of control in aseptic rooms against objectionable microorganisms.\nFor example, your firm utilized (b)(4) as an (b)(4) decontamination of aseptic filling lines (b)(4). Your investigation reported several instances of spore-forming bacteria during (b)(4), in ISO 7 areas. The identified bacteria included species such as Paenibacillus provencensis\u002Fshunpengii\u002Furinalis, Bacillus infantis, Niallia circulans complex, Metabacillus halosaccharovorans, Peribacillus simplex, Bacillus subtilis group and Bacillus cereus group. The root cause was identified as an “inadequate process for (b)(4) sanitization,” which was “unclear and may be causing the growth of spore forming bacteria in Grade B.” Additionally, the same (b)(4) decontamination cycle showed positive biological indicators (BIs) on aseptic lines (b)(4) during (b)(4) periods ((b)(4)). The results indicate the (b)(4) decontamination process is ineffective.\nIn your response, you state the BIs were used for informational purposes only and not as an evaluation of the (b)(4) decontamination process. You acknowledge the title of the SOP “(b)(4) Sanitization – Decontamination of rooms at Bulk Production” is misleading and the use of (b)(4) is not implemented as a routine decontamination process. You corrected the title to be “Disinfection of grade A and B areas within Bulk Production with (b)(4).” You state that you will collaborate with your vendor to perform a mapping study to verify the effectiveness of the disinfection process.\nYour response is inadequate. You do not provide evidence the (b)(4) decontamination process provides adequate surface coverage of all areas on the aseptic line, is compatible with materials, and ensures that residual (b)(4) that may remain on equipment does not affect product quality. Critical cleaning and sanitization agents must be validated. A mapping study is not validation of the disinfectant. Validation requires documented evidence that the disinfection process consistently removes or inactivates known or possible pathogens.\nB. Our investigators observed walls and floors of numerous ISO 8 production rooms were sticky and left visible (b)(4) residue when wiped by the hand. The investigators additionally noted fibers from disposable coveralls stuck to the walls in one of the production rooms. Such residual contamination can compromise product sterility and safety potentially resulting in patient harm.\nIn your response, you state that your Quality Control Microbiology (QCM) group discovered the sticky floors and walls (b)(4). Your deviation investigation concluded that the probable root causes were a build-up of new cleaning disinfectants and a possible interaction with materials in the facility. Your CAPA included wiping surfaces with (b)(4) after cleaning.\nYour response is inadequate. You did not provide the deviation investigation for the evaluation and identification of the (b)(4) residue and a risk assessment of contamination to the drug product. Furthermore, you did not provide an assessment of your cleaning validation with regard to the new cleaning agents.\nIn response to this letter, provide:\nA CAPA plan, based on the retrospective assessment of your cleaning and disinfection program, that includes appropriate remediations to your cleaning and disinfection processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning and disinfection. Describe improvements to your cleaning and disinfection program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning and disinfection execution for all products and equipment; and all other needed remediations.\nAppropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include, but not be limited to, identification and evaluation of all worst-case:\no Drugs with higher toxicities\no Drugs with higher drug potencies\no Drugs of lower solubility in their cleaning solvents\no Drugs with characteristics that make them difficult to clean\no Swabbing locations for areas that are most difficult to clean\no Maximum hold times before cleaning\nIn addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\nA summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\n4. Your firm failed to maintain buildings used in the manufacture, processing, packing, or holding of drug products in a good state of repair (21 CFR 211.58).\nYour firm did not properly maintain classified areas and cleanrooms used in the manufacture of drug products. Our investigators observed peeling paint on the ceiling as well as bubbled paint and rust at the bottom of the door in ISO 7 room (b)(4). Room (b)(4) provides access into aseptic filling line (b)(4).\nThese deficiencies were discussed with your management at the time of the walk-through of the aseptic areas. Management stated the peeling paint surfaces above the (b)(4) door may be caused by the surface material being incompatible with the cleaning agent used to clean the production facility. It is critical that the building is maintained to prevent exposure of sterile articles to potential contamination hazards in the manufacturing operation.\nIn response to this letter, provide your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA refusing admission of articles manufactured at Rechon Life Science AB at Soldattorpsvagen 5, Limhamn, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days1. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3002806978 and ATTN: Erika V. Butler.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n___________________\n1 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","Rechon Life Science AB","rechon-life-science-ab-701040-04302025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frechon-life-science-ab-701040-04302025","2026-10-26T08:09:47.863026+00:00","2025-06-03","701040","Mr. Roland Holmqvist","2026-08-19T16:43:19.573+00:00","VIA EMAIL WITH READ RECEIPT","320-25-68","2025-04-30",{"id":146,"raw":147,"subject":149,"body_html":150,"body_text":151,"firm_name":152,"letter_id":153,"created_at":90,"fei_number":20,"letter_url":154,"updated_at":155,"action_type":23,"case_status":24,"posted_date":93,"marcs_cms_no":156,"product_type":73,"closeout_date":20,"issuing_office":62,"recipient_name":157,"body_fetched_at":158,"delivery_method":98,"recipient_title":20,"reference_number":159,"action_taken_date":100,"medical_device_id":20,"response_letter_date":20},121,[82,83,148,62,149,13,13,13],"\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fzydus-lifesciences-limited-722576-06022026\">Zydus Lifesciences Limited \u003C\u002Fa>","Request for Records\u002FCGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-92\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Dr. Sharvil Patel\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Managing Director \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Zydus Lifesciences Limited \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Near Vaishnodevi Circle, S. G. Highway\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Ahmedabad\u003C\u002Fspan> \u003Cspan>382481\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Gujarat\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>India\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-92\u003C\u002Fp>\u003Cp>June 2, 2026\u003C\u002Fp>\u003Cp>Dear Dr. Patel:\u003C\u002Fp>\u003Cp>Your facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of prescription drug products. FDA has reviewed the records you submitted in response to our November 7, 2025 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) for your facility, Zydus Lifesciences Limited, FEI 3005430968, at Village Swaraj Majra, P.O. Baddi, Tehsil-Nalagarh, Solan Himachal Pradesh.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 351(a)(2)(B)).\u003C\u002Fp>\u003Cp>Following review of records and other information provided pursuant to section 704(a)(4) of the FD&amp;C Act, significant violations were observed including, but not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to withhold from use each lot of components, drug product containers, and closures until the lot had been sampled, tested, or examined, as appropriate, and failed to test samples for conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures prescription \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products containing talc. \u003Cstrong>(b)(4)\u003C\u002Fstrong> USP is composed of more than \u003Cstrong>(b)(4)\u003C\u002Fstrong>% talc. Both talc and asbestos are naturally occurring minerals that may be found in close proximity in the earth. Asbestos is a potential contaminant in talc and is a known human carcinogen when inhaled.\u003Cem>\u003Cstrong>\u003Csup>1,2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Additionally, published scientific literature dating back to the 1960s has suggested a possible association between the use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> containing talc in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> area and the incidence of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, potentially linked to asbestos contamination of the talc.\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> The \u003Cstrong>(b)(4)\u003C\u002Fstrong> you produce can be used on areas of the body which may be an exposure risk (e.g., inhalation or\u003Cstrong> (b)(4) \u003C\u002Fstrong>area). Your product is also labeled for use in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your drug product, \u003Cstrong>(b)(4)\u003C\u002Fstrong> USP, is considered a higher-risk drug as it pertains to patient safety regarding asbestos contamination of talc due to the risk of inadvertent inhalation or potential use in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> area.\u003C\u002Fp>\u003Cp>You have not demonstrated that you have appropriately tested incoming talc, a drug component, used in the manufacture of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products. For example, your internal testing procedures and specifications are written in accordance with the current United States Pharmacopeia (USP) specification for absence of asbestos, however, your records do not demonstrate you are testing to current USP requirements. For asbestos testing your data refers to identification testing by Infrared (IR) Spectroscopy. Current USP absence of asbestos procedure \u003Cstrong>(b)(4)\u003C\u002Fstrong> by Infrared (IR) Spectroscopy includes the evaluation of the presence of tremolite chlorite and serpentines, through scale expansions of spectra at the required wavenumbers at \u003Cstrong>(b)(4)\u003C\u002Fstrong> cm-\u003Csup>1\u003C\u002Fsup>, and in the range of \u003Cstrong>(b)(4)\u003C\u002Fstrong> cm-\u003Csup>1\u003C\u002Fsup> to \u003Cstrong>(b)(4)\u003C\u002Fstrong> cm-\u003Csup>1\u003C\u002Fsup>. Your instrument reports for the identification spectroscopy was from \u003Cstrong>(b)(4)\u003C\u002Fstrong> cm-\u003Csup>1\u003C\u002Fsup> to \u003Cstrong>(b)(4)\u003C\u002Fstrong> cm-\u003Csup>1\u003C\u002Fsup> wavenumbers and did not include any scale expansions. Your identification spectra does not evaluate for the presence of serpentines in the range of \u003Cstrong>(b)(4)\u003C\u002Fstrong> cm-\u003Csup>1\u003C\u002Fsup> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> cm-\u003Csup>1\u003C\u002Fsup>. Furthermore, review of the available spectral data reveals absorption features in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> cm⁻¹ and \u003Cstrong>(b)(4)\u003C\u002Fstrong> cm⁻¹ region across multiple lots, which encompasses the critical \u003Cstrong>(b)(4)\u003C\u002Fstrong> cm⁻¹ range specified for tremolite\u002Fchlorite detection, yet no scale expansion analysis was documented in any of the analytical records as per the current USP monograph.\u003C\u002Fp>\u003Cp>As a manufacturer, you have a responsibility to sample, test, and examine, as appropriate, drug components before use in production to ensure acceptable specifications for identity, strength, quality, and purity are met. Because you have not performed appropriate testing that detects asbestos in your talc components, among other things, you failed to assure the acceptability of these drug components for use in manufacture of your drug products.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>Using an independent laboratory, appropriate asbestos testing results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of talc (drug component) used in the manufacture of your drug products within expiry. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for asbestos.\u003C\u002Fli>\u003Cli>A comprehensive independent assessment of your laboratory practices, procedures, methods, and specifications. Based on this review, provide a detailed plan to remediate deficiencies and evaluate the effectiveness of corrections in your laboratory system.\u003C\u002Fli>\u003Cli>A full risk assessment for drug products that are within expiry which contain any ingredient at risk for asbestos contamination. Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain asbestos. Appropriate actions could include customer notifications and drug product recalls for any contaminated lots.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products are manufactured in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your quality unit (QU) did not effectively exercise its authority to ensure appropriate testing is conducted. Your records submitted for talc identification testing by IR spectroscopy show that an out-of-specification (OOS) wavenumber result was removed from an infrared instrument report and multiple passing wavenumbers were added. These changes allowed a failing identification test to appear as if it met release specifications. Your QU failed in its responsibility to maintain data integrity and provide adequate oversight of testing procedures, demonstrating a lack of authority and control over critical quality decisions. Furthermore, a review of all submitted certificates of analysis for talc show a pattern of numerous wavenumbers that may be statistically unlikely and raises concerns regarding the authenticity of the reported results. Between 2022 and 2025, out of 29 approved analytical results, 21 reports have identical maxima at \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> cm⁻¹ across different lots and dates.\u003C\u002Fp>\u003Cp>Your QU is responsible for fully exercising its authority and responsibilities, including responsibility for approving or rejecting all procedures or specifications impacting the identity, strength, quality, and purity of the drug product. Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>ICH Q10 Pharmaceutical Quality System\u003C\u002Fem>, as well as \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem>, for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71553\u002Fdownload and https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload, respectively.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>Results from a comprehensive investigation into the extent of the data anomalies identified in this letter and a report including any corrective and preventative action for the investigation for drugs distributed to the United States. To aid in your investigation, you may refer to FDA’s guidance document \u003Cem>Data Integrity and Compliance with Drug CGMP: Questions and Answers\u003C\u002Fem> for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\u003C\u002Fli>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>o A complete and final review of representative batches within expiry and their related information before the QU disposition decision\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff may also allow you to meet obligations you may have to report permanent discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(a). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA refusing admission of articles manufactured at Zydus Lifesciences Limited, FEI 3005430968, at Village Swaraj Majra, P.O. Baddi, Tehsil-Nalagarh, Solan Himachal Pradesh into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days.\u003Cem>\u003Cstrong>\u003Csup>4\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Specify what you have done to address any violations and to prevent their recurrence. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion. If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3005430968 and ATTN: Nancy Espinal.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>CC: Mr. Prashant Sharma\u003Cbr>Chief Technical Officer\u003Cbr>Zydus Lifesciences Limited\u003Cbr>Village Swaraj Majra,\u003Cbr>P.O. Baddi, Tehsil-Nalagarh\u003Cbr>Solan Himachal Pradesh 173205 India\u003C\u002Fp>\u003Cp>CC:\u003Cbr>Zydus Pharmaceuticals (USA) Inc.\u003Cbr>Mr. Srinivas Gurram (Srini)\u003Cbr>Senior Vice President - Head of RA and CQA lead -Americas,\u003Cbr>73-B, Route 31 North\u003Cbr>Pennington, NJ 08534\u003C\u002Fp>\u003Cp>____________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> https:\u002F\u002Fwww.cancer.gov\u002Fabout-cancer\u002Fcauses-prevention\u002Frisk\u002Fsubstances\u002Fasbestos\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> https:\u002F\u002Fwww.atsdr.cdc.gov\u002Fasbestos\u002Fhealth-effects\u002F\u003C\u002Fp>\u003Cp>\u003Cstrong>3 \u003C\u002Fstrong>https:\u002F\u002Fwww.fda.gov\u002Fcosmetics\u002Fcosmetic-ingredients\u002Ftalc\u003C\u002Fp>\u003Cp>\u003Cstrong>4\u003C\u002Fstrong> Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\u003Cp>&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nReference #:\n\n320-26-92\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nDr. Sharvil Patel\n\nRecipient Title\n\nManaging Director\n\nZydus Lifesciences Limited\n\nNear Vaishnodevi Circle, S. G. Highway\n\nAhmedabad 382481\n\nGujarat\n\nIndia\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-92\nJune 2, 2026\nDear Dr. Patel:\nYour facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of prescription drug products. FDA has reviewed the records you submitted in response to our November 7, 2025 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility, Zydus Lifesciences Limited, FEI 3005430968, at Village Swaraj Majra, P.O. Baddi, Tehsil-Nalagarh, Solan Himachal Pradesh.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 351(a)(2)(B)).\nFollowing review of records and other information provided pursuant to section 704(a)(4) of the FD&C Act, significant violations were observed including, but not limited to, the following:\n1. Your firm failed to withhold from use each lot of components, drug product containers, and closures until the lot had been sampled, tested, or examined, as appropriate, and failed to test samples for conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84).\nYour firm manufactures prescription (b)(4) drug products containing talc. (b)(4) USP is composed of more than (b)(4)% talc. Both talc and asbestos are naturally occurring minerals that may be found in close proximity in the earth. Asbestos is a potential contaminant in talc and is a known human carcinogen when inhaled.1,2 Additionally, published scientific literature dating back to the 1960s has suggested a possible association between the use of (b)(4) containing talc in the (b)(4) area and the incidence of (b)(4), potentially linked to asbestos contamination of the talc.3 The (b)(4) you produce can be used on areas of the body which may be an exposure risk (e.g., inhalation or (b)(4) area). Your product is also labeled for use in (b)(4). Your drug product, (b)(4) USP, is considered a higher-risk drug as it pertains to patient safety regarding asbestos contamination of talc due to the risk of inadvertent inhalation or potential use in the (b)(4) area.\nYou have not demonstrated that you have appropriately tested incoming talc, a drug component, used in the manufacture of your (b)(4) drug products. For example, your internal testing procedures and specifications are written in accordance with the current United States Pharmacopeia (USP) specification for absence of asbestos, however, your records do not demonstrate you are testing to current USP requirements. For asbestos testing your data refers to identification testing by Infrared (IR) Spectroscopy. Current USP absence of asbestos procedure (b)(4) by Infrared (IR) Spectroscopy includes the evaluation of the presence of tremolite chlorite and serpentines, through scale expansions of spectra at the required wavenumbers at (b)(4) cm-1, and in the range of (b)(4) cm-1 to (b)(4) cm-1. Your instrument reports for the identification spectroscopy was from (b)(4) cm-1 to (b)(4) cm-1 wavenumbers and did not include any scale expansions. Your identification spectra does not evaluate for the presence of serpentines in the range of (b)(4) cm-1 and (b)(4) cm-1. Furthermore, review of the available spectral data reveals absorption features in the (b)(4) cm⁻¹ and (b)(4) cm⁻¹ region across multiple lots, which encompasses the critical (b)(4) cm⁻¹ range specified for tremolite\u002Fchlorite detection, yet no scale expansion analysis was documented in any of the analytical records as per the current USP monograph.\nAs a manufacturer, you have a responsibility to sample, test, and examine, as appropriate, drug components before use in production to ensure acceptable specifications for identity, strength, quality, and purity are met. Because you have not performed appropriate testing that detects asbestos in your talc components, among other things, you failed to assure the acceptability of these drug components for use in manufacture of your drug products.\nIn response to this letter, provide:\nUsing an independent laboratory, appropriate asbestos testing results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of talc (drug component) used in the manufacture of your drug products within expiry. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for asbestos.\nA comprehensive independent assessment of your laboratory practices, procedures, methods, and specifications. Based on this review, provide a detailed plan to remediate deficiencies and evaluate the effectiveness of corrections in your laboratory system.\nA full risk assessment for drug products that are within expiry which contain any ingredient at risk for asbestos contamination. Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain asbestos. Appropriate actions could include customer notifications and drug product recalls for any contaminated lots.\n2. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products are manufactured in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nYour quality unit (QU) did not effectively exercise its authority to ensure appropriate testing is conducted. Your records submitted for talc identification testing by IR spectroscopy show that an out-of-specification (OOS) wavenumber result was removed from an infrared instrument report and multiple passing wavenumbers were added. These changes allowed a failing identification test to appear as if it met release specifications. Your QU failed in its responsibility to maintain data integrity and provide adequate oversight of testing procedures, demonstrating a lack of authority and control over critical quality decisions. Furthermore, a review of all submitted certificates of analysis for talc show a pattern of numerous wavenumbers that may be statistically unlikely and raises concerns regarding the authenticity of the reported results. Between 2022 and 2025, out of 29 approved analytical results, 21 reports have identical maxima at (b)(4), and (b)(4) cm⁻¹ across different lots and dates.\nYour QU is responsible for fully exercising its authority and responsibilities, including responsibility for approving or rejecting all procedures or specifications impacting the identity, strength, quality, and purity of the drug product. Your firm’s quality systems are inadequate. See FDA’s guidance document ICH Q10 Pharmaceutical Quality System, as well as Quality Systems Approach to Pharmaceutical CGMP Regulations, for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71553\u002Fdownload and https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload, respectively.\nIn response to this letter, provide:\nResults from a comprehensive investigation into the extent of the data anomalies identified in this letter and a report including any corrective and preventative action for the investigation for drugs distributed to the United States. To aid in your investigation, you may refer to FDA’s guidance document Data Integrity and Compliance with Drug CGMP: Questions and Answers for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\no A complete and final review of representative batches within expiry and their related information before the QU disposition decision\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff may also allow you to meet obligations you may have to report permanent discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(a). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA refusing admission of articles manufactured at Zydus Lifesciences Limited, FEI 3005430968, at Village Swaraj Majra, P.O. Baddi, Tehsil-Nalagarh, Solan Himachal Pradesh into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days.4 Specify what you have done to address any violations and to prevent their recurrence. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion. If you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3005430968 and ATTN: Nancy Espinal.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\nCC: Mr. Prashant Sharma\nChief Technical Officer\nZydus Lifesciences Limited\nVillage Swaraj Majra,\nP.O. Baddi, Tehsil-Nalagarh\nSolan Himachal Pradesh 173205 India\nCC:\nZydus Pharmaceuticals (USA) Inc.\nMr. Srinivas Gurram (Srini)\nSenior Vice President - Head of RA and CQA lead -Americas,\n73-B, Route 31 North\nPennington, NJ 08534\n____________________\n1 https:\u002F\u002Fwww.cancer.gov\u002Fabout-cancer\u002Fcauses-prevention\u002Frisk\u002Fsubstances\u002Fasbestos\n2 https:\u002F\u002Fwww.atsdr.cdc.gov\u002Fasbestos\u002Fhealth-effects\u002F\n3 https:\u002F\u002Fwww.fda.gov\u002Fcosmetics\u002Fcosmetic-ingredients\u002Ftalc\n4 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","Zydus Lifesciences Limited","zydus-lifesciences-limited-722576-06022026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fzydus-lifesciences-limited-722576-06022026","2026-10-26T08:10:40.165964+00:00","722576","Dr. Sharvil Patel","2026-08-19T04:38:28.567+00:00","320-26-92",{"id":161,"raw":162,"subject":166,"body_html":167,"body_text":168,"firm_name":169,"letter_id":170,"created_at":90,"fei_number":20,"letter_url":171,"updated_at":172,"action_type":23,"case_status":24,"posted_date":173,"marcs_cms_no":174,"product_type":73,"closeout_date":20,"issuing_office":62,"recipient_name":175,"body_fetched_at":176,"delivery_method":177,"recipient_title":20,"reference_number":178,"action_taken_date":179,"medical_device_id":20,"response_letter_date":20},267,[163,164,165,62,166,13,13,13],"\u003Ctime datetime=\"2026-03-17T04:00:00Z\">03\u002F17\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-03-09T04:00:00Z\">03\u002F09\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvedic-lifesciences-pvt-ltd-722446-03092026\">Vedic Lifesciences Pvt. Ltd.\u003C\u002Fa>","Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE AND VIA E-MAIL\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>26-HFD-45-03-02\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jayesh Chaudhary\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Vedic Lifesciences Pvt. Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>203, Morya Landmark 1, Off New Link Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Andheri West\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Mumbai\u003C\u002Fspan> \u003Cspan>400053\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Maharashtra\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>India\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA Ref. No.: 26-HFD-45-03-02\u003C\u002Fp>\u003Cp>Dear Mr. Chaudhary:\u003C\u002Fp>\u003Cp>This Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted between January 13 and 15, 2025. The investigators representing FDA reviewed the role of Vedic Lifesciences Pvt. Ltd. (Vedic) as the testing facility of the following nonclinical laboratory studies of the investigational drug \u003Cstrong>(b)(4)\u003C\u002Fstrong>, performed for \u003Cstrong>(b)(4)\u003C\u002Fstrong>.:\u003C\u002Fp>\u003Cp>• Study No.\u003Cstrong>(b)(4)\u003C\u002Fstrong>: “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”\u003Cbr>• Study No.\u003Cstrong>(b)(4)\u003C\u002Fstrong>: “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”\u003Cbr>• Study No.\u003Cstrong>(b)(4)\u003C\u002Fstrong>: “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”\u003C\u002Fp>\u003Cp>This inspection was conducted as part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure the quality and integrity of study data, in accordance with Title 21 of the Code of Federal Regulations, part 58 (21 CFR 58), Good Laboratory Practice for Nonclinical Laboratory Studies.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection, the FDA investigators presented and discussed with you the Form FDA 483, Inspectional Observations. We acknowledge receipt of your February 3, 2025, written response to the Form FDA 483.\u003C\u002Fp>\u003Cp>From our review of the FDA Establishment Inspection Report, the documents submitted with that report, and your written response dated February 3, 2025, it appears that you did not adhere to the applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) and applicable regulations contained in 21 CFR 58 governing the conduct of nonclinical laboratory studies. We wish to emphasize the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>You failed to prepare a final report for each nonclinical laboratory study that includes, but is not limited to, the following: (1) name and address of the testing facility; (2) name of the study director and other scientists or professionals involved in the study; (3) locations where all specimens, raw data, and final reports are to be stored; and (4) study director’s signature and date [21 CFR 58.185(a)(1), 58.185(a)(10), 58.185(a)(13), and 58.185(b)].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>A final report must be prepared for each nonclinical laboratory study and must contain certain information, including but not limited to: (1) the name and address of the testing facility performing the study; (2) the names of the study director and other scientists or professionals involved in the study; and (3) the location where all specimens, raw data, and the final report are stored. The final report must also be signed and dated by the study director.\u003C\u002Fp>\u003Cp>You failed to adhere to these requirements. Specifically, the final reports for studies \u003Cstrong>(b)(4)\u003C\u002Fstrong> that Vedic submitted to the sponsor did not contain complete and accurate information for the above-described items that were required to be included in the final report. Examples include but are not limited to the following:\u003C\u002Fp>\u003Cp>1. The final reports for studies \u003Cstrong>(b)(4)\u003C\u002Fstrong> did not accurately identify the testing facility that performed the studies. Specifically, the testing facility that performed studies \u003Cstrong>(b)(4)\u003C\u002Fstrong> was \u003Cstrong>(b)(4) \u003C\u002Fstrong>(\u003Cstrong>(b)(4)\u003C\u002Fstrong>), and the testing facility that performed Study \u003Cstrong>(b)(4)\u003C\u002Fstrong> was \u003Cstrong>(b)(4)\u003C\u002Fstrong> (\u003Cstrong>(b)(4)\u003C\u002Fstrong>). However, before submitting the final reports to the sponsor, Vedic changed the final reports to falsely include the name and address of Vedic as the testing facility that performed the study.\u003C\u002Fp>\u003Cp>2. The final reports for studies \u003Cstrong>(b)(4)\u003C\u002Fstrong> did not include the correct names of the study director and other scientists or professionals involved in the study, such as the quality assurance unit (QAU) personnel. Specifically, before submitting the final reports to the sponsor, Vedic changed the final reports provided by the testing facilities that performed the study to falsely include the names of Vedic personnel as the study director or QAU personnel.\u003C\u002Fp>\u003Cp>3. The final reports for studies \u003Cstrong>(b)(4)\u003C\u002Fstrong> did not accurately identify the storage location for all specimens, raw data, and final reports. Specifically, before submitting the final reports to the sponsor, Vedic changed the final reports to falsely identify Vedic as the storage location; however, all specimens, raw data, and final reports were stored at \u003Cstrong>(b)(4)\u003C\u002Fstrong> for studies \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and at \u003Cstrong>(b)(4)\u003C\u002Fstrong> for Study \u003Cstrong>(b)(4)\u003C\u002Fstrong>, the testing facilities that actually performed these studies.\u003C\u002Fp>\u003Cp>4. The study directors for studies \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4) \u003C\u002Fstrong>did not sign the final reports for these studies. In accordance with 21 CFR 58.33, the study director is the individual responsible for the overall conduct of the study. For these three studies, Vedic personnel signed the final reports. However, the Vedic personnel who signed the final reports were not involved in the conduct of these studies because the studies were performed at other testing facilities. Therefore, the Vedic personnel who signed the final reports were not the individuals responsible for the overall conduct of the studies. As a result, the final reports for studies \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> did not include accurate study director signatures.\u003C\u002Fp>\u003Cp>We acknowledge that some of these findings were not included on the Form FDA 483 you received, and therefore your written response does not directly address all the violations discussed in this letter.\u003C\u002Fp>\u003Cp>However, during the inspection, the Manager of Quality Assurance stated that Vedic personnel do not serve as study directors, Vedic does not maintain study archives, Vedic has never had an animal facility, and Vedic is not a testing facility where the toxicology studies are conducted. Additionally, in your February 3, 2025, written response to the Form FDA 483, you acknowledged that Vedic outsourced Studies \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and Study \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You stated that Vedic is not a toxicology testing facility and instead operates as a liaison to prospective clients who are looking to conduct toxicology studies. You stated that it was your earlier practice to withhold from sponsors the names and contact information of partner testing facilities, study directors, QAU personnel, and archive locations to “prevent circumvention by the testing facility.” You further stated that in accordance with Vedic’s standard operating procedure (SOP), the Vedic study monitor was the single point of study control and therefore was captured as the single point of study control in the reports.\u003C\u002Fp>\u003Cp>In your written response, you stated that as part of your corrective and preventive actions, since 2022, you have stopped mentioning Vedic as a testing facility, and the details of the testing facility are now shared with the study sponsors. You also stated that you realized that your practice of listing the Vedic study monitor as the single point of study control in reports is not correct, and that the actual study director is now mentioned in final reports. You also stated that you amended the final report for Study \u003Cstrong>(b)(4)\u003C\u002Fstrong> to add the name of the correct testing facility and study director. However, since the \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing facility has closed its operations, you were unable to retrieve and amend the study reports for Studies \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Additionally, you stated that you revised your SOP for Toxicological Operations to implement the following practices: (1) The name and address of the study director will be included in the final report; (2) Vedic will be identified as the sponsor representative in the study plan and report; (3) the Vedic study monitor will sign the study plan and report; and (4) testing facility management of the GLP facility will ensure that the study director approves the study plan and report.\u003C\u002Fp>\u003Cp>While we acknowledge the actions that your site has taken and plans to take, your written response is inadequate because you did not provide sufficient details about your corrective action plan. Specifically, you did not provide sufficient details about the procedures and practices for preparing final reports that have been or will be implemented at your site to prevent similar violations in the future. For example, you did not provide details regarding any training for Vedic personnel on your updated procedures and practices. Also, the SOP that you provided does not include all the practices identified in your written response, such as including the name and address of the study director in the final report. Without this information, we cannot undertake an informed evaluation of your written response, and it is not clear whether your corrective and preventive actions will adequately ensure that ongoing and future studies will be conducted in compliance with applicable FDA regulations, including the requirements for preparing final reports.\u003C\u002Fp>\u003Cp>Failure to include accurate and complete information in the final study report raises significant concerns about the quality and integrity of the study records and data from Studies \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The final study report of an investigation is crucial to the reconstruction of the events that led to the collection and reporting of the data, and it must contain accurate and complete information regarding the conduct of the study. The information in these essential documents forms the basis for establishing scientific interpretations and conclusions and must therefore reflect all circumstances affecting the quality and integrity of the data.\u003C\u002Fp>\u003Cp>We further emphasize that nonclinical laboratory studies submitted to FDA must be accurately and completely reported in accordance with FDA regulations, to ensure the quality and integrity of study data. Your failure to provide final reports for all three studies, containing accurate and complete information that is required to be submitted to support FDA’s review of a nonclinical laboratory study, raises significant concerns about the validity and integrity of the data that were collected and submitted for these nonclinical laboratory studies.\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive list of deficiencies with the nonclinical laboratory studies of investigational drugs for which Vedic was the testing facility, as represented in final reports submitted to FDA. It is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations. You should address any deficiencies and establish procedures to ensure that any ongoing or future studies comply with FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you with an opportunity to address the deficiencies noted above. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions you have taken to prevent similar violations in the future. Failure to address this matter adequately may lead to regulatory action without further notice to you. If you believe that you have complied with the FD&amp;C Act and relevant regulations, please include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Should you have any questions or concerns about this letter or the inspection, please email FDA at CDER-OSI-Communications@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Your written response and any pertinent documentation should be addressed to:\u003C\u002Fp>\u003Cp>Brittany L. Garr, MPH\u003Cbr>Branch Chief\u003Cbr>Compliance Enforcement Branch\u003Cbr>Division of Enforcement and Postmarketing Safety\u003Cbr>Office of Scientific Investigations\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003Cbr>Building 51, Room 5352\u003Cbr>10903 New Hampshire Avenue\u003Cbr>Silver Spring, MD 20993\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>{See appended electronic signature page}\u003Cbr>David C. Burrow, Pharm.D., J.D.\u003Cbr>Director\u003Cbr>Office of Scientific Investigations\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003Cbr>\u003Cbr>--------------------------------------------------------------------------------------------\u003Cbr>This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.\u003Cbr>--------------------------------------------------------------------------------------------\u003Cbr>\u002Fs\u002F\u003Cbr>------------------------------------------------------------\u003Cbr>DAVID C BURROW\u003Cbr>03\u002F09\u002F2026 10:48:01 AM\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE AND VIA E-MAIL\n\nReference #:\n\n26-HFD-45-03-02\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nJayesh Chaudhary\n\nRecipient Title\n\nCEO\n\nVedic Lifesciences Pvt. Ltd.\n\n203, Morya Landmark 1, Off New Link Road\n\nAndheri West\n\nMumbai 400053\n\nMaharashtra\n\nIndia\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nFDA Ref. No.: 26-HFD-45-03-02\nDear Mr. Chaudhary:\nThis Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted between January 13 and 15, 2025. The investigators representing FDA reviewed the role of Vedic Lifesciences Pvt. Ltd. (Vedic) as the testing facility of the following nonclinical laboratory studies of the investigational drug (b)(4), performed for (b)(4).:\n• Study No.(b)(4): “(b)(4)”\n• Study No.(b)(4): “(b)(4)”\n• Study No.(b)(4): “(b)(4)”\nThis inspection was conducted as part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure the quality and integrity of study data, in accordance with Title 21 of the Code of Federal Regulations, part 58 (21 CFR 58), Good Laboratory Practice for Nonclinical Laboratory Studies.\nAt the conclusion of the inspection, the FDA investigators presented and discussed with you the Form FDA 483, Inspectional Observations. We acknowledge receipt of your February 3, 2025, written response to the Form FDA 483.\nFrom our review of the FDA Establishment Inspection Report, the documents submitted with that report, and your written response dated February 3, 2025, it appears that you did not adhere to the applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&C Act) and applicable regulations contained in 21 CFR 58 governing the conduct of nonclinical laboratory studies. We wish to emphasize the following:\nYou failed to prepare a final report for each nonclinical laboratory study that includes, but is not limited to, the following: (1) name and address of the testing facility; (2) name of the study director and other scientists or professionals involved in the study; (3) locations where all specimens, raw data, and final reports are to be stored; and (4) study director’s signature and date [21 CFR 58.185(a)(1), 58.185(a)(10), 58.185(a)(13), and 58.185(b)].\nA final report must be prepared for each nonclinical laboratory study and must contain certain information, including but not limited to: (1) the name and address of the testing facility performing the study; (2) the names of the study director and other scientists or professionals involved in the study; and (3) the location where all specimens, raw data, and the final report are stored. The final report must also be signed and dated by the study director.\nYou failed to adhere to these requirements. Specifically, the final reports for studies (b)(4) that Vedic submitted to the sponsor did not contain complete and accurate information for the above-described items that were required to be included in the final report. Examples include but are not limited to the following:\n1. The final reports for studies (b)(4) did not accurately identify the testing facility that performed the studies. Specifically, the testing facility that performed studies (b)(4) was (b)(4) ((b)(4)), and the testing facility that performed Study (b)(4) was (b)(4) ((b)(4)). However, before submitting the final reports to the sponsor, Vedic changed the final reports to falsely include the name and address of Vedic as the testing facility that performed the study.\n2. The final reports for studies (b)(4) did not include the correct names of the study director and other scientists or professionals involved in the study, such as the quality assurance unit (QAU) personnel. Specifically, before submitting the final reports to the sponsor, Vedic changed the final reports provided by the testing facilities that performed the study to falsely include the names of Vedic personnel as the study director or QAU personnel.\n3. The final reports for studies (b)(4) did not accurately identify the storage location for all specimens, raw data, and final reports. Specifically, before submitting the final reports to the sponsor, Vedic changed the final reports to falsely identify Vedic as the storage location; however, all specimens, raw data, and final reports were stored at (b)(4) for studies (b)(4), and at (b)(4) for Study (b)(4), the testing facilities that actually performed these studies.\n4. The study directors for studies (b)(4) and (b)(4) did not sign the final reports for these studies. In accordance with 21 CFR 58.33, the study director is the individual responsible for the overall conduct of the study. For these three studies, Vedic personnel signed the final reports. However, the Vedic personnel who signed the final reports were not involved in the conduct of these studies because the studies were performed at other testing facilities. Therefore, the Vedic personnel who signed the final reports were not the individuals responsible for the overall conduct of the studies. As a result, the final reports for studies (b)(4), and (b)(4) did not include accurate study director signatures.\nWe acknowledge that some of these findings were not included on the Form FDA 483 you received, and therefore your written response does not directly address all the violations discussed in this letter.\nHowever, during the inspection, the Manager of Quality Assurance stated that Vedic personnel do not serve as study directors, Vedic does not maintain study archives, Vedic has never had an animal facility, and Vedic is not a testing facility where the toxicology studies are conducted. Additionally, in your February 3, 2025, written response to the Form FDA 483, you acknowledged that Vedic outsourced Studies (b)(4) to (b)(4), and Study (b)(4) to (b)(4). You stated that Vedic is not a toxicology testing facility and instead operates as a liaison to prospective clients who are looking to conduct toxicology studies. You stated that it was your earlier practice to withhold from sponsors the names and contact information of partner testing facilities, study directors, QAU personnel, and archive locations to “prevent circumvention by the testing facility.” You further stated that in accordance with Vedic’s standard operating procedure (SOP), the Vedic study monitor was the single point of study control and therefore was captured as the single point of study control in the reports.\nIn your written response, you stated that as part of your corrective and preventive actions, since 2022, you have stopped mentioning Vedic as a testing facility, and the details of the testing facility are now shared with the study sponsors. You also stated that you realized that your practice of listing the Vedic study monitor as the single point of study control in reports is not correct, and that the actual study director is now mentioned in final reports. You also stated that you amended the final report for Study (b)(4) to add the name of the correct testing facility and study director. However, since the (b)(4) testing facility has closed its operations, you were unable to retrieve and amend the study reports for Studies (b)(4). Additionally, you stated that you revised your SOP for Toxicological Operations to implement the following practices: (1) The name and address of the study director will be included in the final report; (2) Vedic will be identified as the sponsor representative in the study plan and report; (3) the Vedic study monitor will sign the study plan and report; and (4) testing facility management of the GLP facility will ensure that the study director approves the study plan and report.\nWhile we acknowledge the actions that your site has taken and plans to take, your written response is inadequate because you did not provide sufficient details about your corrective action plan. Specifically, you did not provide sufficient details about the procedures and practices for preparing final reports that have been or will be implemented at your site to prevent similar violations in the future. For example, you did not provide details regarding any training for Vedic personnel on your updated procedures and practices. Also, the SOP that you provided does not include all the practices identified in your written response, such as including the name and address of the study director in the final report. Without this information, we cannot undertake an informed evaluation of your written response, and it is not clear whether your corrective and preventive actions will adequately ensure that ongoing and future studies will be conducted in compliance with applicable FDA regulations, including the requirements for preparing final reports.\nFailure to include accurate and complete information in the final study report raises significant concerns about the quality and integrity of the study records and data from Studies (b)(4). The final study report of an investigation is crucial to the reconstruction of the events that led to the collection and reporting of the data, and it must contain accurate and complete information regarding the conduct of the study. The information in these essential documents forms the basis for establishing scientific interpretations and conclusions and must therefore reflect all circumstances affecting the quality and integrity of the data.\nWe further emphasize that nonclinical laboratory studies submitted to FDA must be accurately and completely reported in accordance with FDA regulations, to ensure the quality and integrity of study data. Your failure to provide final reports for all three studies, containing accurate and complete information that is required to be submitted to support FDA’s review of a nonclinical laboratory study, raises significant concerns about the validity and integrity of the data that were collected and submitted for these nonclinical laboratory studies.\nThis letter is not intended to be an all-inclusive list of deficiencies with the nonclinical laboratory studies of investigational drugs for which Vedic was the testing facility, as represented in final reports submitted to FDA. It is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations. You should address any deficiencies and establish procedures to ensure that any ongoing or future studies comply with FDA regulations.\nThis letter notifies you of our findings and provides you with an opportunity to address the deficiencies noted above. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions you have taken to prevent similar violations in the future. Failure to address this matter adequately may lead to regulatory action without further notice to you. If you believe that you have complied with the FD&C Act and relevant regulations, please include your reasoning and any supporting information for our consideration.\nShould you have any questions or concerns about this letter or the inspection, please email FDA at CDER-OSI-Communications@fda.hhs.gov.\nYour written response and any pertinent documentation should be addressed to:\nBrittany L. Garr, MPH\nBranch Chief\nCompliance Enforcement Branch\nDivision of Enforcement and Postmarketing Safety\nOffice of Scientific Investigations\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\nBuilding 51, Room 5352\n10903 New Hampshire Avenue\nSilver Spring, MD 20993\nSincerely,\n{See appended electronic signature page}\nDavid C. Burrow, Pharm.D., J.D.\nDirector\nOffice of Scientific Investigations\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n\n--------------------------------------------------------------------------------------------\nThis is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.\n--------------------------------------------------------------------------------------------\n\u002Fs\u002F\n------------------------------------------------------------\nDAVID C BURROW\n03\u002F09\u002F2026 10:48:01 AM","Vedic Lifesciences Pvt. Ltd.","vedic-lifesciences-pvt-ltd-722446-03092026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvedic-lifesciences-pvt-ltd-722446-03092026","2026-10-26T08:10:26.834215+00:00","2026-03-17","722446","Jayesh Chaudhary","2026-08-19T04:51:25.466+00:00","VIA UNITED PARCEL SERVICE AND VIA E-MAIL","26-HFD-45-03-02","2026-03-09",{"id":181,"raw":182,"subject":63,"body_html":187,"body_text":188,"firm_name":152,"letter_id":189,"created_at":19,"fei_number":20,"letter_url":190,"updated_at":191,"action_type":23,"case_status":192,"posted_date":193,"marcs_cms_no":194,"product_type":73,"closeout_date":195,"issuing_office":62,"recipient_name":157,"body_fetched_at":196,"delivery_method":98,"recipient_title":20,"reference_number":197,"action_taken_date":198,"medical_device_id":20,"response_letter_date":20},1269,[183,184,185,62,63,13,186,13],"\u003Ctime datetime=\"2024-09-10T13:20:00Z\">09\u002F10\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-08-29T04:00:00Z\">08\u002F29\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fzydus-lifesciences-limited-685224-08292024\">Zydus Lifesciences Limited\u003C\u002Fa>","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fzydus-lifesciences-limited-685224-12092025\">\u003Ctime datetime=\"2025-12-16T05:00:00Z\">12\u002F16\u002F2025\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-24-58\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Dr. Sharvil Patel\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Managing Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Zydus Lifesciences Limited\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Zydus Corporate Park, S.G. Highway\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Nr. Vashnodevi Circle\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Ahmedabad\u003C\u002Fspan> \u003Cspan>382482\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>India\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-24-58\u003C\u002Fp>\n\n\u003Cp>August 29, 2024\u003C\u002Fp>\n\n\u003Cp>Dear Dr. Patel:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Zydus Lifesciences Limited, FEI 3013712903, at Survey No. 434\u002F6\u002FB &amp; 434\u002F1\u002FK, Vadodara – Halol Highway Village - Jarod, Taluka - Waghodia, Gujarat, from April 15 to 23, 2024.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your May 14, 2024 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to adequately investigate contamination identified in your drug products.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Cross-contamination\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Over approximately 3 months, you experienced multiple cross-contamination events. Your firm identified cross-contamination from \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug product in at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> subsequent other drug product batches manufactured with shared equipment due to inadequate cleaning. Your investigation failed to consider all impacted batches, all manufacturing equipment involved, and the adequacy of your testing methods used to release contaminated drug products.\u003C\u002Fp>\n\n\u003Cp>Notably, your initial cleaning study failed to assess whether your cleaning methods were adequate to clean \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug product, which you later found to be “stickier” on product contact surfaces. Your subsequent cleaning studies also did not assess all product contact surfaces. Your firm attempted to implement improved cleaning as a corrective action and preventive action (CAPA) but continued to manufacture and identify cross-contamination.\u003C\u002Fp>\n\n\u003Cp>Furthermore, you released some batches of drug products with results of “not detected” for \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination despite identifying contamination that was out of trend (OOT) in other related batches. You provided no rationale for how the samples tested were representative of the potential for overall batch contamination.\u003C\u002Fp>\n\n\u003Cp>In your response, you state that you decided to use dedicated equipment for \u003Cstrong>(b)(4)\u003C\u002Fstrong> and committed to monitor batches made on shared equipment through their shelf life for related substances because you continued to observe cross-contamination.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because this type of contamination is generally nonuniformly distributed and testing alone is insufficient to determine the scope of the cross-contamination issue and mitigate associated risks.\u003C\u002Fp>\n\n\u003Cp>On July 2, 2024, you conducted a voluntary recall for Verapamil Hydrochloride Injection, USP 5 mg \u002F 2mL, batches L300255, L300262, L300263; Verapamil Hydrochloride Injection, USP 10 mg\u002F4 mL, batch L300269 for cross-contamination with other products as noted on the following FDA website: https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002F?Event=94912.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Glass Particulate Contamination\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Your firm failed to adequately investigate and determine the root cause of glass particulate contamination in multiple batches of Cyanocobalamin Injection USP 1000mcg\u002FmL, 1mL found out of limits (OOL) or above alert limits. Without identifying a root cause, you conducted successive visual inspections of batches until glass particulates were within specification and then released batches of Cyanocobalamin Injection USP 1000mcg\u002FmL, 1mL, even though there was potential for glass contamination.\u003C\u002Fp>\n\n\u003Cp>In addition, your operators performing manual visual inspections were not adequately qualified for their ability to identify these defects. For example, your visual inspection qualification kit for Cyanocobalamin Injection USP 1000mcg\u002FmL, 1mL, qualified the operators’ ability to identify glass particles as low as \u003Cstrong>(b)(4)\u003C\u002Fstrong> micrometers in unlabeled \u003Cstrong>(b)(4)\u003C\u002Fstrong> vials. However, the visual inspection of commercial drug product lots of Cyanocobalamin Injection USP 1000mcg\u002FmL, 1mL investigated for glass particle contamination was conducted in labeled \u003Cstrong>(b)(4)\u003C\u002Fstrong> vials that found glass particulates as small as 150 micrometers.\u003C\u002Fp>\n\n\u003Cp>In your response, you state that you discontinued the manufacturing of Cyanocobalamin Injection 1000mcg\u002FmL, 1mL in August 2022, and that so far you have not received complaints for glass found in the product. You also state that your visual inspection qualification kits now include appropriately sized particles based on probability of detection and that you will inspect control samples monthly through expiry for particles.\u003C\u002Fp>\n\n\u003Cp>You response is inadequate. The lack of current customer complaints alone is neither a verification of a robust quality system nor indication that you have appropriate process controls in place to conclude that glass fragments may not be present in your products.\u003C\u002Fp>\n\n\u003Cp>On June 27, 2024, you conducted a voluntary recall for Cyanocobalamin Injection USP 1000mcg\u002FmL, 1mL, Batches L200253, L200281, and L200301, for the presence of glass particulate matter as noted on the following FDA website: https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002F?Event=94914.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide a comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit (QU) oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to ensure adequate aseptic behavior and adequate airflow simulations to prevent potential contamination.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Poor Aseptic Behavior\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Our investigators observed multiple instances of poor aseptic techniques during the start-up and filling of \u003Cstrong>(b)(4)\u003C\u002Fstrong> for injection, batch \u003Cstrong>(b)(4)\u003C\u002Fstrong>. For example, operators disrupted first-air in your ISO-5 areas by reaching over sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> vials, \u003Cstrong>(b)(4)\u003C\u002Fstrong> stoppers, and the stopper \u003Cstrong>(b)(4)\u003C\u002Fstrong> during interventions without removing the affected vials or stoppers. Additionally, your operators touched \u003Cstrong>(b)(4)\u003C\u002Fstrong> stoppers with the \u003Cstrong>(b)(4)\u003C\u002Fstrong> restricted access barrier system (\u003Cstrong>(b)(4)\u003C\u002Fstrong>-RABS) \u003Cstrong>(b)(4)\u003C\u002Fstrong> while aligning the stopper \u003Cstrong>(b)(4)\u003C\u002Fstrong> during setup.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Inadequate Airflow Simulations\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>You produced and distributed drug product purporting to be sterile without first conducting adequate process simulations. Specifically, your airflow simulations (smoke studies) for filling line \u003Cstrong>(b)(4)\u003C\u002Fstrong> did not adequately demonstrate unidirectional airflow during \u003Cstrong>(b)(4)\u003C\u002Fstrong> interventions within the \u003Cstrong>(b)(4)\u003C\u002Fstrong>-RABS ISO 5 area. For example, airflow was observed flowing outward and upward during \u003Cstrong>(b)(4)\u003C\u002Fstrong> interventions. However, the simulation did not adequately depict airflow (the smoke was not visible) to determine whether HEPA filtered air was reaching the critical \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Additionally, the design of the stopper conveyer track exiting the stopper \u003Cstrong>(b)(4)\u003C\u002Fstrong> appears to block first-air for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> stoppers moving along the track.\u003C\u002Fp>\n\n\u003Cp>In your response, you state that the lack of visible smoke was due to the location and limited number of smoke sticks during the \u003Cstrong>(b)(4)\u003C\u002Fstrong> condition. You also state that you have conducted new smoke studies. Further, you state that your operators followed procedures, that these “interventions are evaluated during airflow studies,” and that you observed no discrepancies. Lastly, you indicate that there were no media fill or sterility failures for the past 2 years.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because your response does not adequately address the poor aseptic technique that was observed. You also did not address how you will ensure adequate review and approval of qualification and validation studies where deficiencies may exist. In addition, you do not commit to perform a comprehensive review of similar qualification and validation studies to ensure their adequacy.\u003C\u002Fp>\n\n\u003Cp>Any intervention or stoppage during an aseptic process can increase the risk of contamination. The risk to finished product sterility assurance increases with operator interventions in an aseptic processing operation. Your aseptic manufacturing processes should be designed, and operations executed, to prevent contamination hazards to your sterile product. Flaws in the design of cleanrooms and aseptic processing lines, or improper execution of aseptic operations, can promote influx of contamination into the \u003Cstrong>(b)(4)\u003C\u002Fstrong> (ISO 5) processing area.\u003C\u002Fp>\n\n\u003Cp>For additional guidance on aseptic processing see FDA’s guidance document \u003Cem>Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including an independent assessment that includes, but is not limited to:\u003Cbr>\n&nbsp; o All human interactions within the ISO 5 area\u003Cbr>\n&nbsp; o Equipment placement and ergonomics\u003Cbr>\n&nbsp; o Air quality in the ISO 5 area and surrounding room\u003Cbr>\n&nbsp; o Facility layout\u003Cbr>\n&nbsp; o Personnel Flows and Material Flows (throughout all rooms used to conduct and support sterile operations)\u003C\u002Fp>\n\n\u003Cp>• A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control.\u003C\u002Fp>\n\n\u003Cp>• Your plan to ensure appropriate aseptic practices and cleanroom behavior during production. Include steps to ensure routine and effective supervisory oversight for all production batches. Also describe the frequency of QU oversight (e.g., audit) during aseptic processing and its support operations.\u003C\u002Fp>\n\n\u003Cp>• A thorough retrospective review and risk assessment that evaluates how poor aseptic technique and cleanroom behavior may have affected the quality and sterility of your drugs.\u003C\u002Fp>\n\n\u003Cp>• An evaluation of the design of the stopper conveyer track to assess the adequacy of unidirectional airflow interacting with your equipment.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish adequate written procedures for production and process control designed to assure that drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess, and to follow all of your written production and process control procedures (21 CFR 211.100 (a) and 211.100 (b).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your process performance qualifications (PPQ) lack adequate supporting data to assess variability in your manufacturing processes. Specifically, statistical sampling plans were not adequately established and followed to evaluate intra- and inter-batch variation in your PPQs. For example, your PPQ study for \u003Cstrong>(b)(4)\u003C\u002Fstrong> Injection USP \u003Cstrong>(b)(4)\u003C\u002Fstrong>mg\u002Fvial failed to establish acceptance criteria for intra- and inter-batch variation. Instead, \u003Cstrong>(b)(4)\u003C\u002Fstrong> sampling was conducted, reporting singular results for critical quality attributes (CQAs), including assay, impurities, and pH. Sampling and testing between your \u003Cstrong>(b)(4)\u003C\u002Fstrong> used for the PPQ batches also failed to include acceptance criteria for intra- and inter-batch variability for \u003Cstrong>(b)(4)\u003C\u002Fstrong> content.\u003C\u002Fp>\n\n\u003Cp>You also failed to collect \u003Cstrong>(b)(4)\u003C\u002Fstrong> data during your PPQ studies for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products to assess whether stoppering of the vials within your \u003Cstrong>(b)(4)\u003C\u002Fstrong> adequately prevented unintended ingress of air and maintained specified \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>In your response, you state that adequate sampling was conducted and that your products are in a state of control, and specifically, that your PPQ intra- and inter-batch variability was observed below \u003Cstrong>(b)(4)\u003C\u002Fstrong>% standard deviation for the CQAs and critical process parameters (CPPs). You commit to revising your procedures to include acceptance criteria for intra- and inter-batch evaluations for variability for your drug products, conduct retrospective reviews, and additional PPQ studies. You also state that you now conduct 100% leak tests for your sterile injectable drug products.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because your evaluation of variability does not appear to be the result of enhanced sampling, but from analytical testing results already provided in your PPQ summary reports which consisted of composite samples and results.\u003C\u002Fp>\n\n\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluate batches to determine whether an initial state of control has been established.\u003C\u002Fp>\n\n\u003Cp>Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document \u003Cem>Process Validation: General Principles and Practices\u003C\u002Fem> for general principles and approaches that the FDA considers appropriate elements of process validation, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\u003Cbr>\n\u003Cbr>\nIn response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• An assessment of each drug product process to ensure that there is a data-driven and scientifically sound program that identifies and controls all sources of variability, such that your production processes, and will consistently meet appropriate specifications and manufacturing standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, sufficiency of detectability in your monitoring and testing systems, quality of input materials, and reliability of each manufacturing process step and control.\u003C\u002Fp>\n\n\u003Cp>• Timelines for completing further PPQ studies for marketed drug products for which a state of control has not been adequately\u002Ffully established.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\u003C\u002Fp>\n\n\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\n\n\u003Cp>Failure to address any violations may also result in the FDA refusing admission of articles manufactured at Zydus Lifesciences Limited, Survey No. 434\u002F6\u002FB &amp; 434\u002F1\u002FK, Vadodara – Halol Highway Village - Jarod, Taluka - Waghodia, Gujarat into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3013712903 and ATTN: Michael Klapal.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>__________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nReference #:\n\n320-24-58\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nDr. Sharvil Patel\n\nRecipient Title\n\nManaging Director\n\nZydus Lifesciences Limited\n\nZydus Corporate Park, S.G. Highway\n\nNr. Vashnodevi Circle\n\nAhmedabad 382482\n\nIndia\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-24-58\n\nAugust 29, 2024\n\nDear Dr. Patel:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Zydus Lifesciences Limited, FEI 3013712903, at Survey No. 434\u002F6\u002FB & 434\u002F1\u002FK, Vadodara – Halol Highway Village - Jarod, Taluka - Waghodia, Gujarat, from April 15 to 23, 2024.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your May 14, 2024 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\n\nYou failed to adequately investigate contamination identified in your drug products.\n\nCross-contamination\n\nOver approximately 3 months, you experienced multiple cross-contamination events. Your firm identified cross-contamination from (b)(4) drug product in at least (b)(4) subsequent other drug product batches manufactured with shared equipment due to inadequate cleaning. Your investigation failed to consider all impacted batches, all manufacturing equipment involved, and the adequacy of your testing methods used to release contaminated drug products.\n\nNotably, your initial cleaning study failed to assess whether your cleaning methods were adequate to clean (b)(4) drug product, which you later found to be “stickier” on product contact surfaces. Your subsequent cleaning studies also did not assess all product contact surfaces. Your firm attempted to implement improved cleaning as a corrective action and preventive action (CAPA) but continued to manufacture and identify cross-contamination.\n\nFurthermore, you released some batches of drug products with results of “not detected” for (b)(4) contamination despite identifying contamination that was out of trend (OOT) in other related batches. You provided no rationale for how the samples tested were representative of the potential for overall batch contamination.\n\nIn your response, you state that you decided to use dedicated equipment for (b)(4) and committed to monitor batches made on shared equipment through their shelf life for related substances because you continued to observe cross-contamination.\n\nYour response is inadequate because this type of contamination is generally nonuniformly distributed and testing alone is insufficient to determine the scope of the cross-contamination issue and mitigate associated risks.\n\nOn July 2, 2024, you conducted a voluntary recall for Verapamil Hydrochloride Injection, USP 5 mg \u002F 2mL, batches L300255, L300262, L300263; Verapamil Hydrochloride Injection, USP 10 mg\u002F4 mL, batch L300269 for cross-contamination with other products as noted on the following FDA website: https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002F?Event=94912.\n\nGlass Particulate Contamination\n\nYour firm failed to adequately investigate and determine the root cause of glass particulate contamination in multiple batches of Cyanocobalamin Injection USP 1000mcg\u002FmL, 1mL found out of limits (OOL) or above alert limits. Without identifying a root cause, you conducted successive visual inspections of batches until glass particulates were within specification and then released batches of Cyanocobalamin Injection USP 1000mcg\u002FmL, 1mL, even though there was potential for glass contamination.\n\nIn addition, your operators performing manual visual inspections were not adequately qualified for their ability to identify these defects. For example, your visual inspection qualification kit for Cyanocobalamin Injection USP 1000mcg\u002FmL, 1mL, qualified the operators’ ability to identify glass particles as low as (b)(4) micrometers in unlabeled (b)(4) vials. However, the visual inspection of commercial drug product lots of Cyanocobalamin Injection USP 1000mcg\u002FmL, 1mL investigated for glass particle contamination was conducted in labeled (b)(4) vials that found glass particulates as small as 150 micrometers.\n\nIn your response, you state that you discontinued the manufacturing of Cyanocobalamin Injection 1000mcg\u002FmL, 1mL in August 2022, and that so far you have not received complaints for glass found in the product. You also state that your visual inspection qualification kits now include appropriately sized particles based on probability of detection and that you will inspect control samples monthly through expiry for particles.\n\nYou response is inadequate. The lack of current customer complaints alone is neither a verification of a robust quality system nor indication that you have appropriate process controls in place to conclude that glass fragments may not be present in your products.\n\nOn June 27, 2024, you conducted a voluntary recall for Cyanocobalamin Injection USP 1000mcg\u002FmL, 1mL, Batches L200253, L200281, and L200301, for the presence of glass particulate matter as noted on the following FDA website: https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002F?Event=94914.\n\nIn response to this letter, provide a comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit (QU) oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\n\n2. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\n\nYou failed to ensure adequate aseptic behavior and adequate airflow simulations to prevent potential contamination.\n\nPoor Aseptic Behavior\n\nOur investigators observed multiple instances of poor aseptic techniques during the start-up and filling of (b)(4) for injection, batch (b)(4). For example, operators disrupted first-air in your ISO-5 areas by reaching over sterile (b)(4) vials, (b)(4) stoppers, and the stopper (b)(4) during interventions without removing the affected vials or stoppers. Additionally, your operators touched (b)(4) stoppers with the (b)(4) restricted access barrier system ((b)(4)-RABS) (b)(4) while aligning the stopper (b)(4) during setup.\n\nInadequate Airflow Simulations\n\nYou produced and distributed drug product purporting to be sterile without first conducting adequate process simulations. Specifically, your airflow simulations (smoke studies) for filling line (b)(4) did not adequately demonstrate unidirectional airflow during (b)(4) interventions within the (b)(4)-RABS ISO 5 area. For example, airflow was observed flowing outward and upward during (b)(4) interventions. However, the simulation did not adequately depict airflow (the smoke was not visible) to determine whether HEPA filtered air was reaching the critical (b)(4).\n\nAdditionally, the design of the stopper conveyer track exiting the stopper (b)(4) appears to block first-air for the (b)(4) stoppers moving along the track.\n\nIn your response, you state that the lack of visible smoke was due to the location and limited number of smoke sticks during the (b)(4) condition. You also state that you have conducted new smoke studies. Further, you state that your operators followed procedures, that these “interventions are evaluated during airflow studies,” and that you observed no discrepancies. Lastly, you indicate that there were no media fill or sterility failures for the past 2 years.\n\nYour response is inadequate because your response does not adequately address the poor aseptic technique that was observed. You also did not address how you will ensure adequate review and approval of qualification and validation studies where deficiencies may exist. In addition, you do not commit to perform a comprehensive review of similar qualification and validation studies to ensure their adequacy.\n\nAny intervention or stoppage during an aseptic process can increase the risk of contamination. The risk to finished product sterility assurance increases with operator interventions in an aseptic processing operation. Your aseptic manufacturing processes should be designed, and operations executed, to prevent contamination hazards to your sterile product. Flaws in the design of cleanrooms and aseptic processing lines, or improper execution of aseptic operations, can promote influx of contamination into the (b)(4) (ISO 5) processing area.\n\nFor additional guidance on aseptic processing see FDA’s guidance document Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\n\nIn response to this letter, provide:\n\n• A comprehensive risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including an independent assessment that includes, but is not limited to:\n\no All human interactions within the ISO 5 area\n\no Equipment placement and ergonomics\n\no Air quality in the ISO 5 area and surrounding room\n\no Facility layout\n\no Personnel Flows and Material Flows (throughout all rooms used to conduct and support sterile operations)\n\n• A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control.\n\n• Your plan to ensure appropriate aseptic practices and cleanroom behavior during production. Include steps to ensure routine and effective supervisory oversight for all production batches. Also describe the frequency of QU oversight (e.g., audit) during aseptic processing and its support operations.\n\n• A thorough retrospective review and risk assessment that evaluates how poor aseptic technique and cleanroom behavior may have affected the quality and sterility of your drugs.\n\n• An evaluation of the design of the stopper conveyer track to assess the adequacy of unidirectional airflow interacting with your equipment.\n\n3. Your firm failed to establish adequate written procedures for production and process control designed to assure that drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess, and to follow all of your written production and process control procedures (21 CFR 211.100 (a) and 211.100 (b).\n\nYour process performance qualifications (PPQ) lack adequate supporting data to assess variability in your manufacturing processes. Specifically, statistical sampling plans were not adequately established and followed to evaluate intra- and inter-batch variation in your PPQs. For example, your PPQ study for (b)(4) Injection USP (b)(4)mg\u002Fvial failed to establish acceptance criteria for intra- and inter-batch variation. Instead, (b)(4) sampling was conducted, reporting singular results for critical quality attributes (CQAs), including assay, impurities, and pH. Sampling and testing between your (b)(4) used for the PPQ batches also failed to include acceptance criteria for intra- and inter-batch variability for (b)(4) content.\n\nYou also failed to collect (b)(4) data during your PPQ studies for your (b)(4) drug products to assess whether stoppering of the vials within your (b)(4) adequately prevented unintended ingress of air and maintained specified (b)(4).\n\nIn your response, you state that adequate sampling was conducted and that your products are in a state of control, and specifically, that your PPQ intra- and inter-batch variability was observed below (b)(4)% standard deviation for the CQAs and critical process parameters (CPPs). You commit to revising your procedures to include acceptance criteria for intra- and inter-batch evaluations for variability for your drug products, conduct retrospective reviews, and additional PPQ studies. You also state that you now conduct 100% leak tests for your sterile injectable drug products.\n\nYour response is inadequate because your evaluation of variability does not appear to be the result of enhanced sampling, but from analytical testing results already provided in your PPQ summary reports which consisted of composite samples and results.\n\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluate batches to determine whether an initial state of control has been established.\n\nSuccessful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\n\nSee FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that the FDA considers appropriate elements of process validation, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\n\nIn response to this letter, provide:\n\n• An assessment of each drug product process to ensure that there is a data-driven and scientifically sound program that identifies and controls all sources of variability, such that your production processes, and will consistently meet appropriate specifications and manufacturing standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, sufficiency of detectability in your monitoring and testing systems, quality of input materials, and reliability of each manufacturing process step and control.\n\n• Timelines for completing further PPQ studies for marketed drug products for which a state of control has not been adequately\u002Ffully established.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\n\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\n\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\n\nFailure to address any violations may also result in the FDA refusing admission of articles manufactured at Zydus Lifesciences Limited, Survey No. 434\u002F6\u002FB & 434\u002F1\u002FK, Vadodara – Halol Highway Village - Jarod, Taluka - Waghodia, Gujarat into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days1. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3013712903 and ATTN: Michael Klapal.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\n__________________\n\n1 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","zydus-lifesciences-limited-685224-08292024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fzydus-lifesciences-limited-685224-08292024","2026-10-26T08:10:40.099496+00:00","Closed Out","2024-09-10","685224","2025-12-16","2026-08-19T23:49:53.34+00:00","320-24-58","2024-08-29",{"id":200,"raw":201,"subject":205,"body_html":206,"body_text":207,"firm_name":208,"letter_id":209,"created_at":90,"fei_number":20,"letter_url":210,"updated_at":211,"action_type":23,"case_status":24,"posted_date":212,"marcs_cms_no":213,"product_type":73,"closeout_date":20,"issuing_office":62,"recipient_name":20,"body_fetched_at":214,"delivery_method":54,"recipient_title":20,"reference_number":20,"action_taken_date":215,"medical_device_id":20,"response_letter_date":20},241,[202,203,204,62,205,13,13,13],"\u003Ctime datetime=\"2026-04-07T04:00:00Z\">04\u002F07\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-03-31T04:00:00Z\">03\u002F31\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fprime-sciences-721805-03312026\">Prime Sciences\u003C\u002Fa>","Unapproved New Drugs Sold Over the Internet","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Prime Sciences\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>14500 N. Northsight Blvd, STE 100\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Scottsdale\u003C\u002Fspan>, \u003Cspan>AZ\u003C\u002Fspan> \u003Cspan>85260\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@prime-sciences.com\"> info@prime-sciences.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:support@prime-sciences.com\"> support@prime-sciences.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>March 31, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>RE: 721805\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Prime Sciences:\u003C\u002Fp>\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at https:\u002F\u002Fprime-sciences.com\u002F from January to March 2026. The FDA has observed that your website offers “Cagrilintide,” “GLP1-R,” “GLP1-S,” “GLP1-T,” “Mazdutide,” and “BAC water” (hereinafter Prime Sciences products) for sale in the United States. Based on our review, these products are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>These products are especially concerning from a public health perspective because injectable drug products can pose risks of serious harm to users. Injectable products are delivered directly into the body, sometimes directly into the bloodstream, and therefore, bypass some of the body’s key defenses against toxins and microorganisms that can lead to serious and life-threatening conditions.\u003C\u002Fp>\u003Cp>Despite statements on your product labeling marketing your products for “laboratory research purposes only” and “not for human consumption, medical use or veterinary use,” evidence obtained from your website establishes that your products are intended to be drugs for human use. Your products are drugs as defined by section 201(g)(1) of the FD&amp;C Act 21, U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For intended to affect the structure or function of the body.\u003C\u002Fp>\u003Cp>Examples from your product labeling, including on your website, that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cu>Cagrilintide\u003C\u002Fu>\u003Cbr>On the webpage https:\u002F\u002Fprime-sciences.com\u002Fproduct\u002Fcagrilintide:\u003C\u002Fp>\u003Cul>\u003Cli>“In one study, weight loss of 25% or more was achieved in 40.4% of patients receiving Cagri compared to 16.2% with semaglutide alone.”\u003C\u002Fli>\u003Cli>“Mechanism of action: Cagrilintide promotes weight loss through various mechanisms: Slowing gastric emptying. Reducing food intake. Modulating postprandial glucose spikes. Inducing satiety (feeling of fullness).”\u003C\u002Fli>\u003Cli>“Application: Research peptide with potential in diabetes management and obesity treatment.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>GLP1-R (10MG) (identified as Retatrutide)\u003C\u002Fu>\u003Cbr>On the webpage https:\u002F\u002Fprime-sciences.com\u002Fproduct\u002Fglp1-r:\u003C\u002Fp>\u003Cul>\u003Cli>“Retatrutide has shown higher weight loss results in clinical trials, with an average of up to 28% body weight reduction, compared to around 15% with semaglutide or Tirzapeptide.”\u003C\u002Fli>\u003Cli>“Retatrutide is a drug that works similarly to semaglutide and tirzepatide, but works in three different ways. Semaglutide targets your receptor of the GLP-1 hormone, which stabilizes your blood sugar, helping to reduce cravings while helping you to eat less, as well as slowing down your digestive system to help you feel fuller longer.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>GLP1-S (10MG) (identified as Semaglutide)\u003C\u002Fu>\u003Cbr>On the webpage https:\u002F\u002Fprime-sciences.com\u002Fproduct\u002Fglp1-s:\u003C\u002Fp>\u003Cul>\u003Cli>“Ozempic – Weight Loss Supplement.”\u003C\u002Fli>\u003Cli>“Semaglutide peptide therapy benefits include:\u003Cbr>o Participants taking semaglutide lost an average of 15.2% of their initial body weight . . .\u003Cbr>o Stimulates the pancreas to produce insulin and reduces the hunger hormone ghrelin\u003Cbr>o Reduces blood sugar levels to promote weight loss”\u003C\u002Fli>\u003Cli>“Application: Research peptide with potential in diabetes management and obesity treatment.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>GLP1-T (10MG) (identified as Tirzepatide)\u003C\u002Fu>\u003Cbr>On the webpage https:\u002F\u002Fprime-sciences.com\u002Fproduct\u002Fglp1-t:\u003C\u002Fp>\u003Cul>\u003Cli>“Tirzepatide therapy benefits include:\u003Cbr>o A phase 3 randomized, controlled clinical trial demonstrated that Tirzepatide led to a 20 percent reduction in body weight\u003Cbr>o Stimulates the production of insulin to lower blood sugar\u003Cbr>o Reduces appetite by slowing the time it takes the stomach to empty”\u003C\u002Fli>\u003Cli>“Application: Functionally, Tirzepatide stimulates insulin release from the pancreas and reduces hyperglycemia.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>MAZDUTIDE (10MG)\u003C\u002Fu>\u003Cbr>On the webpage https:\u002F\u002Fprime-sciences.com\u002Fproduct\u002Fmazdutide:\u003C\u002Fp>\u003Cul>\u003Cli>“Mazdutide peptide therapy benefits include:\u003Cbr>o Weight Management\u003Cbr>􀂃 Significant weight loss: In a phase 3 trial (GLORY-1), once-weekly mazdutide led to an average body weight reduction of up to 14.8%.”\u003C\u002Fli>\u003Cli>“Improved metabolic health\u003Cbr>o Enhanced glycemic control: In patients with type 2 diabetes, mazdutide has been shown to significantly reduce blood glucose levels (HbA1c) and improve insulin sensitivity.\u003Cbr>o Reduced liver fat . . . some participants in a phase 3 trial achieving up to an 80% reduction.”\u003Cbr>o Lowered cardiometabolic risk factors: . . . Reduced blood pressure . . . Decreased total cholesterol and LDL . . . Lowered triglycerides”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>BAC water\u003C\u002Fu>\u003Cbr>Your firm offers a “Reconstitution Kit” for sale, which contains “BAC water” and a syringe. This kit is offered for sale alongside peptide products, which are drugs intended for injection and require reconstitution, including the above-mentioned products. The sale of a kit containing the “BAC water” and a means of injection (a syringe) with these peptide drugs demonstrates that you intend for the “BAC water” to be used in combination for injection. Therefore, your “BAC water” is a drug.\u003C\u002Fp>\u003Cp>Your Prime Sciences products are “new drugs” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the above-described conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may lead to regulatory or legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\u003C\u002Fp>\u003Cp>Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov. Please include your firm name and the unique identifier “721805” in the subject line of the email.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>Food and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nPrime Sciences\n\n14500 N. Northsight Blvd, STE 100\n\nScottsdale, AZ 85260\n\nUnited States\n\ninfo@prime-sciences.com\n\nsupport@prime-sciences.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nMarch 31, 2026\nRE: 721805\nPrime Sciences:\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at https:\u002F\u002Fprime-sciences.com\u002F from January to March 2026. The FDA has observed that your website offers “Cagrilintide,” “GLP1-R,” “GLP1-S,” “GLP1-T,” “Mazdutide,” and “BAC water” (hereinafter Prime Sciences products) for sale in the United States. Based on our review, these products are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nThese products are especially concerning from a public health perspective because injectable drug products can pose risks of serious harm to users. Injectable products are delivered directly into the body, sometimes directly into the bloodstream, and therefore, bypass some of the body’s key defenses against toxins and microorganisms that can lead to serious and life-threatening conditions.\nDespite statements on your product labeling marketing your products for “laboratory research purposes only” and “not for human consumption, medical use or veterinary use,” evidence obtained from your website establishes that your products are intended to be drugs for human use. Your products are drugs as defined by section 201(g)(1) of the FD&C Act 21, U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For intended to affect the structure or function of the body.\nExamples from your product labeling, including on your website, that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:\nCagrilintide\nOn the webpage https:\u002F\u002Fprime-sciences.com\u002Fproduct\u002Fcagrilintide:\n“In one study, weight loss of 25% or more was achieved in 40.4% of patients receiving Cagri compared to 16.2% with semaglutide alone.”\n“Mechanism of action: Cagrilintide promotes weight loss through various mechanisms: Slowing gastric emptying. Reducing food intake. Modulating postprandial glucose spikes. Inducing satiety (feeling of fullness).”\n“Application: Research peptide with potential in diabetes management and obesity treatment.”\nGLP1-R (10MG) (identified as Retatrutide)\nOn the webpage https:\u002F\u002Fprime-sciences.com\u002Fproduct\u002Fglp1-r:\n“Retatrutide has shown higher weight loss results in clinical trials, with an average of up to 28% body weight reduction, compared to around 15% with semaglutide or Tirzapeptide.”\n“Retatrutide is a drug that works similarly to semaglutide and tirzepatide, but works in three different ways. Semaglutide targets your receptor of the GLP-1 hormone, which stabilizes your blood sugar, helping to reduce cravings while helping you to eat less, as well as slowing down your digestive system to help you feel fuller longer.”\nGLP1-S (10MG) (identified as Semaglutide)\nOn the webpage https:\u002F\u002Fprime-sciences.com\u002Fproduct\u002Fglp1-s:\n“Ozempic – Weight Loss Supplement.”\n“Semaglutide peptide therapy benefits include:\no Participants taking semaglutide lost an average of 15.2% of their initial body weight . . .\no Stimulates the pancreas to produce insulin and reduces the hunger hormone ghrelin\no Reduces blood sugar levels to promote weight loss”\n“Application: Research peptide with potential in diabetes management and obesity treatment.”\nGLP1-T (10MG) (identified as Tirzepatide)\nOn the webpage https:\u002F\u002Fprime-sciences.com\u002Fproduct\u002Fglp1-t:\n“Tirzepatide therapy benefits include:\no A phase 3 randomized, controlled clinical trial demonstrated that Tirzepatide led to a 20 percent reduction in body weight\no Stimulates the production of insulin to lower blood sugar\no Reduces appetite by slowing the time it takes the stomach to empty”\n“Application: Functionally, Tirzepatide stimulates insulin release from the pancreas and reduces hyperglycemia.”\nMAZDUTIDE (10MG)\nOn the webpage https:\u002F\u002Fprime-sciences.com\u002Fproduct\u002Fmazdutide:\n“Mazdutide peptide therapy benefits include:\no Weight Management\n􀂃 Significant weight loss: In a phase 3 trial (GLORY-1), once-weekly mazdutide led to an average body weight reduction of up to 14.8%.”\n“Improved metabolic health\no Enhanced glycemic control: In patients with type 2 diabetes, mazdutide has been shown to significantly reduce blood glucose levels (HbA1c) and improve insulin sensitivity.\no Reduced liver fat . . . some participants in a phase 3 trial achieving up to an 80% reduction.”\no Lowered cardiometabolic risk factors: . . . Reduced blood pressure . . . Decreased total cholesterol and LDL . . . Lowered triglycerides”\nBAC water\nYour firm offers a “Reconstitution Kit” for sale, which contains “BAC water” and a syringe. This kit is offered for sale alongside peptide products, which are drugs intended for injection and require reconstitution, including the above-mentioned products. The sale of a kit containing the “BAC water” and a means of injection (a syringe) with these peptide drugs demonstrates that you intend for the “BAC water” to be used in combination for injection. Therefore, your “BAC water” is a drug.\nYour Prime Sciences products are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the above-described conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may lead to regulatory or legal action including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\nYour response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov. Please include your firm name and the unique identifier “721805” in the subject line of the email.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nFood and Drug Administration","Prime Sciences","prime-sciences-721805-03312026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fprime-sciences-721805-03312026","2026-10-26T08:09:44.094362+00:00","2026-04-07","721805","2026-08-19T04:49:30.204+00:00","2026-03-31",{"id":217,"raw":218,"subject":63,"body_html":222,"body_text":223,"firm_name":224,"letter_id":225,"created_at":90,"fei_number":20,"letter_url":226,"updated_at":227,"action_type":23,"case_status":24,"posted_date":228,"marcs_cms_no":229,"product_type":73,"closeout_date":20,"issuing_office":62,"recipient_name":230,"body_fetched_at":231,"delivery_method":232,"recipient_title":20,"reference_number":233,"action_taken_date":234,"medical_device_id":20,"response_letter_date":20},355,[219,220,221,62,63,13,13,13],"\u003Ctime datetime=\"2026-02-03T05:00:00Z\">02\u002F03\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-01-30T05:00:00Z\">01\u002F30\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcohance-lifesciences-limited-718812-01302026\">Cohance Lifesciences Limited\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-40\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Dr. Vetukuri Venkata Naga Kali Vara Prasada Raju\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Managing Director &amp; Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Cohance Lifesciences Limited\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>202, 2nd Floor, A-wing, Galaxy by Aurobindo Realty, Sy. No. 83\u002F1\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Hyderabad Knowledge City, TSIIC, Raidurg, Panmaktha, Opp. IKEA\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Hyderabad\u003C\u002Fspan> \u003Cspan>500081\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Telangana\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>India\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-40\u003C\u002Fp>\u003Cp>January 30, 2026\u003C\u002Fp>\u003Cp>Dear Dr. Raju:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Cohance Lifesciences Limited, FEI 3008768274, at Plot No. A-19\u002FC, A-23A, A-23B, Road No. 18, IDA Nacharam, Uppal Mandal, Medchal-Malkajgiri, from August 4 to August 12, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your September 2, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures various \u003Cstrong>(b)(4)\u003C\u002Fstrong> dosage forms, including \u003Cstrong>(b)(4)\u003C\u002Fstrong> and medications for the treatment of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your investigations into drug-product quality issues were inadequate because they lacked thoroughness, adequate root-cause determination, and appropriate corrective action and preventive action (CAPA). For example, you received a customer complaint about \u003Cstrong>(b)(4)\u003C\u002Fstrong> tablets USP \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg from two different batches that were reported to be crumbling, disintegrating, pitted, and with dust in the bottle. Your complaint investigation could not identify a root cause and concluded that the complaint was “Not Substantiated.” You noted in your investigation that “the appearance of pitted\u002Fcrumbly tablets is due to the inherent nature of the raw material ‘\u003Cstrong>(b)(4)\u003C\u002Fstrong>’ in the formulation.” Furthermore, your investigation noted two additional complaint investigations for the same issue in three other batches of the same drug product.\u003C\u002Fp>\u003Cp>In your response, you state that you re-opened this investigation and revised your attributable root cause to your raw material, \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Your response is inadequate. Despite identifying a root cause, your response lacks information on chemical testing of reserve samples to confirm that affected tablets meet specifications, and your response does not contain a commitment to perform such testing. Your response lacks remediation for the root cause identified in your re-opened investigation and does not evaluate the quality of your raw materials or consider changes to your formulation to prevent the issue. Additionally, your response fails to consider whether other drug products containing \u003Cstrong>(b)(4)\u003C\u002Fstrong> could also be affected.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A summary of analytical testing, including dissolution, of reserve samples exhibiting crumbling, disintegrating, pitted \u003Cstrong>(b)(4)\u003C\u002Fstrong> tablets USP \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg, and an action plan to address this product-quality issue, such as reformulation studies or additional transportation studies.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification (OOS) results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include but not be limited to significant improvements in investigation competencies, scope determination, root-cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\u003Cli>An independent assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root-cause analysis, ensures CAPA effectiveness, analyzes investigations trends, improves the CAPA program when needed, implements final quality unit decisions, and is fully supported by executive management.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements (21 CFR 211.67(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to adequately clean and maintain your nondedicated drug manufacturing equipment. For example, our investigator observed visible stains within the \u003Cstrong>(b)(4)\u003C\u002Fstrong> duct of a \u003Cstrong>(b)(4)\u003C\u002Fstrong> (PD\u002F\u003Cstrong>(b)(4)\u003C\u002Fstrong>-01) and visible residues on a capsule filling machine (PD\u002FCFM-03) that were documented as clean and had undergone drug product changeover cleaning. Your analytical testing of these stains and residues confirmed the presence of multiple active pharmaceutical ingredients (APIs) with values exceeding your allowable limit.\u003C\u002Fp>\u003Cp>In your response, you provide investigations into these findings, including a retrospective review of analytical and stability data for all drug products previously manufactured on the pieces of equipment mentioned above. Your investigations attribute the root cause of the cleaning deficiencies to procedural gaps in the cleaning instructions for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and the capsule-filling machine. You state that you plan to revise your cleaning procedures and cleaning checklists.\u003C\u002Fp>\u003Cp>Your response is inadequate because your review of analytical data and cleaning procedures fails to scientifically demonstrate that your drug products are free of contaminants from the visibly dirty equipment. Your response lacks information about reserve sample testing of drug products released to the U.S. market and within expiry, that were manufactured on these pieces of nondedicated equipment, for cross-contamination potential posed by all previously manufactured drug products.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated drug products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices, and encompass each piece of manufacturing equipment used to manufacture more than one drug product.\u003C\u002Fli>\u003Cli>A CAPA plan, based on the retrospective assessment of your cleaning program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all drug products and equipment; and all other needed remediations.\u003C\u002Fli>\u003Cli>In addition to this holistic remediation, provide specific CAPA activities that are being undertaken to effectively remediate the conditions that caused the specific cross-contamination incidents discussed above. Provide an independent review by your consultant that determines the effectiveness of your CAPA, including but not limited to:\u003Cbr>o A list of all enhancements to cleaning and maintenance procedures, including specific frequencies and locations to be cleaned in all relevant equipment (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong>)\u003Cbr>o Identification of any sources of cross-contamination other than \u003Cstrong>(b)(4)\u003C\u002Fstrong> equipment, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and ductwork\u003Cbr>o Determination of the adequacy of your analytical methodology to identify residual carryover\u003Cbr>o Your investigations into any unknown (unidentified) peaks detected in your reserve samples\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You have not demonstrated that your cleaning practices are adequate to remove contaminants from the shared equipment used to manufacture multiple drug products. Your 2018 cleaning validation study failed to use the identified worst-case drug product, making it inadequate to ensure cleaning effectiveness. You also did not re-evaluate your cleaning validation program when introducing new drug products on shared manufacturing equipment, and you lack routine cleaning verification. Inadequate removal of drug residues during cleaning can cause cross-contamination in subsequently manufactured drugs on the same equipment.\u003C\u002Fp>\u003Cp>In your response, you state that the results of your cleaning verification studies from 2019 to 2024 demonstrate that your cleaning processes are effective. You state that you have engaged an independent third-party consultant to review your cleaning validation program and cleaning practices.\u003C\u002Fp>\u003Cp>Your response is inadequate because your cleaning validation and verification program does not adequately evaluate the effectiveness of your cleaning procedures. Your cleaning verification lacks the ability to detect cross-contamination from carryover.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst-case in your drug manufacturing operation. This should include but not be limited to identification and evaluation of all worst-case:\u003Cbr>o Drugs with higher toxicities\u003Cbr>o Drugs with higher drug potencies\u003Cbr>o Drugs of lower solubility in their cleaning solvents\u003Cbr>o Drugs with characteristics that make them difficult to clean\u003Cbr>o Swabbing locations for areas that are most difficult to clean\u003Cbr>o Maximum hold times before cleaning\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new drug product.\u003C\u002Fp>\u003Cul>\u003Cli>A summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for drug products, processes, and equipment.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Drug Production Suspended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We acknowledge your commitment to temporarily suspend manufacturing and release of drug products from this facility as of August 16, 2025. In response to this letter, clarify when you intend to resume manufacturing of drugs for the U.S. market at this facility.\u003C\u002Fp>\u003Cp>Before you resume any manufacturing operations regulated under the FD&amp;C Act, notify this office. You are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all CAPA.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA refusing admission of articles manufactured at Cohance Lifesciences Limited, FEI 3008768274, at Plot No. A-19\u002FC, A-23A, A-23B, Road No. 18, IDA Nacharam, Uppal Mandal, Medchal-Malkajgiri, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3008768274 and ATTN: Marisa Heayn.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>______________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nReference #:\n\n320-26-40\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nDr. Vetukuri Venkata Naga Kali Vara Prasada Raju\n\nRecipient Title\n\nManaging Director & Chief Executive Officer\n\nCohance Lifesciences Limited\n\n202, 2nd Floor, A-wing, Galaxy by Aurobindo Realty, Sy. No. 83\u002F1\n\nHyderabad Knowledge City, TSIIC, Raidurg, Panmaktha, Opp. IKEA\n\nHyderabad 500081\n\nTelangana\n\nIndia\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-40\nJanuary 30, 2026\nDear Dr. Raju:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Cohance Lifesciences Limited, FEI 3008768274, at Plot No. A-19\u002FC, A-23A, A-23B, Road No. 18, IDA Nacharam, Uppal Mandal, Medchal-Malkajgiri, from August 4 to August 12, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your September 2, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following:\n1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\nYour firm manufactures various (b)(4) dosage forms, including (b)(4) and medications for the treatment of (b)(4). Your investigations into drug-product quality issues were inadequate because they lacked thoroughness, adequate root-cause determination, and appropriate corrective action and preventive action (CAPA). For example, you received a customer complaint about (b)(4) tablets USP (b)(4) mg from two different batches that were reported to be crumbling, disintegrating, pitted, and with dust in the bottle. Your complaint investigation could not identify a root cause and concluded that the complaint was “Not Substantiated.” You noted in your investigation that “the appearance of pitted\u002Fcrumbly tablets is due to the inherent nature of the raw material ‘(b)(4)’ in the formulation.” Furthermore, your investigation noted two additional complaint investigations for the same issue in three other batches of the same drug product.\nIn your response, you state that you re-opened this investigation and revised your attributable root cause to your raw material, (b)(4).\nYour response is inadequate. Despite identifying a root cause, your response lacks information on chemical testing of reserve samples to confirm that affected tablets meet specifications, and your response does not contain a commitment to perform such testing. Your response lacks remediation for the root cause identified in your re-opened investigation and does not evaluate the quality of your raw materials or consider changes to your formulation to prevent the issue. Additionally, your response fails to consider whether other drug products containing (b)(4) could also be affected.\nIn response to this letter, provide:\nA summary of analytical testing, including dissolution, of reserve samples exhibiting crumbling, disintegrating, pitted (b)(4) tablets USP (b)(4) mg, and an action plan to address this product-quality issue, such as reformulation studies or additional transportation studies.\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification (OOS) results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include but not be limited to significant improvements in investigation competencies, scope determination, root-cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\nAn independent assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root-cause analysis, ensures CAPA effectiveness, analyzes investigations trends, improves the CAPA program when needed, implements final quality unit decisions, and is fully supported by executive management.\n2. Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements (21 CFR 211.67(a)).\nYou failed to adequately clean and maintain your nondedicated drug manufacturing equipment. For example, our investigator observed visible stains within the (b)(4) duct of a (b)(4) (PD\u002F(b)(4)-01) and visible residues on a capsule filling machine (PD\u002FCFM-03) that were documented as clean and had undergone drug product changeover cleaning. Your analytical testing of these stains and residues confirmed the presence of multiple active pharmaceutical ingredients (APIs) with values exceeding your allowable limit.\nIn your response, you provide investigations into these findings, including a retrospective review of analytical and stability data for all drug products previously manufactured on the pieces of equipment mentioned above. Your investigations attribute the root cause of the cleaning deficiencies to procedural gaps in the cleaning instructions for the (b)(4) and the capsule-filling machine. You state that you plan to revise your cleaning procedures and cleaning checklists.\nYour response is inadequate because your review of analytical data and cleaning procedures fails to scientifically demonstrate that your drug products are free of contaminants from the visibly dirty equipment. Your response lacks information about reserve sample testing of drug products released to the U.S. market and within expiry, that were manufactured on these pieces of nondedicated equipment, for cross-contamination potential posed by all previously manufactured drug products.\nIn response to this letter, provide:\nA comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated drug products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices, and encompass each piece of manufacturing equipment used to manufacture more than one drug product.\nA CAPA plan, based on the retrospective assessment of your cleaning program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all drug products and equipment; and all other needed remediations.\nIn addition to this holistic remediation, provide specific CAPA activities that are being undertaken to effectively remediate the conditions that caused the specific cross-contamination incidents discussed above. Provide an independent review by your consultant that determines the effectiveness of your CAPA, including but not limited to:\no A list of all enhancements to cleaning and maintenance procedures, including specific frequencies and locations to be cleaned in all relevant equipment (e.g., (b)(4))\no Identification of any sources of cross-contamination other than (b)(4) equipment, (b)(4), and ductwork\no Determination of the adequacy of your analytical methodology to identify residual carryover\no Your investigations into any unknown (unidentified) peaks detected in your reserve samples\n3. Your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).\nYou have not demonstrated that your cleaning practices are adequate to remove contaminants from the shared equipment used to manufacture multiple drug products. Your 2018 cleaning validation study failed to use the identified worst-case drug product, making it inadequate to ensure cleaning effectiveness. You also did not re-evaluate your cleaning validation program when introducing new drug products on shared manufacturing equipment, and you lack routine cleaning verification. Inadequate removal of drug residues during cleaning can cause cross-contamination in subsequently manufactured drugs on the same equipment.\nIn your response, you state that the results of your cleaning verification studies from 2019 to 2024 demonstrate that your cleaning processes are effective. You state that you have engaged an independent third-party consultant to review your cleaning validation program and cleaning practices.\nYour response is inadequate because your cleaning validation and verification program does not adequately evaluate the effectiveness of your cleaning procedures. Your cleaning verification lacks the ability to detect cross-contamination from carryover.\nIn response to this letter, provide:\nAppropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst-case in your drug manufacturing operation. This should include but not be limited to identification and evaluation of all worst-case:\no Drugs with higher toxicities\no Drugs with higher drug potencies\no Drugs of lower solubility in their cleaning solvents\no Drugs with characteristics that make them difficult to clean\no Swabbing locations for areas that are most difficult to clean\no Maximum hold times before cleaning\nIn addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new drug product.\nA summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for drug products, processes, and equipment.\nDrug Production Suspended\nWe acknowledge your commitment to temporarily suspend manufacturing and release of drug products from this facility as of August 16, 2025. In response to this letter, clarify when you intend to resume manufacturing of drugs for the U.S. market at this facility.\nBefore you resume any manufacturing operations regulated under the FD&C Act, notify this office. You are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all CAPA.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA refusing admission of articles manufactured at Cohance Lifesciences Limited, FEI 3008768274, at Plot No. A-19\u002FC, A-23A, A-23B, Road No. 18, IDA Nacharam, Uppal Mandal, Medchal-Malkajgiri, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days.1 Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3008768274 and ATTN: Marisa Heayn.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n______________________\n1 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","Cohance Lifesciences Limited","cohance-lifesciences-limited-718812-01302026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcohance-lifesciences-limited-718812-01302026","2026-10-26T08:08:16.746596+00:00","2026-02-03","718812","Dr. Vetukuri Venkata Naga Kali Vara Prasada Raju","2026-08-19T05:07:44.869+00:00","VIA Electronic Mail","320-26-40","2026-01-30",{"id":236,"raw":237,"subject":63,"body_html":242,"body_text":243,"firm_name":244,"letter_id":245,"created_at":46,"fei_number":20,"letter_url":246,"updated_at":247,"action_type":23,"case_status":24,"posted_date":248,"marcs_cms_no":249,"product_type":73,"closeout_date":20,"issuing_office":241,"recipient_name":250,"body_fetched_at":251,"delivery_method":98,"recipient_title":20,"reference_number":20,"action_taken_date":252,"medical_device_id":20,"response_letter_date":20},1954,[238,239,240,241,63,13,13,13],"\u003Ctime datetime=\"2023-08-08T13:20:00Z\">08\u002F08\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-08-03T04:00:00Z\">08\u002F03\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Forchid-lifesciences-663478-08032023\">Orchid Lifesciences\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Smit Patel Managing\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Director and Marketing Head\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Orchid Lifesciences\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>68-72 Tribhuvan Industrial Estate\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Nr. Road No. 11, Kathwada\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Ahmedabad, Kathwada\u003C\u002Fspan> \u003Cspan>382430\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>India\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:smit@orchidlifesciences.com\"> smit@orchidlifesciences.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-23-23\u003C\u002Fp>\n\n\u003Cp>August 3, 2023\u003Cbr>\n\u003Cbr>\nDear Mr. Smit Patel:\u003C\u002Fp>\n\n\u003Cp>Your facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our January 25, 2023 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) for your facility, Orchid Lifesciences, FEI 3015154915, 68-72 Tribhuvan Industrial Estate, Nr. Road No. 11, Kathwada, Ahmedabad, Kathwada, India 382430.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act (21 U.S.C. 351(a)(2)(B)).\u003C\u002Fp>\n\n\u003Cp>Following review of records and other information provided pursuant to section 704(a)(4) of the FD&amp;C Act, significant violations were observed including, but not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You manufacture several over-the-counter (OTC) drug products including toothpaste and topical analgesics. Based on the records and information you provided, you did not demonstrate that you adequately tested each shipment of each lot of the incoming components at high-risk of diethylene glycol (DEG) or ethylene glycol (EG) contamination. These include, but are not limited to, testing of glycerin, propylene glycol, and sorbitol solution, you used in manufacturing drug products to determine their appropriate identity. Identity testing for these and certain other high-risk drug components\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> include a limit test in the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for levels of DEG or EG. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in manufacture of your drug products.\u003C\u002Fp>\n\n\u003Cp>The use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of DEG and EG.\u003C\u002Fli>\n\t\u003Cli>A full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination. Take prompt and appropriate actions to determine the safety of all lots of the components and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective action and preventive action (CAPA) that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\u003C\u002Fli>\n\t\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s certificate of analysis (COA) instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high- risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\u003C\u002Fli>\n\t\u003Cli>The chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The records and information you provided demonstrate that your quality unit (QU) did not effectively exercise its responsibilities to oversee the quality of your drug manufacturing operations. Specifically, your QU did not adequately exercise its authority in the approval or rejection of components in your Materials System.\u003C\u002Fp>\n\n\u003Cp>Your QU is responsible for fully exercising its authority and responsibilities. FDA is concerned that your QU may also not be conducting appropriate oversight regarding other CGMP operations, including Production, Facilities &amp; Equipment, Laboratory Controls, and Packaging &amp; Labelling Systems.\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>\n&nbsp; &nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>\n&nbsp; &nbsp; o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>\n&nbsp; &nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system audit\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPA before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\n\n\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>FDA placed your firm on Import Alert 66-40 on March 23, 2023.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect your facility to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 30 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3015154915 and ATTN: Matthew R. Dionne, Pharm.D., Compliance Officer.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>CC (via email):\u003Cbr>\nLiberty Management Group Ltd.\u003Cbr>\nManoj@libertymanagement.us\u003C\u002Fp>\n\n\u003Cp>____________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Components with higher risk of DEG or EG contamination compared to other drug components.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> i.e., Quality System, Facilities &amp; Equipment System, Materials System, Production System, Packaging &amp; Labeling System, and Laboratory Control System per FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nSmit Patel Managing\n\nRecipient Title\n\nDirector and Marketing Head\n\nOrchid Lifesciences\n\n68-72 Tribhuvan Industrial Estate\n\nNr. Road No. 11, Kathwada\n\nAhmedabad, Kathwada 382430\n\nIndia\n\nsmit@orchidlifesciences.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-23-23\n\nAugust 3, 2023\n\nDear Mr. Smit Patel:\n\nYour facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our January 25, 2023 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility, Orchid Lifesciences, FEI 3015154915, 68-72 Tribhuvan Industrial Estate, Nr. Road No. 11, Kathwada, Ahmedabad, Kathwada, India 382430.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act (21 U.S.C. 351(a)(2)(B)).\n\nFollowing review of records and other information provided pursuant to section 704(a)(4) of the FD&C Act, significant violations were observed including, but not limited to, the following:\n\n1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).\n\nYou manufacture several over-the-counter (OTC) drug products including toothpaste and topical analgesics. Based on the records and information you provided, you did not demonstrate that you adequately tested each shipment of each lot of the incoming components at high-risk of diethylene glycol (DEG) or ethylene glycol (EG) contamination. These include, but are not limited to, testing of glycerin, propylene glycol, and sorbitol solution, you used in manufacturing drug products to determine their appropriate identity. Identity testing for these and certain other high-risk drug components1 include a limit test in the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for levels of DEG or EG. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in manufacture of your drug products.\n\nThe use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\n\nIn response to this letter, provide:\n\nA commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of DEG and EG.\n\nA full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination. Take prompt and appropriate actions to determine the safety of all lots of the components and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective action and preventive action (CAPA) that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\n\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s certificate of analysis (COA) instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high- risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\n\nThe chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\n\nA comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\n\n2. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\n\nThe records and information you provided demonstrate that your quality unit (QU) did not effectively exercise its responsibilities to oversee the quality of your drug manufacturing operations. Specifically, your QU did not adequately exercise its authority in the approval or rejection of components in your Materials System.\n\nYour QU is responsible for fully exercising its authority and responsibilities. FDA is concerned that your QU may also not be conducting appropriate oversight regarding other CGMP operations, including Production, Facilities & Equipment, Laboratory Controls, and Packaging & Labelling Systems.\n\nSee FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nIn response to this letter, provide:\n\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\n\no A complete and final review of each batch and its related information before the QU disposition decision\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system audit2 of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPA before you pursue resolution of your firm’s compliance status with FDA.\n\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nFDA placed your firm on Import Alert 66-40 on March 23, 2023.\n\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect your facility to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 30 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3015154915 and ATTN: Matthew R. Dionne, Pharm.D., Compliance Officer.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nCC (via email):\n\nLiberty Management Group Ltd.\n\nManoj@libertymanagement.us\n\n____________________________\n\n1 Components with higher risk of DEG or EG contamination compared to other drug components.\n\n2 i.e., Quality System, Facilities & Equipment System, Materials System, Production System, Packaging & Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.","Orchid Lifesciences","orchid-lifesciences-663478-08032023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Forchid-lifesciences-663478-08032023","2026-10-26T08:09:38.852527+00:00","2023-08-08","663478","Smit Patel Managing","2026-08-20T00:48:54.41+00:00","2023-08-03",{"id":254,"raw":255,"subject":260,"body_html":261,"body_text":262,"firm_name":263,"letter_id":264,"created_at":19,"fei_number":20,"letter_url":265,"updated_at":266,"action_type":23,"case_status":24,"posted_date":267,"marcs_cms_no":268,"product_type":269,"closeout_date":20,"issuing_office":259,"recipient_name":270,"body_fetched_at":271,"delivery_method":232,"recipient_title":20,"reference_number":20,"action_taken_date":272,"medical_device_id":20,"response_letter_date":20},1094,[256,257,258,259,260,13,13,13],"\u003Ctime datetime=\"2025-01-14T14:20:00Z\">01\u002F14\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-12-19T05:00:00Z\">12\u002F19\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fintegra-lifesciences-corporation-698850-12192024\">Integra LifeSciences Corporation\u003C\u002Fa>","Center for Devices and Radiological Health","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Jan De Witte\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Integra LifeSciences Corporation\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1100 Campus Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Princeton\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>08540\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(4)@integralife.com\"> (b)(4)@integralife.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS # 698850\u003C\u002Fp>\u003Cp>December 19, 2024\u003C\u002Fp>\u003Cp>Dear Mr. DeWitte:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) conducted the following inspections of your firm’s medical device facilities:\u003C\u002Fp>\u003Cul>\u003Cli>Integra LifeSciences Corporation, located at 11 Cabot Blvd, Mansfield, MA, FEI 3014334038, from March 12, 2024 through June 5, 2024\u003C\u002Fli>\u003Cli>Integra LifeSciences Corporation, located at 105 And 109 Morgan Ln, Plainsboro, NJ, FEI 1121308, from April 9, 2024 through August 22, 2024\u003C\u002Fli>\u003Cli>Integra LifeSciences Corporation, located at 1100 Campus Rd, Princeton, NJ, FEI 3003418325, from March 12, 2034 through August 22, 2024\u003C\u002Fli>\u003C\u002Ful>\u003Cp>During these inspections, FDA investigators and a microbiologist determined that the above firms manufacture a variety of neurological and neurosurgical devices, including but not limited to, cranial perforators, disposable cottonoid patties and strips as well as collagen based medical devices, that are used for wound care, soft tissue repair and reconstruction surgery. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>The above inspections revealed that the above devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received responses from Jeffrey Caldwell, Vice President, Quality Operations dated June 27, 2024, August 27, 2024, and October 25, 2024 concerning our investigator’s and microbiologist’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm’s Mansfield, MA location on June 5, 2024.\u003C\u002Fp>\u003Cp>We received responses from Brenda Romero, Director, Quality Operations, CMC dated September 27, 2024 and December 5, 2024 concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm’s Plainsboro, NJ location on August 22, 2024.\u003C\u002Fp>\u003Cp>We received responses from Jessica Smith, Corporate Vice President, Chief Regulatory Officer, and interim Chief Quality Officer dated September 13, 2024 and from Lacey Gigante, Sr. Director, CAPA &amp; Compliance November 15, 2024 concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm’s Princeton, NJ location on August 22, 2024.\u003C\u002Fp>\u003Cp>We address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to establish and maintain procedures to control product that does not conform to specified requirements. The procedures shall address the identification, documentation, evaluation, segregation, and disposition of nonconforming product. The evaluation of nonconformance shall include a determination of the need for an investigation and notification of the persons or organizations responsible for the nonconformance. The evaluation and any investigation shall be documented, as required by 21 CFR § 820.90(a).\u003C\u002Fp>\u003Cp>Specifically, during an inspection of your Mansfield, MA location, a review of 4 non-conforming reports from October 2022 through June 2023 (NC-101352, NC-101446, NC-101628, and NC-101642) were opened due to Out of Specification (OOS) endotoxin results on three separate lots of surgical patties and one lot of Duraform. In the above instances, after the laboratory investigation concluded there was no assignable laboratory error or root cause, your firm retested the lots, even though your Pyrogen Testing procedure, MPS-PC340, did not specify that a retest was allowed. Your firm then released the above referenced lots without conducting a complete investigation of the manufacturing processes, as required by your Non-Conformance procedure, GSOP-773 and MPS-PC340.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and the adequacy cannot be determined. We acknowledge that your firm initiated a recall of Duraform, lot CT007694 on September 6, 2024 as well as a recall of multiple lots of surgical patties and strips manufactured between 2022 and 2023 on September 20, 2024. However, your firm continues to implement a number of corrective actions at your Mansfield, MA facility that will not be completed until May 2025.\u003C\u002Fp>\u003Cp>2. Failure to establish and maintain procedures for acceptance activities. Acceptance activities include inspections, tests, or other verification activities; as required by 21 CFR § 820.80(a).\u003C\u002Fp>\u003Cp>Specifically, your Plainsboro, NJ location utilizes procedure CMC-MB-049 “Determination of Endotoxin in \u003Cstrong>(b)(4)\u003C\u002Fstrong> Product Using the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Methods” to determine the bacterial endotoxin concentration in products manufactured at the Integra LifeSciences Collagen Manufacturing Center (CMC), Buildings \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, including \u003Cstrong>(b)(4)\u003C\u002Fstrong>. According to section 9.6.3.3 of this procedure, “\u003Cem>the Coefficient of Variation (CV%) for each pair of standard series samples must be less than \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fem>” for the overall test to be considered valid. However, during our inspection we observed that ten of fifty-two tests conducted in 2023 failed due to the CV% exceeding the \u003Cstrong>(b)(4)\u003C\u002Fstrong> limit. These ten tests were observed to be repeatedly retested until the CV% fell below \u003Cstrong>(b)(4)\u003C\u002Fstrong>. For example, endotoxin test (LAL-24-2012) and its two subsequent retests (LAL-24-0012 Retest, LAL-24-0012 Retest 2) all failed to meet CV% criteria. It was then retested on a different day under a new ID (LAL-24-0013) and finally passed on the fourth attempt (LAL-24-0013 Retest 3). Your firm’s microbiology manager attributed the CV% failures to low endotoxin concentration in the controls. Additionally, your CMC-MB-049 procedure does not specify the circumstances under which a retest could be performed or which result should be utilized if a retest was conducted.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and the adequacy cannot be determined. We acknowledge that your firm initiated three CAPAs (CAPA-00133, CAPA-00134, and CAPA-00135) to address the observations. As part of these CAPAs, we acknowledge that your firm has performed a statistical assessment of historical reagent qualification data for CV% in which you determined that the appropriate CV% for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> EU\u002FmL standard concentration would be \u003Cstrong>(b)(4)\u003C\u002Fstrong>% and made updates to affected procedures, including CMC-MB-049. However, verification of the effectiveness of the corrective actions are still ongoing with a target date of June 2025. Please provide the results of your firm’s planned 6-month effectiveness check when it becomes available.\u003C\u002Fp>\u003Cp>3. Failure to establish and maintain procedures for finished device acceptance to ensure that each production run, lot, or batch of finished devices meets acceptance criteria, as required by 21 CFR § 820.80(d).\u003C\u002Fp>\u003Cp>Specifically, your Mansfield, MA location utilizes MPS-PC340, Preparing Products for Pyrogen Testing (Rev: 068, Effective Date: 30Mar2023) to describe the procedures and materials needed to prepare test samples for pyrogenicity and how to investigate results that exceed acceptable criteria. However, review of this procedure determined it lacks the following requirements to ensure devices meet established endotoxins specifications for device sterility prior to release. For example,\u003C\u002Fp>\u003Cp> Adequate instructions for OOS laboratory investigations where the original endotoxins results are determined to be valid because no laboratory error or assignable cause was found.\u003Cbr> Documentation of how many times the device lot or device extract may be re- analyzed or retested during the investigation after an OOS result is reported.\u003Cbr> Lack of details regarding sample selection to ensure samples are representative of the entire lot to account for endotoxins not evenly distributed within the lot.\u003Cbr> No requirement to include documentation of endotoxin test result units (EU\u002Fml or EU\u002Fdevice) on the \u003Cem>Post-Sterile Release\u003C\u002Fem> section of your Device History Records.\u003C\u002Fp>\u003Cp>For example, verification of Pyrogen Lab Results receipt for Lot # 7260687 of Product Code \u003Cstrong>(b)(4)\u003C\u002Fstrong> lists the Lab Result as “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” The Endotoxin Action Limit for this product code is \u003Cstrong>(b)(4)\u003C\u002Fstrong> EU\u002FDevice. Your Bacterial Endotoxin Test Final Report (Study Number 1621708-S01), dated June 15, 2023 concluded that the pooled test articles for Lot # 7260687 “exceeded the endotoxin limit of not more than \u003Cstrong>(b)(4)\u003C\u002Fstrong> EU\u002Fdevice.”\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and the adequacy cannot be determined. We acknowledge that your firm initiated NC-001411 on June 7, 2024 and CAPA-100183 on June 11, 2024 to address updates needed to the procedural requirements, updates to DHRs so that BET result units are accurately recorded among other actions. However, your firm continues to implement a number of corrective actions that will not be completed until March 2025.\u003C\u002Fp>\u003Cp>4. Failure to establish and maintain procedures for corrective and preventive action, as required by 21 § CFR 820.100(a). For example,\u003C\u002Fp>\u003Cp>During the inspection of the Princeton, NJ corporate headquarters, your Corrective and Preventive Action (CAPA) Process (GSOP-758; Rev 007), specifically, Section 7.1, describes the process of CAPA Escalation. Section 7.1.2.3 of GSOP-758 describes when a decision is made to not initiate a CAPA, including documentation of the justification for not initiating a CAPA on Form GSOP-758A (CAPA Escalation Decision Form). A review of quality data sources over individual Integra sites, including corrective and preventive actions (CAPAs) and quality plans (QPs) taken at numerous Integra firm locations revealed that site specific CAPAs are not evaluated for escalation to corporate wide CAPAs.\u003C\u002Fp>\u003Cp>For example, CAPA 23-008 opened on April 7, 2023 at the \u003Cstrong>(b)(4)\u003C\u002Fstrong> manufacturing location in \u003Cstrong>(b)(4)\u003C\u002Fstrong> was related to endotoxin testing at that location. Endotoxin testing is performed at other locations, including collagen manufacturing in Plainsboro, NJ and neurological manufacturing in Mansfield, MA. The decision and justification to not escalate endotoxin testing to a corporate wide CAPA was not documented.\u003C\u002Fp>\u003Cp>Additionally, per Section 5.2.1 of the Quality Objectives &amp; Quality Planning document (GSOP-763; Rev. 003) “\u003Cem>quality planning is not used to investigate or correct actual or potential problems or concerns arising from the QMS or its data sources\u003C\u002Fem>.” However, during our inspections, you provided several quality plans that were being utilized for investigating or correcting actual and potential problems with the quality systems. The GSOP-763 procedure used for quality planning does not include pertinent sections required for corrective and preventive actions such as: investigating the cause of nonconformities, identifying the actions needed to correct and prevent recurrence, and verifying or validating the action to ensure it is effective. These sections are found within the CAPA procedure GSOP-758. At the time of our inspections, CAPAs had not been opened to address these issues. Examples of quality plans currently being used to correct problems with the quality system are:\u003C\u002Fp>\u003Cp>• At your Princeton, NJ location\u003Cbr>&nbsp; &nbsp; o QP-2023-12, Quality Plan for Assessing Endotoxin Program Compliance, initiated on March 25, 2024 to assess endotoxin issues across Integra organizations. This quality plan lists a target completion date for site-specific gap assessments as 12\u002F31\u002F2026 and the target due date for developing an action plan to close and\u002For mitigate any identified compliance gaps as 6\u002F30\u002F2027.\u003Cbr>• At your Plainsboro, NJ location\u003Cbr>&nbsp; &nbsp; o QP-2023-02, Quality Plan for the Closure of Overdue SCARs at the Collagen Manufacturing Center, initiated on December 7, 2023 to document the closure of overdue SCARs at the Collagen Manufacturing Center (CMC). Eleven SCARs were identified as overdue in section 2.2 of this document.\u003Cbr>• At your Mansfield, MA location\u003Cbr>&nbsp; &nbsp; o QP-20-001, Quality Plan for CerebroFlo EVD Catheter design history file remediation initiated on April 9, 2020, to address 30 observations found during a third-party review of the CerebroFlo EVD catheter design project.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and the adequacy cannot be determined. We acknowledge that your firm initiated several CAPAs at multiple sites, including a corporate-wide CAPA-00143 on September 6, 2024 to address the extension of CAPAs and Quality Plans across multiple Integra locations including planned implementation of a CAPA escalation decision tree and form by December 15, 2024; planned review of all CAPAs initiated at Integra corporate and all manufacturing sites since November 2, 2022; and planned updates to GSOP-758 to require an evaluation of each CAPA to determine whether it may be applicable to multiple manufacturing sites. However, your firm continues to implement corrective actions that will not be completed until November 2025 when verification of effectiveness is targeted to be completed.\u003C\u002Fp>\u003Cp>5. Failure to review and evaluate process changes and deviations and perform revalidation when changes or process deviations occur, as required by 21 CFR § 820.75(c).\u003C\u002Fp>\u003Cp>For example, at your Mansfield, MA location, your firm failed to assess the impact of annual sterilization requalification parameter failures for Ethylene Oxide (EO) cycle #\u003Cstrong>(b)(4)\u003C\u002Fstrong> used to demonstrate a continued sterility assurance level of \u003Cstrong>(b)(4)\u003C\u002Fstrong> EO sterilization is performed by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. EO cycle #\u003Cstrong>(b)(4)\u003C\u002Fstrong> is used sterilization of several devices manufactured at Mansfield, MA including neurological surgical patties. For example,\u003C\u002Fp>\u003Cp>• On December 2, 2020, a deviation occurred with eight temperature sensors recording temperatures below the minimum \u003Cstrong>(b)(4)\u003C\u002Fstrong> degrees Fahrenheit for the product temperature during the EO exposure dwell phase, failing to meet the predetermined validation acceptance criteria of \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cbr>&nbsp; &nbsp; o Your firm failed to investigate the cause of the temperature failure and the potential effect on the EO cycle for routine sterilization.\u003C\u002Fp>\u003Cp>• The 2022 requalification of the EO cycle \u003Cstrong>(b)(4)\u003C\u002Fstrong> for Vessel #1 and Vessel # 2, (\u003Cstrong>(b)(4)\u003C\u002Fstrong>-0007898) approved by your firm on November 23, 2022, exceeded your firm’s predetermined acceptance criteria for product load relative humidity (RH) of \u003Cstrong>(b)(4)\u003C\u002Fstrong> when RH readings ranged from \u003Cstrong>(b)(4)\u003C\u002Fstrong> during the preconditioning product phase, exceeding the allowable upper RH limit of \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cbr>&nbsp; &nbsp; o Your firm reported this RH protocol deviation as part of the 2022 requalification. However, your firm concluded: “…the re-qualification using dunnage devices has no effect on finished goods and no immediate actions are needed. There is no impact to sterility assurance of EO devices due to this event.” This conclusion was reached without an adequate investigation into the failed re-validation and determination of the root causes of the failure.\u003C\u002Fp>\u003Cp>• The 2023 requalification of the EO cycle \u003Cstrong>(b)(4)\u003C\u002Fstrong> for Vessel # 1 and Vessel #2 (\u003Cstrong>(b)(4)\u003C\u002Fstrong>-0009433) approved by your firm on March 15, 2024, failed to meet your firm’s predetermined acceptance criteria that all internal and external biological indicators (BI) were required to be negative for growth as one external process challenge devices (PCD) resulted in positive growth. Further, the RH specification of \u003Cstrong>(b)(4)\u003C\u002Fstrong> was not met as RH readings ranged from \u003Cstrong>(b)(4)\u003C\u002Fstrong> during the preconditioning product phase, exceeding the allowable upper RH limit of \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cbr>&nbsp; &nbsp; o As a result of the 2023 requalification failures, Vessel #2 was disqualified for EO cycle \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, your firm continues to use Vessel #1 which also failed to meet the same EO requalification predetermined acceptance criteria (RH) that caused your firm to disqualify Vessel #2 and similar conclusions used during the 2022 deviation report were again restated in 2023 to justify continued use of Vessel #1.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and the adequacy cannot be determined. We acknowledge that your firm initiated NC-001007 on June 7, 2024 which was later escalated to CAPA-00179 on June 11, 2024 to address, in part, annual parameter failures associated with EO cycle \u003Cstrong>(b)(4)\u003C\u002Fstrong> including revisions made to your \u003Cem>Annual EO Revalidation \u003C\u002Fem>\u003Cstrong>(b)(4)\u003C\u002Fstrong> work instruction (WI-10007) and planned performance of requalification for EO cycle \u003Cstrong>(b)(4)\u003C\u002Fstrong> for the current year utilizing the updated WI. However, this requalification has not occurred as it has a target date of December 31, 2024.\u003C\u002Fp>\u003Cp>Additionally, at your Princeton, NJ location, your firm initiated a Supplier Change Request (SCAR #NC-101873) to change the pouch sealing machine to \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which supplies pouches (product number \u003Cstrong>(b)(4)\u003C\u002Fstrong>) to your firm’s Le Locle, Switzerland facility for packaging of sterile medical devices after detection that the pouch was opened on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sealing side. Investigation into the seal strength caused your supplier to perform a revalidation of \u003Cstrong>(b)(4)\u003C\u002Fstrong> to challenge the ability to produce product that meets specifications.\u003C\u002Fp>\u003Cp>In the performance qualification protocol performed by your supplier (\u003Cstrong>(b)(4)\u003C\u002Fstrong>-24010), a minimum acceptable seal value lower specification limit (LSL) of \u003Cstrong>(b)(4)\u003C\u002Fstrong> lb\u002Fin was utilized. In your Retrospective Validation Report for Bactiseal Pouch Supplier Sealer Performance (Document ENG-199915-MEMO) the seal strength lower spec. is listed as \u003Cstrong>(b)(4)\u003C\u002Fstrong> lbf\u002Fin. However, the validation qualification report for Package Performance and Package Stability Study for Bactiseal EVD (applicable to your Le Locle, Switzerland and Mansfield, MA locations) concluded that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> minimum specification will meet the \u003Cstrong>(b)(4)\u003C\u002Fstrong> lb\u002Fin post sterilization requirement specified in the BSN 868-5 standard. This validation qualification report was performed in 2021 prior to the change to your supplier’s \u003Cstrong>(b)(4)\u003C\u002Fstrong> and does not account for your supplier’s use of a \u003Cstrong>(b)(4)\u003C\u002Fstrong> lb\u002Fin LSL.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and the adequacy cannot be determined. We acknowledge that your firm initiated CAPA-00146 on September 6, 2024 to address the lack of consistent assessment of validations when changes occur, as well as state a commitment to: update your product and process change decisions tree; create a global procedure for assessment of supplier changes; obsolete your supplier change process at Mansfield and Le Locle; and perform a retrospective review of Integra supplier change procedures. However, your firm continues to implement a number of corrective actions that will not be completed until January 2025\u003C\u002Fp>\u003Cp>6. Failure to establish and maintain procedures to prevent contamination of equipment or product by substances that could reasonably be expected to have an adverse effect on product quality, as required by 21 CFR 820.70(e).\u003C\u002Fp>\u003Cp>For example, the Controlled Environment and Cleanroom Operating and Monitoring Procedure (Rev: 065, Effective Date: 20 April 2021) utilized at your Mansfield, MA location was not followed. Multiple (18) viable and non-viable particulate environmental excursion results, occurring from January 2023 to April 2024, for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleanroom were observed near a \u003Cstrong>(b)(4)\u003C\u002Fstrong>, equipment identification #\u003Cstrong>(b)(4)\u003C\u002Fstrong>) located in room \u003Cstrong>(b)(4)\u003C\u002Fstrong>. As a result, your firm updated the \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning procedure to “\u003Cem>include routine cleaning of the locations which had visible particulate accumulation on the surface\u003C\u002Fem>” and determined the risk to product quality as “Low – no product impact” without adequate investigation or a risk-based assessment to evaluate product impact. Several devices, including surgical patties, are manufactured using the identified \u003Cstrong>(b)(4)\u003C\u002Fstrong> machine, where the \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleanroom failed your firm’s pre-established alert and action limits.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and the adequacy cannot be determined. We acknowledge that your firm initiated CAPA-100180 on June 11, 2024 to address updates needed to address this observation. We also acknowledge that your firm has updated your non-routine cleaning frequency for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> machine, plans to complete a Health Hazard Evaluation, and develop a contamination control plan. However, your firm continues to implement these corrective actions that have a target date in January 2025.\u003C\u002Fp>\u003Cp>For your Plainsboro, NJ location, during review of Particulate Air Sampling records (CNS-G-630A), it was observed that your firm set the \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleanroom action limit at \u003Cstrong>(b)(4)\u003C\u002Fstrong> um sized particles per cubic meter. This action limit selected is the maximum allowance specified in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> standard. Your firm’s action limit being set at the maximum allowable level does not provide an opportunity to take action before exceeding the specification.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and the adequacy cannot be determined. We acknowledge that your firm initiated CAPA-00151 on September 5, 2024 to address updates needed to resolve the observation. We also acknowledge that your firm plans to establish alert\u002Faction limits for \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleanrooms that allow proactive actions to prevent exceeding particulate specifications along with planned changes to associated procedures. However, these corrective actions have not been implemented as a number of corrective actions have target completion dates in February 2025.\u003C\u002Fp>\u003Cp>7. Failure to validate with a high degree of assurance, a process whose results cannot be fully verified by subsequent inspection and test, as required by 21 CFR § 820.75(a).\u003C\u002Fp>\u003Cp>Specifically, your firm failed to follow your corporate-wide procedure for Process Validation (GSOP-738; Rev 007), in that section 5.2.5 states a protocol may be generated for each qualification, and section 5.2.6.6 states a qualification report is required for each qualification activity.\u003C\u002Fp>\u003Cp>For example, at your Plainsboro, NJ location, your firm’s validation of procedure CMC-AH-10, (determination of bacterial endotoxins in Integra products, \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> using the \u003Cstrong>(b)(4)\u003C\u002Fstrong>), lacks a validation protocol and validation report. The validation for the inhibition and enhancement testing for Limulus Amebocyte Lysate (LAL) was performed in 2004 under a previous process validation procedure (MD-029; obsoleted 5\u002F5\u002F2022). The only record for validation of this LAL test were results from Inhibition\u002FEnhancement Testing – \u003Cstrong>(b)(4)\u003C\u002Fstrong> performed on four lots of INTEGRA Dermal Regeneration Template (IRDT)-TS \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> lots of IDRT have been produced since 12\u002F1\u002F2004.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and the adequacy cannot be determined. We acknowledge that your firm initiated CAPA-00136 on September 10, 2024 to address the lack of protocol and report for the validation of inhibition\u002Fenhancement Testing of LAL, as well as a commitment to \u003Cstrong>(b)(4)\u003C\u002Fstrong> validations for all Collagen Manufacturing Center (CMC) products, revisions to your CMC-AH-10 test method, and revisions to your change control procedures. However, your firm continues to implement a number of corrective actions that will not be completed until January 2025.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Assistant Director Gina Brackett at CDRHWarningLetterResponses@fda.hhs.gov. Please include in the subject line \u003Cstrong>CMS Case 698850\u003C\u002Fstrong> when replying. If you have any questions about the contents of this letter, please contact: Sean Moynihan, Consumer Safety Officer at sean.moynihan@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>RDML Sean M. Boyd, MPH, USPHS\u003Cbr>Director Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality&nbsp;&nbsp;\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMr. Jan De Witte\n\nRecipient Title\n\nPresident and CEO\n\nIntegra LifeSciences Corporation\n\n1100 Campus Road\n\nPrinceton, NJ 08540\n\nUnited States\n\n(b)(4)@integralife.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 698850\nDecember 19, 2024\nDear Mr. DeWitte:\nThe United States Food and Drug Administration (FDA) conducted the following inspections of your firm’s medical device facilities:\nIntegra LifeSciences Corporation, located at 11 Cabot Blvd, Mansfield, MA, FEI 3014334038, from March 12, 2024 through June 5, 2024\nIntegra LifeSciences Corporation, located at 105 And 109 Morgan Ln, Plainsboro, NJ, FEI 1121308, from April 9, 2024 through August 22, 2024\nIntegra LifeSciences Corporation, located at 1100 Campus Rd, Princeton, NJ, FEI 3003418325, from March 12, 2034 through August 22, 2024\nDuring these inspections, FDA investigators and a microbiologist determined that the above firms manufacture a variety of neurological and neurosurgical devices, including but not limited to, cranial perforators, disposable cottonoid patties and strips as well as collagen based medical devices, that are used for wound care, soft tissue repair and reconstruction surgery. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nThe above inspections revealed that the above devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received responses from Jeffrey Caldwell, Vice President, Quality Operations dated June 27, 2024, August 27, 2024, and October 25, 2024 concerning our investigator’s and microbiologist’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm’s Mansfield, MA location on June 5, 2024.\nWe received responses from Brenda Romero, Director, Quality Operations, CMC dated September 27, 2024 and December 5, 2024 concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm’s Plainsboro, NJ location on August 22, 2024.\nWe received responses from Jessica Smith, Corporate Vice President, Chief Regulatory Officer, and interim Chief Quality Officer dated September 13, 2024 and from Lacey Gigante, Sr. Director, CAPA & Compliance November 15, 2024 concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm’s Princeton, NJ location on August 22, 2024.\nWe address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to establish and maintain procedures to control product that does not conform to specified requirements. The procedures shall address the identification, documentation, evaluation, segregation, and disposition of nonconforming product. The evaluation of nonconformance shall include a determination of the need for an investigation and notification of the persons or organizations responsible for the nonconformance. The evaluation and any investigation shall be documented, as required by 21 CFR § 820.90(a).\nSpecifically, during an inspection of your Mansfield, MA location, a review of 4 non-conforming reports from October 2022 through June 2023 (NC-101352, NC-101446, NC-101628, and NC-101642) were opened due to Out of Specification (OOS) endotoxin results on three separate lots of surgical patties and one lot of Duraform. In the above instances, after the laboratory investigation concluded there was no assignable laboratory error or root cause, your firm retested the lots, even though your Pyrogen Testing procedure, MPS-PC340, did not specify that a retest was allowed. Your firm then released the above referenced lots without conducting a complete investigation of the manufacturing processes, as required by your Non-Conformance procedure, GSOP-773 and MPS-PC340.\nWe reviewed your firm’s responses and the adequacy cannot be determined. We acknowledge that your firm initiated a recall of Duraform, lot CT007694 on September 6, 2024 as well as a recall of multiple lots of surgical patties and strips manufactured between 2022 and 2023 on September 20, 2024. However, your firm continues to implement a number of corrective actions at your Mansfield, MA facility that will not be completed until May 2025.\n2. Failure to establish and maintain procedures for acceptance activities. Acceptance activities include inspections, tests, or other verification activities; as required by 21 CFR § 820.80(a).\nSpecifically, your Plainsboro, NJ location utilizes procedure CMC-MB-049 “Determination of Endotoxin in (b)(4) Product Using the (b)(4) Methods” to determine the bacterial endotoxin concentration in products manufactured at the Integra LifeSciences Collagen Manufacturing Center (CMC), Buildings (b)(4) and (b)(4), including (b)(4). According to section 9.6.3.3 of this procedure, “the Coefficient of Variation (CV%) for each pair of standard series samples must be less than (b)(4)” for the overall test to be considered valid. However, during our inspection we observed that ten of fifty-two tests conducted in 2023 failed due to the CV% exceeding the (b)(4) limit. These ten tests were observed to be repeatedly retested until the CV% fell below (b)(4). For example, endotoxin test (LAL-24-2012) and its two subsequent retests (LAL-24-0012 Retest, LAL-24-0012 Retest 2) all failed to meet CV% criteria. It was then retested on a different day under a new ID (LAL-24-0013) and finally passed on the fourth attempt (LAL-24-0013 Retest 3). Your firm’s microbiology manager attributed the CV% failures to low endotoxin concentration in the controls. Additionally, your CMC-MB-049 procedure does not specify the circumstances under which a retest could be performed or which result should be utilized if a retest was conducted.\nWe reviewed your firm’s responses and the adequacy cannot be determined. We acknowledge that your firm initiated three CAPAs (CAPA-00133, CAPA-00134, and CAPA-00135) to address the observations. As part of these CAPAs, we acknowledge that your firm has performed a statistical assessment of historical reagent qualification data for CV% in which you determined that the appropriate CV% for the (b)(4) EU\u002FmL standard concentration would be (b)(4)% and made updates to affected procedures, including CMC-MB-049. However, verification of the effectiveness of the corrective actions are still ongoing with a target date of June 2025. Please provide the results of your firm’s planned 6-month effectiveness check when it becomes available.\n3. Failure to establish and maintain procedures for finished device acceptance to ensure that each production run, lot, or batch of finished devices meets acceptance criteria, as required by 21 CFR § 820.80(d).\nSpecifically, your Mansfield, MA location utilizes MPS-PC340, Preparing Products for Pyrogen Testing (Rev: 068, Effective Date: 30Mar2023) to describe the procedures and materials needed to prepare test samples for pyrogenicity and how to investigate results that exceed acceptable criteria. However, review of this procedure determined it lacks the following requirements to ensure devices meet established endotoxins specifications for device sterility prior to release. For example,\n Adequate instructions for OOS laboratory investigations where the original endotoxins results are determined to be valid because no laboratory error or assignable cause was found.\n Documentation of how many times the device lot or device extract may be re- analyzed or retested during the investigation after an OOS result is reported.\n Lack of details regarding sample selection to ensure samples are representative of the entire lot to account for endotoxins not evenly distributed within the lot.\n No requirement to include documentation of endotoxin test result units (EU\u002Fml or EU\u002Fdevice) on the Post-Sterile Release section of your Device History Records.\nFor example, verification of Pyrogen Lab Results receipt for Lot # 7260687 of Product Code (b)(4) lists the Lab Result as “(b)(4).” The Endotoxin Action Limit for this product code is (b)(4) EU\u002FDevice. Your Bacterial Endotoxin Test Final Report (Study Number 1621708-S01), dated June 15, 2023 concluded that the pooled test articles for Lot # 7260687 “exceeded the endotoxin limit of not more than (b)(4) EU\u002Fdevice.”\nWe reviewed your firm’s responses and the adequacy cannot be determined. We acknowledge that your firm initiated NC-001411 on June 7, 2024 and CAPA-100183 on June 11, 2024 to address updates needed to the procedural requirements, updates to DHRs so that BET result units are accurately recorded among other actions. However, your firm continues to implement a number of corrective actions that will not be completed until March 2025.\n4. Failure to establish and maintain procedures for corrective and preventive action, as required by 21 § CFR 820.100(a). For example,\nDuring the inspection of the Princeton, NJ corporate headquarters, your Corrective and Preventive Action (CAPA) Process (GSOP-758; Rev 007), specifically, Section 7.1, describes the process of CAPA Escalation. Section 7.1.2.3 of GSOP-758 describes when a decision is made to not initiate a CAPA, including documentation of the justification for not initiating a CAPA on Form GSOP-758A (CAPA Escalation Decision Form). A review of quality data sources over individual Integra sites, including corrective and preventive actions (CAPAs) and quality plans (QPs) taken at numerous Integra firm locations revealed that site specific CAPAs are not evaluated for escalation to corporate wide CAPAs.\nFor example, CAPA 23-008 opened on April 7, 2023 at the (b)(4) manufacturing location in (b)(4) was related to endotoxin testing at that location. Endotoxin testing is performed at other locations, including collagen manufacturing in Plainsboro, NJ and neurological manufacturing in Mansfield, MA. The decision and justification to not escalate endotoxin testing to a corporate wide CAPA was not documented.\nAdditionally, per Section 5.2.1 of the Quality Objectives & Quality Planning document (GSOP-763; Rev. 003) “quality planning is not used to investigate or correct actual or potential problems or concerns arising from the QMS or its data sources.” However, during our inspections, you provided several quality plans that were being utilized for investigating or correcting actual and potential problems with the quality systems. The GSOP-763 procedure used for quality planning does not include pertinent sections required for corrective and preventive actions such as: investigating the cause of nonconformities, identifying the actions needed to correct and prevent recurrence, and verifying or validating the action to ensure it is effective. These sections are found within the CAPA procedure GSOP-758. At the time of our inspections, CAPAs had not been opened to address these issues. Examples of quality plans currently being used to correct problems with the quality system are:\n• At your Princeton, NJ location\no QP-2023-12, Quality Plan for Assessing Endotoxin Program Compliance, initiated on March 25, 2024 to assess endotoxin issues across Integra organizations. This quality plan lists a target completion date for site-specific gap assessments as 12\u002F31\u002F2026 and the target due date for developing an action plan to close and\u002For mitigate any identified compliance gaps as 6\u002F30\u002F2027.\n• At your Plainsboro, NJ location\no QP-2023-02, Quality Plan for the Closure of Overdue SCARs at the Collagen Manufacturing Center, initiated on December 7, 2023 to document the closure of overdue SCARs at the Collagen Manufacturing Center (CMC). Eleven SCARs were identified as overdue in section 2.2 of this document.\n• At your Mansfield, MA location\no QP-20-001, Quality Plan for CerebroFlo EVD Catheter design history file remediation initiated on April 9, 2020, to address 30 observations found during a third-party review of the CerebroFlo EVD catheter design project.\nWe reviewed your firm’s responses and the adequacy cannot be determined. We acknowledge that your firm initiated several CAPAs at multiple sites, including a corporate-wide CAPA-00143 on September 6, 2024 to address the extension of CAPAs and Quality Plans across multiple Integra locations including planned implementation of a CAPA escalation decision tree and form by December 15, 2024; planned review of all CAPAs initiated at Integra corporate and all manufacturing sites since November 2, 2022; and planned updates to GSOP-758 to require an evaluation of each CAPA to determine whether it may be applicable to multiple manufacturing sites. However, your firm continues to implement corrective actions that will not be completed until November 2025 when verification of effectiveness is targeted to be completed.\n5. Failure to review and evaluate process changes and deviations and perform revalidation when changes or process deviations occur, as required by 21 CFR § 820.75(c).\nFor example, at your Mansfield, MA location, your firm failed to assess the impact of annual sterilization requalification parameter failures for Ethylene Oxide (EO) cycle #(b)(4) used to demonstrate a continued sterility assurance level of (b)(4) EO sterilization is performed by (b)(4). EO cycle #(b)(4) is used sterilization of several devices manufactured at Mansfield, MA including neurological surgical patties. For example,\n• On December 2, 2020, a deviation occurred with eight temperature sensors recording temperatures below the minimum (b)(4) degrees Fahrenheit for the product temperature during the EO exposure dwell phase, failing to meet the predetermined validation acceptance criteria of (b)(4).\no Your firm failed to investigate the cause of the temperature failure and the potential effect on the EO cycle for routine sterilization.\n• The 2022 requalification of the EO cycle (b)(4) for Vessel #1 and Vessel # 2, ((b)(4)-0007898) approved by your firm on November 23, 2022, exceeded your firm’s predetermined acceptance criteria for product load relative humidity (RH) of (b)(4) when RH readings ranged from (b)(4) during the preconditioning product phase, exceeding the allowable upper RH limit of (b)(4).\no Your firm reported this RH protocol deviation as part of the 2022 requalification. However, your firm concluded: “…the re-qualification using dunnage devices has no effect on finished goods and no immediate actions are needed. There is no impact to sterility assurance of EO devices due to this event.” This conclusion was reached without an adequate investigation into the failed re-validation and determination of the root causes of the failure.\n• The 2023 requalification of the EO cycle (b)(4) for Vessel # 1 and Vessel #2 ((b)(4)-0009433) approved by your firm on March 15, 2024, failed to meet your firm’s predetermined acceptance criteria that all internal and external biological indicators (BI) were required to be negative for growth as one external process challenge devices (PCD) resulted in positive growth. Further, the RH specification of (b)(4) was not met as RH readings ranged from (b)(4) during the preconditioning product phase, exceeding the allowable upper RH limit of (b)(4).\no As a result of the 2023 requalification failures, Vessel #2 was disqualified for EO cycle (b)(4). However, your firm continues to use Vessel #1 which also failed to meet the same EO requalification predetermined acceptance criteria (RH) that caused your firm to disqualify Vessel #2 and similar conclusions used during the 2022 deviation report were again restated in 2023 to justify continued use of Vessel #1.\nWe reviewed your firm’s responses and the adequacy cannot be determined. We acknowledge that your firm initiated NC-001007 on June 7, 2024 which was later escalated to CAPA-00179 on June 11, 2024 to address, in part, annual parameter failures associated with EO cycle (b)(4) including revisions made to your Annual EO Revalidation (b)(4) work instruction (WI-10007) and planned performance of requalification for EO cycle (b)(4) for the current year utilizing the updated WI. However, this requalification has not occurred as it has a target date of December 31, 2024.\nAdditionally, at your Princeton, NJ location, your firm initiated a Supplier Change Request (SCAR #NC-101873) to change the pouch sealing machine to (b)(4), which supplies pouches (product number (b)(4)) to your firm’s Le Locle, Switzerland facility for packaging of sterile medical devices after detection that the pouch was opened on the (b)(4) sealing side. Investigation into the seal strength caused your supplier to perform a revalidation of (b)(4) to challenge the ability to produce product that meets specifications.\nIn the performance qualification protocol performed by your supplier ((b)(4)-24010), a minimum acceptable seal value lower specification limit (LSL) of (b)(4) lb\u002Fin was utilized. In your Retrospective Validation Report for Bactiseal Pouch Supplier Sealer Performance (Document ENG-199915-MEMO) the seal strength lower spec. is listed as (b)(4) lbf\u002Fin. However, the validation qualification report for Package Performance and Package Stability Study for Bactiseal EVD (applicable to your Le Locle, Switzerland and Mansfield, MA locations) concluded that the (b)(4) minimum specification will meet the (b)(4) lb\u002Fin post sterilization requirement specified in the BSN 868-5 standard. This validation qualification report was performed in 2021 prior to the change to your supplier’s (b)(4) and does not account for your supplier’s use of a (b)(4) lb\u002Fin LSL.\nWe reviewed your firm’s responses and the adequacy cannot be determined. We acknowledge that your firm initiated CAPA-00146 on September 6, 2024 to address the lack of consistent assessment of validations when changes occur, as well as state a commitment to: update your product and process change decisions tree; create a global procedure for assessment of supplier changes; obsolete your supplier change process at Mansfield and Le Locle; and perform a retrospective review of Integra supplier change procedures. However, your firm continues to implement a number of corrective actions that will not be completed until January 2025\n6. Failure to establish and maintain procedures to prevent contamination of equipment or product by substances that could reasonably be expected to have an adverse effect on product quality, as required by 21 CFR 820.70(e).\nFor example, the Controlled Environment and Cleanroom Operating and Monitoring Procedure (Rev: 065, Effective Date: 20 April 2021) utilized at your Mansfield, MA location was not followed. Multiple (18) viable and non-viable particulate environmental excursion results, occurring from January 2023 to April 2024, for your (b)(4) cleanroom were observed near a (b)(4), equipment identification #(b)(4)) located in room (b)(4). As a result, your firm updated the (b)(4) cleaning procedure to “include routine cleaning of the locations which had visible particulate accumulation on the surface” and determined the risk to product quality as “Low – no product impact” without adequate investigation or a risk-based assessment to evaluate product impact. Several devices, including surgical patties, are manufactured using the identified (b)(4) machine, where the (b)(4) cleanroom failed your firm’s pre-established alert and action limits.\nWe reviewed your firm’s responses and the adequacy cannot be determined. We acknowledge that your firm initiated CAPA-100180 on June 11, 2024 to address updates needed to address this observation. We also acknowledge that your firm has updated your non-routine cleaning frequency for the (b)(4) machine, plans to complete a Health Hazard Evaluation, and develop a contamination control plan. However, your firm continues to implement these corrective actions that have a target date in January 2025.\nFor your Plainsboro, NJ location, during review of Particulate Air Sampling records (CNS-G-630A), it was observed that your firm set the (b)(4) cleanroom action limit at (b)(4) um sized particles per cubic meter. This action limit selected is the maximum allowance specified in the (b)(4) standard. Your firm’s action limit being set at the maximum allowable level does not provide an opportunity to take action before exceeding the specification.\nWe reviewed your firm’s responses and the adequacy cannot be determined. We acknowledge that your firm initiated CAPA-00151 on September 5, 2024 to address updates needed to resolve the observation. We also acknowledge that your firm plans to establish alert\u002Faction limits for (b)(4) cleanrooms that allow proactive actions to prevent exceeding particulate specifications along with planned changes to associated procedures. However, these corrective actions have not been implemented as a number of corrective actions have target completion dates in February 2025.\n7. Failure to validate with a high degree of assurance, a process whose results cannot be fully verified by subsequent inspection and test, as required by 21 CFR § 820.75(a).\nSpecifically, your firm failed to follow your corporate-wide procedure for Process Validation (GSOP-738; Rev 007), in that section 5.2.5 states a protocol may be generated for each qualification, and section 5.2.6.6 states a qualification report is required for each qualification activity.\nFor example, at your Plainsboro, NJ location, your firm’s validation of procedure CMC-AH-10, (determination of bacterial endotoxins in Integra products, (b)(4) and (b)(4) using the (b)(4)), lacks a validation protocol and validation report. The validation for the inhibition and enhancement testing for Limulus Amebocyte Lysate (LAL) was performed in 2004 under a previous process validation procedure (MD-029; obsoleted 5\u002F5\u002F2022). The only record for validation of this LAL test were results from Inhibition\u002FEnhancement Testing – (b)(4) performed on four lots of INTEGRA Dermal Regeneration Template (IRDT)-TS (b)(4). Approximately (b)(4) lots of IDRT have been produced since 12\u002F1\u002F2004.\nWe reviewed your firm’s responses and the adequacy cannot be determined. We acknowledge that your firm initiated CAPA-00136 on September 10, 2024 to address the lack of protocol and report for the validation of inhibition\u002Fenhancement Testing of LAL, as well as a commitment to (b)(4) validations for all Collagen Manufacturing Center (CMC) products, revisions to your CMC-AH-10 test method, and revisions to your change control procedures. However, your firm continues to implement a number of corrective actions that will not be completed until January 2025.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Assistant Director Gina Brackett at CDRHWarningLetterResponses@fda.hhs.gov. Please include in the subject line CMS Case 698850 when replying. If you have any questions about the contents of this letter, please contact: Sean Moynihan, Consumer Safety Officer at sean.moynihan@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nRDML Sean M. Boyd, MPH, USPHS\nDirector Office of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","Integra LifeSciences Corporation","integra-lifesciences-corporation-698850-12192024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fintegra-lifesciences-corporation-698850-12192024","2026-10-26T08:08:59.635431+00:00","2025-01-14","698850","Medical Devices","Mr. Jan De Witte","2026-08-19T17:04:50.521+00:00","2024-12-19",{"id":274,"raw":275,"subject":260,"body_html":280,"body_text":281,"firm_name":263,"letter_id":282,"created_at":46,"fei_number":20,"letter_url":283,"updated_at":284,"action_type":23,"case_status":24,"posted_date":285,"marcs_cms_no":286,"product_type":269,"closeout_date":20,"issuing_office":287,"recipient_name":270,"body_fetched_at":288,"delivery_method":289,"recipient_title":20,"reference_number":20,"action_taken_date":290,"medical_device_id":20,"response_letter_date":20},1934,[276,277,278,279,260,13,13,13],"\u003Ctime datetime=\"2023-08-15T13:20:00Z\">08\u002F15\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-07-17T04:00:00Z\">07\u002F17\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fintegra-lifesciences-corporation-660960-07172023\">Integra LifeSciences Corporation\u003C\u002Fa>"," Division of Medical Device and Radiological Health Division I","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>United Parcel Service\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Jan De Witte\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Integra LifeSciences Corporation\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1100 Campus Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Princeton\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>08540\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:jan.dewitte@integralife.com\"> jan.dewitte@integralife.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Medical Device and Radiological Health Division I\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS # 660960\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>July 17, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Mr. DeWitte:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations, TEI Biosciences, Inc., an Integra LifeSciences Company, located at 7 Elkins Street, Boston, MA, from March 1 through May 17, 2023. During the inspection, FDA investigators determined that your firm is a medical device manufacturer of collagen based medical devices, that are used for wound care, soft tissue repair and reconstruction surgery, including Durepair. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that the above devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\u003C\u002Fp>\n\n\u003Cp>We received your response dated June 8, 2023 from Susan Krause, Corporate Vice President, Chief Quality Officer, Integra Lifesciences Corporation, which responded to the Form FDA 483, List of Inspectional Observations issued to your firm on May 17, 2023. On May 23, 2023, our office also confirmed that TEI initiated a recall of all finished goods manufactured within expiry from March 1, 2018 through May 22, 2023, (RES 92481). We also understand that you have committed to not distributing product until the TEI Bioscience site is operating in substantial conformity with Quality System regulations (QSR). We address your June 8, 2023 response below.\u003C\u002Fp>\n\n\u003Cp>These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to establish and maintain procedures to control product that does not conform to specified requirements, as required by 21 CFR 820.90(a). Specifically:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>On June 19, 2019, your firm released a lot of Durepair,# 1904005 for distribution that indicated a bacterial endotoxin (BET) result of 9.98 EU\u002FDevice. This result exceeded your acceptance criteria of \u003Cstrong>(b)(4)\u003C\u002Fstrong> device as specified in your procedure, QCP-037 - Performance of the \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;Endotoxin Assay. The device history record for this lot of product showed that the lot was approved and released by your firm without an investigation or product risk assessment for the BET result that was out of specification (OOS).\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>We reviewed your firm’s response and conclude it is not adequate. Your response indicated that NC 23-042 was initiated during the inspection when the above Durepair OOS result was brought to your attention. On May 30, 2023, your firm determined the above OOS result was the result of a transcription error and the 9.98 EU result was for a different lot of product where this was an acceptable result (specification was \u003Cstrong>(b)(4)\u003C\u002Fstrong>). Your response indicated that CAPA 23-026 was opened to address the above nonconformance deficiencies, yet you have not provided a copy of the CAPA nor have you identified all necessary corrective actions to demonstrate that your quality system will ensure controls are in place to prevent the release of non-conforming product. We remain concerned that your quality system will be capable of identifying similar OOS errors when you resume operations and will prevent the release of non-conforming products.\u003C\u002Fp>\n\n\u003Cp>2. Failure to establish and maintain procedures for implementing corrective and preventive actions, including requirements for analyzing processes, work operations, concessions, quality audit reports, quality records, service records, complaints, returned product, and other sources of quality data to identify existing and potential causes of nonconforming product, or other quality problems, as required by 21 CFR 820.100(a)(1). Specifically:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>On October 20, 2022, your firm received an internal complaint that alleged quality issues in \u003Cstrong>(b)(4)\u003C\u002Fstrong> manufacturing areas including your \u003Cstrong>(b)(4)\u003C\u002Fstrong> inspection process, bacterial endotoxin testing, bovine hide\u002Fskin thickness measurements, and control of sterilized devices. As the result of your initial investigation, your firm initiated a production hold on December 14, 2022 and also placed \u003Cstrong>(b)(4)\u003C\u002Fstrong> lots of product on hold. You initiated a CAPA to address the \u003Cstrong>(b)(4)\u003C\u002Fstrong> issue, however, CAPAs were not opened to address the remaining \u003Cstrong>(b)(4)\u003C\u002Fstrong> areas of concern, including endotoxin issues. Your CAPA procedure, GSOP-758, rev 005, indicates that “CAPA investigations and any corrections, corrective and\u002F or preventive actions should be \u003Cstrong>(b)(4)\u003C\u002Fstrong>”.\u003C\u002Fli>\n\t\u003Cli>During the inspection, you initiated a health hazard evaluation, 2023-HHE-005 to address the endotoxin concerns and the potential health risk. This HHE, completed on April 12, 2023, was not comprehensive and did not include all complaints that may have been associated with this issue. For example, two complaints of meningitis, complaint #’s 198786 and 198790, associated with your Durepair product were not included in your initial HHE assessment that concluded a field action was not recommended. Your HHE SOP, GSOP-908, rev 015 indicates that the criteria for a HHE initiation would be when “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”.\u003C\u002Fli>\n\t\u003Cli>Your firm failed to \u003Cstrong>(b)(4)\u003C\u002Fstrong> as required per your procedure, GSOP-801 rev 3, \u003Cstrong>(b)(4)\u003C\u002Fstrong>; Rev 03. On December 14, 2022, a hold was placed on \u003Cstrong>(b)(4)\u003C\u002Fstrong> lots identified in the complaint but failed to identify the potential impact on \u003Cstrong>(b)(4)\u003C\u002Fstrong> lots manufactured during the same time frame.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>We reviewed your firm’s response and conclude it is not adequate. We are aware that this is a repeat CAPA deficiency from our 2019 Warning Letter to this facility. Your response indicated that \u003Cstrong>(b)(4)\u003C\u002Fstrong> CAPAs will be initiated to address the above deficiency, however you have not yet identified all necessary corrective actions, nor have you provided a copy of your CAPAs to ensure they will be comprehensive and capable of addressing the systemic issues that have been identified. We understand that you have taken a series of corrective actions, including a recall and production hold, however your response does not indicate how you will prevent such errors from recurring when you resume operations. In response to this Warning Letter, you will need to provide evidence that an effective and sustainable CAPA system will be implemented at your firm.\u003C\u002Fp>\n\n\u003Cp>3. Failure to validate with a high degree of assurance, a process whose results cannot be fully verified by subsequent inspection and test, as required by 21 CFR 820.75(a). Specifically:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your firm failed to adequately validate your test method for testing bacterial endotoxin (BET) of finished medical devices, or the \u003Cstrong>(b)(4)\u003C\u002Fstrong> used during the manufacture of these devices. Review of your BET test method validation, TMVR-009; revealed the following:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>o The TMVR-009 assay reports failed to meet \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing.\u003C\u002Fp>\n\n\u003Cp> \u003Cstrong>(b)(4)\u003C\u002Fstrong>, dated January 28, 2019, excluded \u003Cstrong>(b)(4)\u003C\u002Fstrong> with “Sample Descriptions” of “Negative Control”, invalidating BET test method verification runs for product lots # \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp> \u003Cstrong>(b)(4)\u003C\u002Fstrong>, dated January 2, 2019, excluded \u003Cstrong>(b)(4)\u003C\u002Fstrong> with sample descriptions “Negative Control”, invalidating BET test method verification runs for product lots # \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp> \u003Cstrong>(b)(4)\u003C\u002Fstrong>, dated January 29, 2019, excluded \u003Cstrong>(b)(4)\u003C\u002Fstrong> with lot sample description “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”, “Sample \u003Cstrong>(b)(4)\u003C\u002Fstrong>”, invalidating the BET test method verification for product lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>o Your BET test method protocol, section 7.4 Execution and Documentation of BET Assay, cannot be followed as written, to accurately \u003Cstrong>(b)(4)\u003C\u002Fstrong> for BET analysis of device product testing. For example, Section 7.4, step 4., states, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” However, the referenced table lists the \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>o During routine BET testing, your firm introduced a \u003Cstrong>(b)(4)\u003C\u002Fstrong>, in calculating the Endotoxin Limit which may cause the BET test method to be performed at \u003Cstrong>(b)(4)\u003C\u002Fstrong> to detect bacterial endotoxins. The use of this \u003Cstrong>(b)(4)\u003C\u002Fstrong> was not included in your endotoxin test method validation, TMVR-009.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your firm failed to adequately validate your test method for bioburden testing of finished medical devices. Review of TMVP-014, Revision 00, Test Method Validation Report for Bioburden Testing; Effective Date April 3, 2020, revealed:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>o Your report failed to meet the product bioburden recovery Acceptance Criteria \u003Cstrong>(b)(4)\u003C\u002Fstrong> to monitor device \u003Cstrong>(b)(4)\u003C\u002Fstrong> bioburden loads.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your firm failed to adequately validate your test method for bacterial endotoxin of \u003Cstrong>(b)(4)\u003C\u002Fstrong> used in the manufacture of your finished medical devices. Review of \u003Cstrong>(b)(4)\u003C\u002Fstrong>; Rev 00; Effective Date: April 25, 2019 revealed the following:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>o For BET Report # \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Run Date: 3\u002F27\u002F2019, the negative control replicate original data from \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> were excluded.\u003Cbr>\no \u003Cstrong>(b)(4)\u003C\u002Fstrong> sample and negative control results are evident on the BET analytical result printouts in \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Attachment D. Your firm failed to meet \u003Cstrong>(b)(4)\u003C\u002Fstrong>, requirement, “Perform re-test for invalid assays\u002Fand or samples and document rationale as appropriate.”\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and conclude it is not adequate at this time. Your response indicates that TEI Biosciences has outsourced all BET testing that was previously performed in-house, covering both product and \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing. We also acknowledge that corrective actions include your recent recall and production hold. However, your response also indicated that you initiated CAPA 23-028 to investigate all testing, inspection and method validations at your facility, beyond just BET and bioburden testing. We will need to review this CAPA to ensure it is comprehensive and will be effective in preventing similar failures from recurring when you resume distribution. In response to this Warning Letter, you will need to provide evidence that you have reviewed all your operations to ensure that you have validated processes in place.\u003C\u002Fp>\n\n\u003Cp>4. Failure to store devices in a manner to facilitate proper stock rotation and to assess its condition as appropriate, as required by 21 CFR 820.150(a). Specifically:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>On March 2, 2023, sterile lots of implantable devices were observed by our FDA investigator on an unsecure open shelf located in the QC Quarantine area and were labeled as “non-Sterile”. Your procedure, Shipping and Receiving EBM Products for Sterilization; MBP 300-102, Rev 21, does not adequately prevent mix-ups of sterile\u002Fnon-sterile material. Section 7.1.5 states \u003Cstrong>(b)(4)\u003C\u002Fstrong>. We are aware that a complaint received by your firm on October 20, 2022, also described an example where non-sterile product was being handled in the same area as sterile product. We acknowledge that a CAPA was not initiated at the time to address this issue and to prevent its recurrence.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>We reviewed your firm’s response and conclude it is not adequate. Your response indicated CAPA 23-031 has been opened to address this deficiency, however you have not yet completed your investigation, nor have you provided a copy of your CAPA. We will need to review your CAPA to ensure it is comprehensive and will be effective in preventing similar failures from recurring when you resume distribution. In response to this Warning Letter, you should provide confirmation that all proposed corrective actions are appropriate and effective.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\n\n\u003Cp>We are requesting that you submit to this office on the schedule below, certification by an outside expert consultant that he\u002Fshe has conducted an audit of your establishment's manufacturing and quality assurance systems relative to the requirements of the device QS regulation (21 CFR, Part 820). You should also submit a copy of the consultant's report, and certification by your establishment's Chief Executive Officer (if other than yourself) that he or she has reviewed the consultant's report and that your establishment has initiated or completed all corrections called for in the report. The initial certifications of audit and corrections and subsequent certifications of updated audits and corrections (if required) should be submitted to this office by the following dates:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Initial certifications by consultant and establishment – March 31, 2024\u003C\u002Fli>\n\t\u003Cli>Subsequent certifications – March 31, 2025 and March 31, 2026\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent to: Gina Brackett, Director of Compliance Branch, at oradevices1firmresponse@fda.hhs.gov. Refer to CMS # 660960 when replying. If you have any questions about the contents of this letter, please contact Compliance Officer, Karen Archdeacon at 781-587-7491 or at karen.archdeacon@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Joseph Matrisciano, Jr.\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Device and Radiological Health\u003Cbr>\nDivision 1\u003C\u002Fp>\n\n\u003Cp>Cc: Susan Krause, Corporate Vice President, Chief Quality Officer, susan.krause@integralife.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUnited Parcel Service\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMr. Jan De Witte\n\nRecipient Title\n\nPresident and CEO\n\nIntegra LifeSciences Corporation\n\n1100 Campus Road\n\nPrinceton, NJ 08540\n\nUnited States\n\njan.dewitte@integralife.com\n\nIssuing Office:\n\nDivision of Medical Device and Radiological Health Division I\n\nUnited States\n\nWARNING LETTER\n\nCMS # 660960\n\nJuly 17, 2023\n\nDear Mr. DeWitte:\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations, TEI Biosciences, Inc., an Integra LifeSciences Company, located at 7 Elkins Street, Boston, MA, from March 1 through May 17, 2023. During the inspection, FDA investigators determined that your firm is a medical device manufacturer of collagen based medical devices, that are used for wound care, soft tissue repair and reconstruction surgery, including Durepair. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nThis inspection revealed that the above devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\n\nWe received your response dated June 8, 2023 from Susan Krause, Corporate Vice President, Chief Quality Officer, Integra Lifesciences Corporation, which responded to the Form FDA 483, List of Inspectional Observations issued to your firm on May 17, 2023. On May 23, 2023, our office also confirmed that TEI initiated a recall of all finished goods manufactured within expiry from March 1, 2018 through May 22, 2023, (RES 92481). We also understand that you have committed to not distributing product until the TEI Bioscience site is operating in substantial conformity with Quality System regulations (QSR). We address your June 8, 2023 response below.\n\nThese violations include, but are not limited to, the following:\n\n1. Failure to establish and maintain procedures to control product that does not conform to specified requirements, as required by 21 CFR 820.90(a). Specifically:\n\nOn June 19, 2019, your firm released a lot of Durepair,# 1904005 for distribution that indicated a bacterial endotoxin (BET) result of 9.98 EU\u002FDevice. This result exceeded your acceptance criteria of (b)(4) device as specified in your procedure, QCP-037 - Performance of the (b)(4) Endotoxin Assay. The device history record for this lot of product showed that the lot was approved and released by your firm without an investigation or product risk assessment for the BET result that was out of specification (OOS).\n\nWe reviewed your firm’s response and conclude it is not adequate. Your response indicated that NC 23-042 was initiated during the inspection when the above Durepair OOS result was brought to your attention. On May 30, 2023, your firm determined the above OOS result was the result of a transcription error and the 9.98 EU result was for a different lot of product where this was an acceptable result (specification was (b)(4)). Your response indicated that CAPA 23-026 was opened to address the above nonconformance deficiencies, yet you have not provided a copy of the CAPA nor have you identified all necessary corrective actions to demonstrate that your quality system will ensure controls are in place to prevent the release of non-conforming product. We remain concerned that your quality system will be capable of identifying similar OOS errors when you resume operations and will prevent the release of non-conforming products.\n\n2. Failure to establish and maintain procedures for implementing corrective and preventive actions, including requirements for analyzing processes, work operations, concessions, quality audit reports, quality records, service records, complaints, returned product, and other sources of quality data to identify existing and potential causes of nonconforming product, or other quality problems, as required by 21 CFR 820.100(a)(1). Specifically:\n\nOn October 20, 2022, your firm received an internal complaint that alleged quality issues in (b)(4) manufacturing areas including your (b)(4) inspection process, bacterial endotoxin testing, bovine hide\u002Fskin thickness measurements, and control of sterilized devices. As the result of your initial investigation, your firm initiated a production hold on December 14, 2022 and also placed (b)(4) lots of product on hold. You initiated a CAPA to address the (b)(4) issue, however, CAPAs were not opened to address the remaining (b)(4) areas of concern, including endotoxin issues. Your CAPA procedure, GSOP-758, rev 005, indicates that “CAPA investigations and any corrections, corrective and\u002F or preventive actions should be (b)(4)”.\n\nDuring the inspection, you initiated a health hazard evaluation, 2023-HHE-005 to address the endotoxin concerns and the potential health risk. This HHE, completed on April 12, 2023, was not comprehensive and did not include all complaints that may have been associated with this issue. For example, two complaints of meningitis, complaint #’s 198786 and 198790, associated with your Durepair product were not included in your initial HHE assessment that concluded a field action was not recommended. Your HHE SOP, GSOP-908, rev 015 indicates that the criteria for a HHE initiation would be when “(b)(4)”.\n\nYour firm failed to (b)(4) as required per your procedure, GSOP-801 rev 3, (b)(4); Rev 03. On December 14, 2022, a hold was placed on (b)(4) lots identified in the complaint but failed to identify the potential impact on (b)(4) lots manufactured during the same time frame.\n\nWe reviewed your firm’s response and conclude it is not adequate. We are aware that this is a repeat CAPA deficiency from our 2019 Warning Letter to this facility. Your response indicated that (b)(4) CAPAs will be initiated to address the above deficiency, however you have not yet identified all necessary corrective actions, nor have you provided a copy of your CAPAs to ensure they will be comprehensive and capable of addressing the systemic issues that have been identified. We understand that you have taken a series of corrective actions, including a recall and production hold, however your response does not indicate how you will prevent such errors from recurring when you resume operations. In response to this Warning Letter, you will need to provide evidence that an effective and sustainable CAPA system will be implemented at your firm.\n\n3. Failure to validate with a high degree of assurance, a process whose results cannot be fully verified by subsequent inspection and test, as required by 21 CFR 820.75(a). Specifically:\n\nYour firm failed to adequately validate your test method for testing bacterial endotoxin (BET) of finished medical devices, or the (b)(4) used during the manufacture of these devices. Review of your BET test method validation, TMVR-009; revealed the following:\n\no The TMVR-009 assay reports failed to meet (b)(4) testing.\n\n (b)(4), dated January 28, 2019, excluded (b)(4) with “Sample Descriptions” of “Negative Control”, invalidating BET test method verification runs for product lots # (b)(4), and (b)(4).\n\n (b)(4), dated January 2, 2019, excluded (b)(4) with sample descriptions “Negative Control”, invalidating BET test method verification runs for product lots # (b)(4), and (b)(4).\n\n (b)(4), dated January 29, 2019, excluded (b)(4) with lot sample description “(b)(4)”, “Sample (b)(4)”, invalidating the BET test method verification for product lot # (b)(4).\n\no Your BET test method protocol, section 7.4 Execution and Documentation of BET Assay, cannot be followed as written, to accurately (b)(4) for BET analysis of device product testing. For example, Section 7.4, step 4., states, “(b)(4).” However, the referenced table lists the (b)(4).\n\no During routine BET testing, your firm introduced a (b)(4), in calculating the Endotoxin Limit which may cause the BET test method to be performed at (b)(4) to detect bacterial endotoxins. The use of this (b)(4) was not included in your endotoxin test method validation, TMVR-009.\n\nYour firm failed to adequately validate your test method for bioburden testing of finished medical devices. Review of TMVP-014, Revision 00, Test Method Validation Report for Bioburden Testing; Effective Date April 3, 2020, revealed:\n\no Your report failed to meet the product bioburden recovery Acceptance Criteria (b)(4) to monitor device (b)(4) bioburden loads.\n\nYour firm failed to adequately validate your test method for bacterial endotoxin of (b)(4) used in the manufacture of your finished medical devices. Review of (b)(4); Rev 00; Effective Date: April 25, 2019 revealed the following:\n\no For BET Report # (b)(4), Run Date: 3\u002F27\u002F2019, the negative control replicate original data from (b)(4) and (b)(4) were excluded.\n\no (b)(4) sample and negative control results are evident on the BET analytical result printouts in (b)(4), Attachment D. Your firm failed to meet (b)(4), requirement, “Perform re-test for invalid assays\u002Fand or samples and document rationale as appropriate.”(b)(4)\n\nWe reviewed your firm’s response and conclude it is not adequate at this time. Your response indicates that TEI Biosciences has outsourced all BET testing that was previously performed in-house, covering both product and (b)(4) testing. We also acknowledge that corrective actions include your recent recall and production hold. However, your response also indicated that you initiated CAPA 23-028 to investigate all testing, inspection and method validations at your facility, beyond just BET and bioburden testing. We will need to review this CAPA to ensure it is comprehensive and will be effective in preventing similar failures from recurring when you resume distribution. In response to this Warning Letter, you will need to provide evidence that you have reviewed all your operations to ensure that you have validated processes in place.\n\n4. Failure to store devices in a manner to facilitate proper stock rotation and to assess its condition as appropriate, as required by 21 CFR 820.150(a). Specifically:\n\nOn March 2, 2023, sterile lots of implantable devices were observed by our FDA investigator on an unsecure open shelf located in the QC Quarantine area and were labeled as “non-Sterile”. Your procedure, Shipping and Receiving EBM Products for Sterilization; MBP 300-102, Rev 21, does not adequately prevent mix-ups of sterile\u002Fnon-sterile material. Section 7.1.5 states (b)(4). We are aware that a complaint received by your firm on October 20, 2022, also described an example where non-sterile product was being handled in the same area as sterile product. We acknowledge that a CAPA was not initiated at the time to address this issue and to prevent its recurrence.\n\nWe reviewed your firm’s response and conclude it is not adequate. Your response indicated CAPA 23-031 has been opened to address this deficiency, however you have not yet completed your investigation, nor have you provided a copy of your CAPA. We will need to review your CAPA to ensure it is comprehensive and will be effective in preventing similar failures from recurring when you resume distribution. In response to this Warning Letter, you should provide confirmation that all proposed corrective actions are appropriate and effective.\n\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\n\nWe are requesting that you submit to this office on the schedule below, certification by an outside expert consultant that he\u002Fshe has conducted an audit of your establishment's manufacturing and quality assurance systems relative to the requirements of the device QS regulation (21 CFR, Part 820). You should also submit a copy of the consultant's report, and certification by your establishment's Chief Executive Officer (if other than yourself) that he or she has reviewed the consultant's report and that your establishment has initiated or completed all corrections called for in the report. The initial certifications of audit and corrections and subsequent certifications of updated audits and corrections (if required) should be submitted to this office by the following dates:\n\nInitial certifications by consultant and establishment – March 31, 2024\n\nSubsequent certifications – March 31, 2025 and March 31, 2026\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent to: Gina Brackett, Director of Compliance Branch, at oradevices1firmresponse@fda.hhs.gov. Refer to CMS # 660960 when replying. If you have any questions about the contents of this letter, please contact Compliance Officer, Karen Archdeacon at 781-587-7491 or at karen.archdeacon@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nJoseph Matrisciano, Jr.\n\nProgram Division Director\n\nOffice of Medical Device and Radiological Health\n\nDivision 1\n\nCc: Susan Krause, Corporate Vice President, Chief Quality Officer, susan.krause@integralife.com","integra-lifesciences-corporation-660960-07172023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fintegra-lifesciences-corporation-660960-07172023","2026-10-26T08:08:59.585662+00:00","2023-08-15","660960","Division of Medical Device and Radiological Health Division I","2026-08-20T00:47:43.014+00:00","United Parcel Service","2023-07-17",14,{"510k":293,"classification":294,"enforcement":295,"event":296,"event_backfill":297,"pma":298,"warning_letter":299},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]